8-Oxo-3-azabicyclo[3.2.1]octane compounds or their salts and preparation methods and uses thereof
By developing 8-oxa-3-azabicyclo[3.2.1]octane compounds, the shortcomings of existing ATR inhibitors in ATR inhibitory activity and pharmacokinetic performance were solved, and the ATR-related diseases were achieved Effective treatment and prevention reduces the risk of side effects and toxicity.
Patent Information
- Application Number
- CN202210884665.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2022-07-01
- Filing Date
- 2022-07-26
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2042-07-26
AI Technical Summary
The development of existing ATR inhibitors faces challenges, including inadequate ATR inhibitory activity, improved physicochemical properties, metabolic stability and pharmacokinetic properties, resulting in issues of toxicity risk and therapeutic effects offset.
An 8-oxa-3-azabicyclo[3.2.1]octane compound was developed, and by its preparation method and pharmaceutical composition, it provides selective ATR inhibitory activity, improved pharmacokinetic properties and Compounds that reduce side effects are used to treat or prevent ATR-related diseases.
The compound showed high-efficiency ATR inhibitory activity, good pharmacokinetic properties and reduced side effects, improving therapeutic effects and bioavailability, and reducing the impact on healthy cells.
Smart Images

Figure CN115677730B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of medicinal chemistry, and in particular to a group of 8-oxa-3-azabicyclo[3.2.1]octane compounds used as ATR inhibitors, preparation methods thereof, pharmaceutical compositions containing the same, and their use in treating or preventing ATR-related diseases. Background Art
[0002] Human cells are constantly exposed to DNA damage events due to environmental factors such as UV radiation, X-rays, and endogenous factors such as reactive oxygen species. In cancer cells, there is a higher level of DNA replication stress (a hallmark of cancer) due to being driven by oncogene drivers or induced exogenously by DNA damaging drugs or ionizing radiation (IR). Continuous replication stress leads to DNA breaks, causing tumor cells to experience higher DNA damage. The DNA damage and replication stress constitute the main source of genomic instability.
[0003] If DNA damage is high enough and not repaired, it will be highly toxic to cells and lead to cell death. In order to ensure the integrity of the eukaryotic cell genome, a group of biological pathways collectively called DDR (DNA damage response) have evolved to recognize, transmit signals and repair DNA damage. ATR (ataxia telangiectasia mutated and Rad3-related kinase), ATM (ataxia telangiectasia mutated kinase) and DNA-PK (DNA-dependent protein kinase) are key components of DDR, which function to repair DNA damage by responding to different DNA damages, among which ATM and DNA-PK mainly respond to DNA double-strand breaks, and ATR mainly responds to replication stress.
[0004] ATR is a member of the phosphatidylinositol kinase-related kinase (PIKK) protein family, and its main target is CHK1. When ATR is activated by a variety of DNA damage, especially replication stress, ATR transmits DNA damage signals through the phosphorylation of CHK1, causing the cell cycle to arrest in the S phase or G2 / M, repairing the damage, and relieving the replication stress of the cells, so that the replication can be restarted after the stress is removed.
[0005] Compared with healthy proliferating cells, tumor cells have higher DNA damage and replication stress. To replicate and survive and maintain cell division, they rely more on ATR for DNA repair. Therefore, by inhibiting ATR, the repair function of tumor cells can be inhibited, resulting in increased DNA damage and replication stress that cannot be repaired, ultimately leading to tumor cell death, while having no or less impact on healthy proliferating cells. This forms the basis for the use of ATR inhibitors in cancer treatment, and has also led to ATR inhibition being considered an important cancer treatment approach in recent years.
[0006] Standard cancer therapies such as radiotherapy or chemotherapy exert their therapeutic effects by inducing DNA damage, which is particularly toxic to proliferating cells, and the existence of DNA damage repair mechanisms limits the efficacy of these therapies, thereby generating resistance to chemotherapy or radiotherapy drugs. By inhibiting ATR, increasing replication stress and DNA damage, the sensitivity of tumor cells to these DNA damage-inducing therapies can be enhanced, which helps to overcome the resistance to radiotherapy or chemotherapy drugs caused by damage repair. It can be used to treat patients with tumors with gene mutations or chemotherapy resistance, reduce the dose of chemotherapy or radiotherapy, and thus reduce toxicity to the blood and gastrointestinal organ systems.
[0007] Therefore, for cancer cells with increased replication stress or other cancer cells with impaired or defective DNA damage repair pathways, ATR inhibitors could be used to increase replication stress and induce tumor cell death. Indeed, studies have revealed that ATR inhibitors have synthetic lethal activity against p53 mutant tumors or tumors with loss of ATM function, and have synergistic effects when used in combination with a variety of replication stress / DNA damage-inducing chemotherapeutic agents, such as platinum, ionizing radiation, and PARP inhibitors.
[0008] In addition, ATR inhibition can also prevent the occurrence of cancer because ATR is also an important member of the DNA damage checkpoint. ATR inhibition will limit the proliferation of protocancer cells caused by oncogene activation.
[0009] In recent years, some ATR inhibitors have been developed (e.g., WO2017202748, CN111848605A, WO2020087170, WO2020049017). However, the development of new potent ATR inhibitors remains very challenging. The high identity of the PIKK kinase family with related lipid kinases such as phosphatidylinositol 3-kinase (PI3KS) and mTOR increases the risk of inhibiting other kinases, which may increase toxicity or offset the therapeutic effect of ATR inhibition; in addition, the application of some ATR inhibitors is also limited by physicochemical properties, pharmacokinetic properties, and drug interactions.
[0010] Therefore, there remains a need in the art for new selective ATR inhibitors with enhanced ATR inhibitory activity, particularly ATR inhibitors with improved physicochemical properties, improved metabolic stability, improved pharmacokinetic properties (orally available), and / or minimized CYP450 inhibition. Brief description of the invention
[0011] The inventors have identified through research that the compounds of the present invention show satisfactory ATR inhibitory activity and show good performance in in vivo and / or in vitro pharmacokinetic experiments, indicating improved drugability and improved bioavailability. Therefore, the compounds of the present invention can not only achieve the purpose of preventing or treating diseases related to ATR, but also the prepared drugs are expected to have improved absorption, improved efficacy at the same dose, or provide the same efficacy at a lower dose and / or reduce possible side effects. Therefore, the present invention also provides the use of the compounds of the present invention in the preparation of drugs for preventing or treating diseases related to ATR, pharmaceutical compositions containing the compounds, and methods for preventing and / or treating diseases related to ATR by administering the compounds.
[0012] Therefore, in one aspect of the present invention, there is provided a compound of formula (I), a stereoisomer, a tautomer, a stable isotopic variant, a pharmaceutically acceptable salt or a solvate thereof:
[0013]
[0014] The definitions of the various groups are as described in the detailed description of the invention.
[0015] In another aspect of the present invention, provided is a compound of formula (I) of the present invention having ATR inhibitory activity, which is used as a drug, especially as an ATR inhibitor for treating or preventing ATR-related diseases, or a stereoisomer, tautomer, stable isotope variant, pharmaceutically acceptable salt or solvate thereof.
[0016] In another aspect of the present invention, a pharmaceutical composition comprising the compounds of this invention and a pharmaceutically acceptable excipient is provided. In a specific aspect, the pharmaceutical composition may additionally comprise other therapeutically active ingredients suitable for use in combination with the compounds of this invention. In a specific aspect, a pharmaceutical combination product comprising the compounds of this invention and other activating agents, such as a kit, is provided.
[0017] In another aspect of the present invention, provided is a use of the compound of the present invention or a pharmaceutical composition comprising the same for preventing or treating ATR-related diseases in mammals, especially humans.
[0018] In another aspect of the present invention, there is provided a method for inhibiting ATR in vivo or in vitro, which comprises contacting an effective amount of a compound of the present invention with said ATR.
[0019] In another aspect of the present invention, there is provided a method for preventing or treating a disease associated with ATR in an individual, such as a mammal, particularly a human, which method comprises administering an effective amount of the compound of the present invention as described herein or a pharmaceutical composition comprising the same.
[0020] In another aspect of the present invention, provided is a use of the above-mentioned compound of the present invention or a pharmaceutical composition comprising the same in the preparation of a medicament for preventing or treating ATR-related diseases.
[0021] In additional aspects, methods for synthesizing compounds of the invention are provided, with representative synthetic schemes and pathways being described below.
[0022] Other objects and advantages of the present invention will become apparent to those skilled in the art from a reading of the following detailed description. DETAILED DESCRIPTION OF THE INVENTION
[0024] definition
[0025] Unless otherwise specified, the various terms used in the specification and claims have the following meanings. In the case where a particular term or phrase is not specifically defined, it should not be considered to be uncertain or unclear, but should be understood according to the ordinary meaning in the art and in conjunction with the context of this article.
[0026] Many of the groups defined herein are optionally substituted, and the list of substituents given in the definitions section is merely exemplary and not exhaustive, nor is it intended to limit the substituents defined elsewhere in the specification and claims.
[0027] The term "treatment" as used herein refers to administering one or more compounds of the present invention as described herein to a subject, such as a mammal, such as a human, suffering from the disease or having symptoms of the disease, to cure, alleviate, reduce or affect the disease or the symptoms of the disease. In a specific embodiment of the present invention, the disease is an ATR-related disease as defined below, especially a tumor or cancer.
[0028] The term "prevention" as used herein is well known in the art and refers to the administration of one or more compounds of the invention as described herein to a subject, such as a mammal, such as a human, suspected of suffering from or susceptible to an ATR-related disease as defined herein, especially cancer or a tumor, so that the risk of suffering from the defined disease is reduced. The term "prevention" includes the use of the compounds of the invention before the diagnosis or determination of any clinical and / or pathological symptoms.
[0029] As used herein, the terms "inhibit" and "reduce" or any variants of these terms refer to the ability of a bioactive agent to reduce the signaling activity of a target by interacting directly or indirectly with the target, and refer to any measurable reduction or complete inhibition of the activity of the target. For example, compared to normal, the activity (e.g., ATR activity) can be reduced by about or at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99% or more, or any range derivable therein.
[0030] The term "selective inhibition" as used herein refers to the ability of a bioactive agent to preferentially reduce the signal transduction activity of a target by directly or indirectly interacting with the target compared to off-target signal activity. With respect to the compounds of the present invention, relative to other kinases with high identity, such as the PIKK kinase family and related lipid kinases such as phosphatidylinositol 3-kinase (PI3KS) and mTOR, it is able to selectively inhibit the activity of ATR, thereby reducing the toxicity that may be caused by acting on other kinases at the same time or offsetting the inhibitory effect of ATR. For example, the invention has at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99% or more, or any range derivable therein, inhibition of better activity against ATR as compared to another specific kinase, or at least 1-, 2-, 3-, 4-, 5-, 10-, 25-, 50-, 100-, 250-, or 500-fold better activity against ATR as compared to the activity against another specific kinase.
[0031] The term "cancer" or "tumor" as used herein refers to neoplastic cell growth and proliferation, whether malignant or benign, and all precancerous and cancerous cells and tissues. For the compounds, methods, pharmaceutical compositions, drug combinations and uses of the present invention, the cancer or tumor includes, but is not limited to, colon cancer, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, lung cancer, leukemia, bladder cancer, stomach cancer, cervical cancer, testicular cancer, skin cancer, rectal cancer, thyroid cancer, kidney cancer, uterine cancer, liver cancer, acoustic neuroma, oligodendroglioma, meningioma, neuroblastoma, eye cancer.
[0032] Accordingly, the "anti-cancer effect" or "anti-tumor effect" described herein includes, but is not limited to, the effect on response rate, time to disease progression, and survival rate. The anti-tumor effects of the compounds of the present invention and their medical uses and methods include, but are not limited to, inhibiting tumor growth, delaying tumor growth, regressing tumors, shrinking tumors, prolonging tumor regeneration after treatment cessation, slowing disease progression, and also preventing tumor occurrence.
[0033] The term "therapeutically effective amount" as used herein means an amount that, when administered to an individual for the treatment of a disease, is sufficient to reduce or completely alleviate the symptoms or other adverse effects of the disease; reverse, completely stop or slow the progression of the disease; or reduce the risk of worsening of the disease. The "effective amount" varies depending on the compound, the disease and its severity, and the age, weight, etc. of the individual to be treated.
[0034] As used herein, the term "individual" includes humans or non-human animals. Exemplary human individuals include human individuals (referred to as patients) suffering from diseases (e.g., diseases described herein) or normal individuals. In the present invention, "non-human animals" include all vertebrates, such as non-mammals (e.g., birds, amphibians, reptiles) and mammals, such as non-human primates, livestock and / or domesticated animals (e.g., sheep, dogs, cats, cows, pigs, etc.).
[0035] The term "ATR-related disease" as used herein refers to a disease in which ATR activity promotes the occurrence and development of the disease, or in which inhibition of ATR will reduce the incidence of the disease, reduce or eliminate the symptoms of the disease. For the present invention, "ATR-related disease" preferably refers to an ATR-mediated disease, and more preferably cancer or a tumor. As described herein, ATR kinase inhibitors should have therapeutic or preventive value for the following diseases: hematological malignancies, such as leukemias (including chronic lymphocytic leukemia, acute lymphocytic leukemia, acute myeloid leukemia and chronic myeloid leukemia), multiple myeloma, lymphatic malignancies (such as lymphoma, Hodgkin's disease, non-Hodgkin's lymphoma), myelodysplastic syndrome, and solid tumors, such as carcinomas and sarcomas and their metastases, such as breast cancer, lung cancer (non-small cell lung cancer, small cell lung cancer, squamous cell carcinoma, bronchoalveolar carcinoma), central nervous system tumors (such as gliomas, dysplastic neuroepithelial tumors, glioblastoma multiforme) Cancers of the gastrointestinal tract (e.g., gastric, esophageal, liver, bile duct, colorectal, small intestine, pancreatic), skin, melanoma, thyroid, bone, head and neck, salivary gland, prostate, testicular, ovarian, cervical, uterine, endometrial, vulvar, bladder, kidney, squamous cell carcinoma, sarcomas (e.g., osteosarcoma, chondrosarcoma, leiomyosarcoma, soft tissue sarcoma, Ewing's sarcoma, gastrointestinal tissue cancer, gastrointestinal stromal tumors, Kaposi's sarcoma), and pediatric cancers (e.g., rhabdomyosarcoma and neuroblastoma).
[0036] The compounds of the invention are particularly useful for treating patients suffering from lung cancer, prostate cancer, melanoma, ovarian cancer, breast cancer, endometrial cancer, kidney cancer, gastric cancer, sarcoma, head and neck cancer, central nervous system tumors and their metastases, and patients suffering from acute myeloid leukemia.
[0037] The term "pharmaceutical composition" or "pharmaceutical preparation" as used herein refers to a composition comprising one or more compounds of formula (I) of the present invention or their stereoisomers, tautomers, stable isotopic derivatives, pharmaceutically acceptable salts or solvates and a pharmaceutically acceptable excipient or carrier generally accepted in the art, and may be in solid, semi-solid, liquid or gaseous form.
[0038] The term "drug combination" as used herein means that the compounds of the present invention can be combined with other active agents to achieve the purpose of the present invention. The other active agents may be one or more additional compounds of the present invention, or may be a second or additional (e.g., a third) compound that is compatible with the compounds of the present invention, i.e., does not adversely affect each other, or has complementary activities. Such active agents are suitably combined in an effective amount to achieve the intended purpose. The other active agents may be co-administered with the compounds of the present invention in a single pharmaceutical composition, or administered separately from the compounds of the present invention in different discrete units, such as in the form of a kit, and when administered separately, may be performed simultaneously or sequentially. The sequential administration may be close or distant in time.
[0039] The term "pharmaceutically acceptable" as used herein refers to molecular entities and compositions that are or are approvable by relevant agencies in various countries, or are listed in the generally recognized pharmacopoeia for use in animals, and more particularly in humans, or that do not produce adverse, allergic or other untoward reactions when administered in appropriate amounts to animals, such as humans.
[0040] The term "pharmaceutically acceptable excipient or carrier" as used herein refers to one or more compatible solid or liquid fillers or gel substances, which are pharmacologically inactive, compatible with the other ingredients in the composition, and should be acceptable for administration to warm-blooded animals such as humans, and are used as carriers or media for the compounds of the present invention in the administration form. Examples include, but are not limited to, cellulose and its derivatives (such as sodium carboxymethyl cellulose, cellulose acetate, etc.), gelatin, talc, solid lubricants (such as magnesium stearate), calcium sulfate, vegetable oils, polyols (such as propylene glycol, glycerol, mannitol, sorbitol, etc.), emulsifiers (such as Tweens), wetting agents (such as sodium lauryl sulfate), colorants, flavorings, stabilizers, antioxidants, preservatives, etc.
[0041] The term "pharmaceutically acceptable salt" as used herein means a salt of the compound of the present invention that is pharmaceutically acceptable and has the desired pharmacological activity of the parent compound. Specifically, such salts are non-toxic and may be inorganic acid addition salts or organic acid addition salts and base addition salts. Specifically, such salts include: (1) acid addition salts formed with inorganic acids, such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, etc.; or acid addition salts formed with organic acids, such as acetic acid, propionic acid, hexanoic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, 2-naphthalenesulfonic acid, 4-toluenesulfonic acid. or (2) salts formed when an acidic proton present in the parent compound is replaced by a metal ion such as an alkali metal ion, an alkaline earth metal ion or an aluminum ion, or coordinated with an organic base such as ethanolamine, diethanolamine, triethanolamine, N-methylglucamine, etc. Those skilled in the art will be aware of the general principles and techniques for preparing pharmaceutically acceptable salts, such as those described in Berge et al., Pharm ScL, 66, 1-19. (1977).
[0042] The term "stereoisomer" as used herein refers to an isomer formed by at least one asymmetric center. In compounds with one or more, such as 1, 2, 3 or 4 asymmetric centers, racemic mixtures, single enantiomers, diastereomers and individual diastereomers can be produced. Specific molecules can also exist as geometric isomers (cis / trans). The compounds of the present invention can also exist as mixtures of two or more structurally different forms in rapid equilibrium, commonly referred to as tautomers, representative examples include keto-enol, phenol-ketone, nitroso-oxime tautomers, etc. It should be understood that the scope of the present invention covers all such isomers and mixtures of any proportion thereof, such as 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%.
[0043] The term "solvate" as used herein refers to a solvent addition form containing a stoichiometric or non-stoichiometric amount of a solvent, including any solvated form of the compounds of the invention, including, for example, solvates with water, such as hydrates, or solvates with organic solvents, such as methanol, ethanol or acetonitrile, i.e., as methanolates, ethanolates or acetonitrile, respectively; or in the form of any polymorph. It should be understood that such solvates of the compounds of the invention also include solvates of pharmaceutically acceptable salts of the compounds of the invention.
[0044] The term "prodrug" as used herein means a compound having a cleavable group and becoming a pharmaceutically active compound of the invention in vivo by solvolysis or under physiological conditions. Prodrugs include acid derivatives well known in the art, such as esters prepared by reacting the parent acid with a suitable alcohol, or amides prepared by reacting the parent acid compound with a substituted or unsubstituted amine, or anhydrides or mixed anhydrides. Simple aliphatic or aromatic esters, amides and anhydrides derived from the acid groups pendant to the compounds of the invention are particularly useful prodrugs. Specific such prodrugs are C 1-8 Alkyl, C 2-8 Alkenyl, optionally substituted C 6-10 Aryl and (C 6-10 Aryl)-(C 1-4 alkyl) esters.
[0045] The term "isotopic variant" as used herein refers to a compound containing an unnatural ratio of isotopes on one or more atoms constituting the compound. The compounds of the present invention may contain unnatural ratios of atomic isotopes on one or more atoms constituting the compound, thereby forming isotopic variations, whether or not they are radioactive, and are intended to be included within the scope of the present invention. Examples of isotopes that can be incorporated into the compounds of the present invention and their pharmaceutically acceptable salts include, but are not limited to, isotopes of hydrogen (e.g., 2H, 3H); isotopes of carbon (e.g., 11C, 13C, and 14C); isotopes of chlorine (e.g., 36Cl); isotopes of fluorine (e.g., 18F); isotopes of iodine (e.g., 123I and 125I); isotopes of nitrogen (e.g., 13N and 15N); isotopes of oxygen (e.g., 15O, 17O, and 18O); isotopes of phosphorus (e.g., 32P); and isotopes of sulfur (e.g., 35S). It will be appreciated that isotopic variations of the compounds of the present invention can generally be prepared by conventional procedures using appropriate isotopic variations of suitable reagents.
[0046] In the structural formula of the compound of general formula (I) herein It represents an aromatic ring, that is, the selection of A1 to A5 makes the formed ring satisfy the valence bond theory of an aromatic ring and is chemically feasible and stable.
[0047] The compound structural formula or structural fragment used in this article or Indicates the existence of stereoisomers and the absolute configuration of an asymmetric center, and is usually represented by R or S in the naming of the compounds or intermediates provided by the present invention. When present in a racemic mixture, the real and dashed wedge symbols define the relative stereochemistry, not the absolute stereochemistry.
[0048] The structural fragments used in this article The bonds indicated to be crossed are the bonds connecting the structural fragment to the rest of the molecule.
[0049] As used herein, the term "halo" or "halogen" refers to fluorine (F), chlorine (Cl), bromine (Br) and iodine (I). Preferred halo is fluorine or chlorine.
[0050] As used herein, the term "halogen-substituted" groups is intended to include mono- or poly-halogenated groups in which one or more (e.g., 2, 3, 4, 5 or 6) identical or different halogens replace one or more (e.g., 2, 3, 4, 5 or 6) hydrogens in the group.
[0051] As used herein, the term "cyano" refers to the group -CN.
[0052] As used herein, the term "hydroxy" refers to -OH.
[0053] The term "oxo" as used herein refers to =0.
[0054] As used herein, term " alkyl " refers to the straight or branched saturated hydrocarbon group consisting of carbon atoms and hydrogen atoms. Specifically, alkyl has 1-10, such as 1 to 6, 1 to 5, 1 to 4, 1 to 3 or 1 to 2 carbon atoms. For example, as used herein, term " C1-C6 alkyl " refers to the straight or branched saturated hydrocarbon group with 1 to 6 carbon atoms, and its example is methyl, ethyl, propyl (including n-propyl and isopropyl), butyl (including n-butyl, isobutyl, sec-butyl or tert-butyl), pentyl (including n-pentyl, isopentyl, neopentyl), n-hexyl, 2-methylpentyl etc. Specific alkyl has 1 to 3 carbon atoms.
[0055] The term "alkoxy" as used herein refers to the group -O-alkyl, wherein alkyl has the meaning given herein. Specifically, the term includes the group -OC 1-6 Alkyl, more specifically -OC 1-3 Alkyl. Representative examples of alkoxy include, but are not limited to, methoxy, ethoxy, propoxy (including n-propoxy, isopropoxy), butoxy (including n-butoxy, isobutoxy, tert-butoxy), pentoxy (including n-pentoxy, isopentoxy, neopentoxy), hexoxy (including n-hexoxy, isohexoxy), etc. Specific alkoxy groups have 1 to 3 carbon atoms.
[0056] As used herein, the term "alkylene" alone or in combination with other groups refers to a saturated straight or branched chain divalent hydrocarbon group. For example, the term "C 1-3 The term "alkylene" refers to an alkylene group having 1 to 3 carbon atoms, for example, methylene, ethylene, propylene, 1-methylethylene, 2-methylethylene, and the like.
[0057] The term "cycloalkyl" as used herein refers to a monocyclic, fused polycyclic, bridged polycyclic or spirocyclic non-aromatic saturated monovalent hydrocarbon ring structure having a specified number of ring atoms. A cycloalkyl group may have 3 to 12 carbon atoms (i.e., C3-C 12 Cycloalkyl), such as C 3-10 Cycloalkyl, C 3-8 Cycloalkyl, C 3-6 Cycloalkyl, C 5-6 Cycloalkyl. Examples of suitable cycloalkyl groups include, but are not limited to, monocyclic structures such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl; or polycyclic (e.g., bicyclic) structures, including spiro, fused or bridged systems, such as bicyclo[1.1.1]pentyl, bicyclo[2.2.1]heptyl, spiro[3.4]octanyl, bicyclo[3.1.1]hexanyl, bicyclo[3.1.1]heptyl or bicyclo[3.2.1]octanyl, etc.
[0058] The term "aryl" as used herein means a monovalent aromatic hydrocarbon radical derived by removing one hydrogen atom from a single carbon atom in an aromatic ring system. Specifically, aryl refers to a monocyclic or fused polycyclic aromatic ring structure having the specified number of ring atoms. Specifically, the term includes groups containing 6 to 14, e.g., 6 to 10, preferably 6 ring members. Specific aryl groups include phenyl and naphthyl, the most specific aryl being phenyl.
[0059] As used herein, the term "substituted" or "substituted" means that one or more (e.g., 1, 2, 3 or 4) hydrogen atoms on the designated atom are replaced by the designated group, provided that the normal valence of the designated atom in the current situation is not exceeded and a stable compound is formed. Combinations of substituents and variables are permitted only if such combinations form stable compounds.
[0060] The term "optionally substituted", as used herein, unless otherwise indicated, means that the group may be unsubstituted or substituted with one or more (e.g., 0, 1, 2, 3, 4 or 5 or more) of the substituents listed for that group, wherein the substituents may be the same or different.
[0061] Unless otherwise specified, C in the definition of compounds of the present invention is n-n+m or C n -C m Including various cases from n to n+m carbons, such as C 1-6 Including C1, C2, C3, C4, C5 and C6, and also including any range from n to n+m, such as C 0-6 Including C1, C2, C3, C4, C5, C6, C 0-1 , C 0-2 , C 0-3 , C 0-4 , C 0-5 , C 1-2, C 1-3 , C 1-4 , C 2-3 Similarly, the n-membered to n+m-membered in the definition of the compound of the present invention means that the number of ring atoms can be any one between n and n+m, and also includes any range of n to n+m-membered.
[0062] As used in this specification and the claims that follow, the words "comprise", "include" and "contain" mean "including but not limited to", and do not exclude, for example, other additives, ingredients, integers or steps. It should be understood that the term includes the technical solution of "consisting of" or "essentially consisting of" the ingredients, steps or conditions.
[0063] It should be understood that the dosages referred to herein when describing the compounds of the present invention, pharmaceutical compositions, pharmaceutical combinations containing the same, and related uses and methods are based on the weight of the free form, and not on any salts, hydrates or solvates thereof, etc., unless otherwise defined in the specification.
[0064] Compounds of the present invention
[0065] The terms "invented compounds" and "compounds of the present invention" and the like used throughout this application, unless otherwise indicated, encompass compounds of formula (I) as defined in the various embodiments herein and in specific or preferred embodiments thereof, their stereoisomers, tautomers, stable isotopic variants, pharmaceutically acceptable salts or solvates, and prodrugs. The stereoisomers, tautomers, stable isotopic variants, pharmaceutically acceptable salts or solvates, and prodrugs are as described in the definition section above. Preferably, the compound of the present invention is a free form of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof; most preferably, it is a free form of a compound of formula (I) or a pharmaceutically acceptable salt thereof.
[0066] Certain compounds of the present invention may exist in multiple crystalline or amorphous forms, which also fall within the scope of the present invention. When in solid crystalline form, compounds of formula (I) may be in the form of co-crystals with another chemical entity, and the present specification includes all such co-crystals.
[0067] In the presence of chiral centers, the compounds of the present invention may exist as individual enantiomers or mixtures of enantiomers, and those skilled in the art are able to determine stable and viable isomeric forms of the compounds of the present invention. According to one embodiment, there is provided a compound of formula (I) or a pharmaceutically acceptable salt thereof, which is a single enantiomer with an enantiomeric excess (%ee) >95, >98% or >99%. Preferably, a single enantiomer is present with an enantiomeric excess (%ee) >99%.
[0068] The compounds of the present invention also encompass possible N-oxides, and those skilled in the art are able to determine stable and feasible N-oxides of the compounds of the present invention. The compounds of the present invention also encompass metabolites of the compounds of the present invention, i.e., substances formed in vivo by oxidation, reduction, hydrolysis, amidation, esterification, etc. when the compounds of the present invention are administered, which can be identified by techniques well known in the art.
[0069] Specifically, in one aspect, the present invention provides a compound of formula (I), a stereoisomer, a tautomer, a stable isotopic variant, a pharmaceutically acceptable salt or a solvate thereof:
[0070]
[0071] in
[0072] A1, A2 and A5 are each independently C or N;
[0073] A3 and A4 are each independently CR4, N or NR5;
[0074] X is O, C(R6)2 or NR7;
[0075] Y is N or CR8;
[0076] R1, R2 and R3 are each independently H, -OH, oxo, halogen, CN, -C 1-6 Alkyl or -OC 1-6 Alkyl, where C 1-6 The alkyl group is optionally substituted with one or more halogen or hydroxyl groups; or R1 and R2 are linked together to form a C 1-3 Alkylene bridge;
[0077] R4 is H, oxo, halogen or -C 1-6 Alkyl, where C 1-6 The alkyl group is optionally substituted with one or more halogen or hydroxyl groups;
[0078] R5 is H or -C 1-6 Alkyl, where C 1-6 The alkyl group is optionally substituted with one or more halogens;
[0079] R6 are each independently H, halogen, CN, -OH, -NH2, -NH-C 1-6 Alkyl, -N(C 1-6 Alkyl)2, -C 1-6 Alkyl, -OC 1-6 Alkyl, -C(O)-C 1-6 Alkyl, -C(O)-C 3-6 Cycloalkyl, -SO2-C 1-6 Alkyl, -SO2-C 3-6 Cycloalkyl, -SO-C1-6 Alkyl, -SO-C 3-6 Cycloalkyl, C 6-10 Aryl or C 3-6 Cycloalkyl, where -C 1-6 Alkyl, C 6-10 Aryl or C 3-6 The cycloalkyl group is optionally substituted with one or more halogen, hydroxy, -OC 1-6 Alkyl, -C 1-6 Alkyl, halogen or hydroxy substituted C 1-6 Alkyl substitution;
[0080] R7 is H, -C 1-6 Alkyl, -C(O)-C 1-6 Alkyl, -C(O)-C 3-6 Cycloalkyl, -SO2-C 1-6 Alkyl, -SO2-C 3-6 Cycloalkyl, -SO-C 1-6 Alkyl or -SO-C 3-6 Cycloalkyl, where -C 1-6 Alkyl or C 3-6 The cycloalkyl group is optionally substituted with one or more halogen, hydroxy, -OC 1-6 Alkyl, -C 1-6 Alkyl, halogen or hydroxy substituted C 1-6 Alkyl substitution;
[0081] R8 is H, -OH or halogen;
[0082] n and m are each independently an integer from 0 to 4.
[0083] In one embodiment of the compound of formula (I), at least two of A1, A2, A3, A4 and A5 are N or NR5, and the others are C or CR4; preferably two of them are N or NR5, and the others are C or CR4.
[0084] In one embodiment of the compound of formula (I), the six-membered and five-membered heteroaryl moiety comprising A1 to A5 has a structure selected from the following:
[0085]
[0086] In one embodiment of the compound of formula (I), the six-membered and five-membered heteroaryl moiety comprising A1 to A5 is selected from:
[0087]
[0088] Preferably selected from More preferred
[0089] In one embodiment of the compound of formula (I), the six-membered and five-membered heteroaryl moiety comprising A1 to A5 is preferably
[0090]
[0091] In one embodiment of the compound of formula (I), the six-membered and five-membered heteroaryl moiety comprising A1 to A5 is preferably
[0092]
[0093] In one embodiment of the compound of formula (I), the six-membered and five-membered heteroaryl moiety comprising A1 to A5 is preferably
[0094]
[0095] In one embodiment of the compound of formula (I), the six-membered and five-membered heteroaryl moiety comprising A1 to A5 is preferably
[0096]
[0097] In one embodiment of the compounds of formula (I), R4 is H.
[0098] In one embodiment of the compounds of formula (I), R4 is oxo or halogen.
[0099] In one embodiment of the compound of formula (I), R4 is -C 1-6 Alkyl, optionally substituted with one or more halogen or hydroxyl; for example, but not limited to, methyl, ethyl, propyl (including n-propyl and isopropyl), butyl (including n-butyl, isobutyl, sec-butyl or tert-butyl), pentyl (including n-pentyl, isopentyl, neopentyl), n-hexyl, 2-methylpentyl, -CH2F, -CHF2, -CF3, -C2F5, -CH2CF3, -CH2Cl, -CH2CH2CF3, -CH(CF3)2, -CH2OH or -CH2CH2OH. Preferably R4 is -C 1-3 Alkyl, for example, methyl, ethyl, propyl, isopropyl, most preferably methyl.
[0100] In the aforementioned embodiments of the compounds of formula (I), R4 is preferably H.
[0101] In one embodiment of the compounds of formula (I), R5 is H.
[0102] In one embodiment of the compound of formula (I), R5 is -C 1-6Alkyl, optionally substituted with one or more halogens; for example, but not limited to, methyl, ethyl, propyl (including n-propyl and isopropyl), butyl (including n-butyl, isobutyl, sec-butyl or tert-butyl), pentyl (including n-pentyl, isopentyl, neopentyl), n-hexyl, 2-methylpentyl, -CH2F, -CHF2, -CF3, -C2F5, -CH2CF3, -CH2Cl, -CH2CH2CF3 or -CH(CF3)2.
[0103] In the aforementioned embodiments of the compounds of formula (I), R5 is preferably C 1-3 Alkyl, for example, methyl, ethyl, propyl, isopropyl, most preferably methyl.
[0104] In one embodiment of the compounds of formula (I), X is O.
[0105] In one embodiment of the compounds of formula (I), X is C(R6)2, wherein each R6 is H.
[0106] In one embodiment of the compounds of formula (I), X is C(R6)2, wherein one of R6 is H and the other is selected from halogen, CN, -OH, -C 1-6 Alkyl, -OC 1-6 Alkyl, -C(O)-C 1-6 Alkyl, -C(O)-C 3-6 Cycloalkyl, -SO2-C 1-6 Alkyl, -SO2-C 3-6 Cycloalkyl, -SO-C 1-6 Alkyl, -SO-C 3-6 Cycloalkyl, C 6-10 Aryl or C 3-6 Cycloalkyl, where -C 1-6 Alkyl, C 6-10 Aryl or C 3-6 The cycloalkyl group is optionally substituted with one or more halogen, hydroxy, -OC 1-6 Alkyl, -C 1-6 Alkyl, halogen or hydroxy substituted -C 1-6 Alkyl substitution.
[0107] In one embodiment of the compounds of formula (I), X is C(R6)2, wherein one of R6 is H and the other is selected from halogen, such as fluorine, chlorine, bromine, iodine.
[0108] In one embodiment of the compounds of formula (I), X is C(R6)2, wherein one of R6 is H and the other is OH, CN, NH2, -NH-C 1-6 Alkyl, -N(C 1-6alkyl)2, such as, but not limited to, OH, CN, -NH2, -NH-CH3, -NH-CH2-CH3, -N(CH3)2, -N(CH2-CH3)2, -N(CH3)(CH2-CH3).
[0109] In one embodiment of the compounds of formula (I), X is C(R6)2, wherein one of R6 is H and the other is -C 1-6 Alkyl, optionally substituted by one or more halogen, hydroxyl or -OC 1-6 Alkyl substitutions such as, but not limited to, methyl, ethyl, propyl (including n-propyl and isopropyl), butyl (including n-butyl, isobutyl, sec-butyl or tert-butyl), pentyl (including n-pentyl, isopentyl, neopentyl), n-hexyl, 2-methylpentyl, -CH2F, -CHF2, -CF3, -C2F5, -CH2CF3, -CH2Cl, -CH2CH2CF3, -CH(CF3)2, -CH2OH, -CH2CH2OH, -CH2OCH3 and -CH2OCH2CH3.
[0110] In one embodiment of the compounds of formula (I), X is C(R6)2, wherein one of R6 is H and the other is -OC 1-6 Alkyl, where -C 1-6 The alkyl group is optionally substituted with one or more halogen, hydroxyl or -OC 1-6 Alkyl substitutions, such as but not limited to -OCH3, -OCH2CH3, -OCF3, -OCH2CF3, -OCH2CH2OH, -OCH2CH2OCH3.
[0111] In one embodiment of the compounds of formula (I), X is C(R6)2, wherein one of R6 is H and the other is -C(O)-C 1-6 Alkyl, -C(O)-C 3-6 Cycloalkyl, -SO2-C 1-6 Alkyl, -SO2-C 3-6 Cycloalkyl, -SO-C 1-6 Alkyl, -SO-C 3-6 Cycloalkyl, C 6-10 Aryl or C 3-6Cycloalkyl, such as but not limited to -C(O)-CH3, -C(O)-CH2CH3, C(O)-CH2CH2CH3, -C(O)-CH(CH3)2, -C(O)-cyclopropyl, -C(O)-cyclopentyl, -C(O)-cyclohexyl, -SO2-CH3, -SO2-CH2CH3, SO2-CH2CH2CH3, SO2-CH(CH3)2, -SO2-cyclopropyl, -SO2-cyclopentyl, -SO-CH3, -SO-CH2CH3, SO-CH2CH2CH3, SO-CH(CH3)2, -SO-cyclopropyl, -SO2-cyclopentyl, -SO-CH3, -SO-CH2CH3, SO-CH2CH2CH3, SO-CH(CH3)2, -SO-cyclopropyl, -SO-cyclopentyl, phenyl, cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, wherein -C 1-6 Alkyl, C 6-10 Aryl or C 3-6 The cycloalkyl group is optionally substituted with one or more halogen, hydroxy, -OC 1-6 Alkyl, -C 1-6 Alkyl, halogen or hydroxy substituted -C 1-6 Alkyl substituted, substituents such as but not limited to fluorine, chlorine, bromine, iodine, -OH, -CH3, -CH2CH3, -CH2CH2CH3, -CH(CH3)2, -O-CH3, -O-CH2CH3, -O-CH2CH2CH3, -O CH(CH3)2, -CF3, -CH2CF3, -CH2OH, -CH2CH2OH.
[0112] In one embodiment of the compound of formula (I), X is C(R6)2, wherein each R6 is independently -C 1-6 Alkyl, halogen, CN, -OH, -NH2, -NH-C 1-6 Alkyl, -N(C 1-6 Alkyl)2, -OC 1-6 Alkyl, where -C 1-6 The alkyl group is optionally substituted with one or more halogen, hydroxyl or -OC 1-6 Alkyl substitution;
[0113] For example, but not limited to, two R6 are halogen at the same time, are C optionally substituted (such as halogen) at the same time 1-6 alkyl, one is halogen and the other is said C optionally substituted (eg halogen) 1-6 Alkyl, one is OH or -OC 1-6 alkyl and the other is said C optionally substituted (eg halogen) 1-6 Alkyl, one is NH2, -NH-C 1-6 Alkyl or -N(C 1-6 alkyl)2 and the other is said C optionally substituted (eg halogen) 1-6alkyl, one is CN and the other is said optionally substituted (eg halogen) C 1-6 alkyl;
[0114] X can be, for example but not limited to, CF2, CCl2, CBr2, CFCl, C(CH3)2, C(CH2CH3)2, C(CH3)(CH2CH3), C(CF3)(CF3), C(CH3)(CF3), C(CH3)(CH2OH), C(CH3)(CH2OCH3), C(CH3)(F), C(CH3)(OCH3), C(CH3)(OH), C(CH3)(NH2), -C(CH3)(NHCH3)-.
[0115] In one embodiment of the compounds of formula (I), X is C(R6)2, wherein each R6 is independently selected from H or halogen, such as both are H, or both are halogen, such as both are F.
[0116] In one embodiment of the compounds of formula (I), X is NR7 and R7 is H.
[0117] In one embodiment of the compound of formula (I), X is NR7, R7 is -C 1-6 Alkyl, optionally substituted by one or more halogen, hydroxyl or -OC 1-6 Alkyl substitution, for example but not limited to methyl, ethyl, propyl (including n-propyl and isopropyl), butyl (including n-butyl, isobutyl, sec-butyl or tert-butyl), pentyl (including n-pentyl, isopentyl, neopentyl), n-hexyl, 2-methylpentyl, -CH2F, -CHF2, -CF3, -C2F5, -CH2CF3, -CH2Cl, -CH2CH2CF3, -CH(CF3)2, -CH2OH, -CH2CH2OH, -CH2OCH3 and -CH2OCH2CH3; preferably R7 is methyl, ethyl, propyl or isopropyl.
[0118] In one embodiment of the compound of formula (I), X is NR7, R7 is -C(O)-C 1-6 Alkyl, -C(O)-C 3-6 Cycloalkyl, -SO2-C 1-6 Alkyl, -SO2-C 3-6 Cycloalkyl, -SO-C 1-6 Alkyl or -SO-C 3-6Cycloalkyl groups such as, but not limited to, -C(O)-CH3, -C(O)-CH2CH3, C(O)-CH2CH2CH3, -C(O)-CH(CH3)2, -C(O)-cyclopropyl, -C(O)-cyclobutyl, -C(O)-cyclopentyl, -C(O)-cyclohexyl, -SO2-CH3, -SO2-CH2CH3, SO2-CH2CH2CH3, SO2-CH(CH3)2, -SO2-cyclopropyl, -SO2-cyclobutyl, -SO2-cyclopentyl, -SO2-cyclohexyl, -SO-CH3, -SO-CH2CH3, SO-CH2CH2CH3, SO-CH(CH3)2, -SO2-cyclopropyl, -SO2-cyclobutyl, -SO2-cyclopentyl, -SO2-cyclohexyl, -SO-CH3, -SO-CH2CH3, SO-CH2CH2CH3, SO-CH(CH3)2, -SO-cyclopropyl, -SO-cyclobutyl, -SO-cyclopentyl or -SO-cyclohexyl, wherein each -C 1-6 Alkyl or C 3-6 The cycloalkyl group is optionally substituted with one or more halogen, hydroxy, -OC 1-6 Alkyl, -C 1-6 Alkyl, halogen or hydroxy substituted C 1-6 Alkyl substituted, substituents such as but not limited to fluorine, chlorine, bromine, iodine, -OH, -CH3, -CH2CH3, -CH2CH2CH3, -CH(CH3)2, -O-CH3, -O-CH2CH3, -O-CH2CH2CH3, -O CH(CH3)2, -CF3, -CH2CF3, -CH2OH, -CH2CH2OH, -CH2OCH3 and -CH2OCH2CH3.
[0119] In one embodiment of the compound of formula (I), X is NR7, R7 is selected from H, -C 1-6 Alkyl and -C(O)-C 1-6 Alkyl, preferably -C 1-6 Alkyl, or preferably -C(O)-C 1-6 Alkyl groups, such as but not limited to methyl, ethyl, propyl, isopropyl, -C(O)-CH3, -C(O)-CH2CH3, C(O)-CH2CH2CH3 or -C(O)-CH(CH3)2.
[0120] In the aforementioned embodiments of the compound of formula (I), X is preferably -O-, -NH-, -N(C 1-6 -alkyl)-, -CH2-, -C(halogen)2-, for example -O-, -NH-, -N(CH3)-, -CH2-, -C(F)2-.
[0121] In the aforementioned embodiments of the compound of formula (I), X is preferably -O-, -N(C 1-6 Alkyl)-, -N(CO-C 1-6 alkyl)-, -CH2-, -CH(C 1-6Alkyl)-, -C(C 1-6 -C(alkyl)2- or -C(halogen)2-, for example -O-, -N(CH3)-, -N(CO-CH3)-, -CH2-, -C(F)2-.
[0122] In one embodiment of the compounds of formula (I), Y is N.
[0123] In one embodiment of the compounds of formula (I), Y is CR8, wherein R8 is H.
[0124] In one embodiment of the compounds of formula (I), Y is CR8, wherein R8 is OH.
[0125] In one embodiment of the compounds of formula (I), Y is CR8, wherein R8 is halogen, such as fluorine, chlorine, bromine, iodine, preferably F.
[0126] In the aforementioned embodiments of the compounds of formula (I), Y is preferably N, or CR8, wherein R8 is OH; more preferably Y is N.
[0127] In one embodiment of the compound of formula (I), the six-membered ring comprising X and Y Selected from Preferably the six-membered ring comprising X and Y is selected from More preferably, the six-membered ring comprising X and Y is selected from R6, R7 and R8 have the meanings defined in the above respective embodiments, preferably R6 is selected from H, halogen and C 1-6 Alkyl, R7 is selected from C 1-6 Alkyl and -CO-C 1-6 alkyl.
[0128] In one embodiment of the compounds of formula (I), R1 and R2 are each independently H.
[0129] In one embodiment of the compound of formula (I), R1 and R2 are each independently -OH, oxo, halogen, CN, -C 1-6 Alkyl or -OC 1-6 Alkyl, where C 1-6 The alkyl group is optionally substituted with one or more halogen or hydroxy groups, for example but not limited to -OH, oxo, fluorine, chlorine, bromine, iodine, CN, -CH3, -CH2CH3, -O-CH3, -O-CH2CH3, -CF3, -CH2CF3, -CH2OH, -CH2CH2OH, preferably -CH3, -CF3 or -CH2CH3, most preferably -CH3.
[0130] In one embodiment of the compound of formula (I), R1 and R2 are linked together to form C 1-3Alkylene bridge, for example -CH2-, -CH2CH2-, -CH2CH2CH2-.
[0131] In one embodiment of the compound of formula (I), R1 and R2 are linked together to form C 1-3 Alkylene bridge, bridging methods such as but not limited to:
[0132] Best Among them, preferably Y is N and X is O.
[0133] In the embodiments of the compounds of the aforementioned formula (I), preferably R1 and R2 are each independently H, -CH3, -CH2CH3, or R1 and R2 are linked together to form C 1-3 Alkylene bridge, preferably C2 ethylene bridge.
[0134] In one embodiment of the compounds of formula (I), m and n are both zero.
[0135] In one embodiment of the compound of formula (I), one of m and n is 0 and the other is 1, in which case R1 or R2 is not hydrogen and may be attached to the ortho position of Y or to the ortho position of X on the ring, preferably to the ortho position of Y. For example, R1 or R2 is C 1-6 Alkyl, such as but not limited to -CH3, -CH2CH3 or -CH(CH3)2, preferably R1 or R2 is -CH3, attached to the ortho position of Y or the ortho position of X, preferably attached to the ortho position of Y.
[0136] In one embodiment of the compound of formula (I), one of m and n is 0 and the other is 2, in which case R1 or R2 is not hydrogen and can be simultaneously attached to the ortho position of Y, the ortho position of X, or respectively to the ortho position of Y and the ortho position of X on the ring, preferably simultaneously to the ortho position of Y. For example, R1 or R2 are each independently C 1-6 Alkyl, such as but not limited to -CH3, -CH2CH3 or -CH2-CH2-CH3, preferably R1 or R2 is -CH3, and is connected to the ortho position of Y.
[0137] In one embodiment of the compound of formula (I), one of m and n is 0 and the other is 3 or 4, and R1 or R2 is not hydrogen, and the R1 or R2 is, for example but not limited to -CH3, -CH2CH3 or -CH2-CH2-CH3, for example, the R1 or R2 is C 1-6 Alkyl, preferably R1 or R2 is -CH3.
[0138] In one embodiment of the compound of formula (I), m and n are both 1, and R1 and R2 are not hydrogen, and each independently can be connected to the ortho position of Y or the ortho position of X on the ring, for example, both are connected to the ortho position of Y, or both are connected to the ortho position of X, or are connected to the ortho position of Y and the ortho position of X respectively; preferably, R1 and R2 are C 1-6 The alkyl groups, more preferably R1 and R2 are -CH3, are both attached to the ortho position of Y, or are both attached to the ortho position of X, or are attached to the ortho position of Y and the ortho position of X respectively.
[0139] In one embodiment of the compound of formula (I), m and n are both 1, in which case R1 and R2 are not hydrogen, and the R1 and R2 attached to, preferably attached to both the ortho position of Y and the ortho position of X are attached together to form C 1-3 Alkylene bridge, for example -CH2-, -CH2CH2-, -CH2CH2CH2-.
[0140] In one embodiment of the compound of formula (I), m is 1 and n is 2, or m is 1 and n is 3, or m is 1 and n is 4, or m is 2 and n is 2, or m is 2 and n is 3, or m is 2 and n is 4, or m is 3 and n is 4, or m is 4 and n is 4, wherein for example R1 and R2 are C 1-6 Alkyl, preferably R1 and R2 are -CH3.
[0141] In one embodiment of the compound of formula (I), one of m and n is 0, the other is 1, and R1 or R2 are each independently C 1-6 Alkyl, optionally substituted by one or more halogens, attached to the ortho position of Y or the ortho position of X;
[0142] or one of m and n is 0, the other is 2, R1 or R2 are each independently C 1-6 Alkyl, optionally substituted by one or more halogens, attached to the ortho position of Y, to the ortho position of X, or to the ortho positions of X and Y respectively;
[0143] or m and n are both 1 and R1 and R2 are each independently C 1-6 The alkyl group, optionally substituted with one or more halogens, is attached to the ring at an ortho position to Y, to an ortho position to X, or to an ortho position to Y and an ortho position to X, respectively.
[0144] In one embodiment of the compound of formula (I), preferably one of m and n is 0, the other is 1, R1 or R2 is C 1-6 The alkyl group is connected to the ortho position of Y or the ortho position of X.
[0145] In one embodiment of the compound of formula (I), one of m and n is 0, the other is 1, R1 or R2 is C 1-6alkyl, optionally substituted by halogen, and attached to the ortho position of Y; or one of m and n is 0, the other is 2, R1 or R2 are each independently C 1-6 The alkyl groups, optionally substituted by halogen, are all attached to Y in the ortho position.
[0146] In the aforementioned embodiments of the compound of formula (I), R1 and / or R2 may be in R or S configuration, preferably R configuration, where chemically feasible.
[0147] In one embodiment of the compound of formula (I), the six-membered ring containing X and Y is, for example but not limited to:
[0148]
[0149] Best More preferred
[0150] In one embodiment of the compounds of formula (I), R3 is H.
[0151] In one embodiment of the compounds of formula (I), R3 is halogen, such as fluorine, chlorine, bromine, iodine, preferably fluorine or chlorine.
[0152] It should be noted that the compounds of the present invention cover each of the above independent embodiments or each specific illustrative embodiment, and also cover embodiments consisting of any combination or sub-combination of the above embodiments or specific illustrative embodiments, and also cover embodiments consisting of any combination of any of the above preferred or illustrative embodiments.
[0153] In one embodiment of the compound of formula (I),
[0154]
[0155] in,
[0156] The six-membered and five-membered heteroaryl moieties comprising A1 to A5 are selected from:
[0157]
[0158] The six-membered ring containing X and Y is selected from
[0159] R1 and R2 are each independently H or -C 1-6 Alkyl, where C 1-6 The alkyl group is optionally substituted with one or more halogens; or R1 and R2 are linked together to form a C 1-3 Alkylene bridge;
[0160] R3 is H or halogen;
[0161] R4 is H;
[0162] R5 is H or -C 1-6 alkyl;
[0163] R6 are each independently H, halogen, -C 1-6 Alkyl or -OC 1-6 Alkyl, where -C 1-6 The alkyl group is optionally substituted with one or more halogens;
[0164] R7 is H or -C 1-6 Alkyl, where -C 1-6 The alkyl group is optionally substituted with one or more halogens;
[0165] R8 is H, -OH or halogen;
[0166] n and m are each independently an integer from 0 to 2.
[0167] In a preferred embodiment of this embodiment, the six-membered and five-membered heteroaryl moieties comprising A1 to A5 are selected from
[0168] In a preferred embodiment of this embodiment, the six-membered ring comprising X and Y is selected from
[0169] In a preferred embodiment of this embodiment, the six-membered ring comprising X and Y is For example, the six-membered ring containing X and Y is Where R1 is each independently C 1-6 alkyl, optionally substituted by halogen, n is selected from 0, 1 or 2; or a six-membered ring containing X and Y R1 and R2 are connected together to form C 1-3 Alkylene bridges, e.g.
[0170] In a preferred embodiment of this embodiment, the six-membered ring comprising X and Y is For example, the six-membered ring containing X and Y is Where R1 is each independently C 1-6 alkyl, optionally substituted by halogen, n is selected from 1 or 2, R7 is selected from C 1-6 Alkyl or -CO-C 1-6 alkyl.
[0171] In a preferred embodiment of this embodiment, the six-membered ring comprising X and Y is For example, the six-membered ring containing X and Y is Where R1 is each independently C 1-6alkyl, optionally substituted by halogen, n is selected from 0 or 1, R6 is selected from H, halogen or C substituted by halogen 1-6 alkyl.
[0172] In a preferred embodiment of this embodiment, the six-membered ring comprising X and Y is selected from
[0173] In a preferred embodiment of this embodiment, the six-membered ring comprising X and Y is selected from
[0174] In the above preferred embodiments of this embodiment, R1 and R2 are each independently H.
[0175] In the above preferred embodiment of this embodiment, R1 and R2 are each independently -C 1-6 Alkyl, optionally substituted by one or more halogens, such as -CH3, -CH2CH3, -CH2CH2CH3, -CH(CH3)2, -CF3 or -CH2CF3, most preferably -CH3.
[0176] In a preferred embodiment of this embodiment, R1 and R2 are linked together to form C 1-3 Alkylene bridge, preferably C2 alkylene bridge.
[0177] In the above preferred embodiments of this embodiment, R3 is H.
[0178] In the above preferred embodiment of this embodiment, R5 is -C 1-6 Alkyl, for example -CH3, -CH2CH3, -CH2CH2CH3, -CH(CH3)2, most preferably -CH3.
[0179] In the above preferred embodiments of this embodiment, R6 is each independently H or halogen, preferably H or F.
[0180] In the above preferred embodiments of this embodiment, R7 is H, or -C 1-6 Alkyl, for example -CH3, -CH2CH3, -CH2CH2CH3, -CH(CH3)2, most preferably -CH3.
[0181] In the above preferred embodiments of this embodiment, R8 is -OH.
[0182] In the above preferred embodiment of this embodiment, one of n and m is 0, the other is 1, R1 or R2 is attached to the ortho position of Y or the ortho position of X on the ring, preferably to the ortho position of Y; for example, R1 or R2 is C 1-6 The alkyl group, preferably R1 or R2 is -CH3, is attached to the ortho position of Y or the ortho position of X, preferably to the ortho position of Y.
[0183] In the above preferred implementation of this embodiment, one of n and m is 0, and the other is 2, and R1 or R2 is simultaneously connected to the ortho position of Y, the ortho position of X, or respectively connected to the ortho position of Y and the ortho position of X on the ring, preferably simultaneously connected to the ortho position of Y. For example, R1 or R2 is C 1-6 The alkyl group, preferably R1 or R2 is -CH3, is attached to Y at the ortho position.
[0184] In the above preferred embodiment of this embodiment, n and m are both 1, and R1 and R2 can be connected to the ortho position of Y or the ortho position of X on the ring independently, for example, both are connected to the ortho position of Y, or both are connected to the ortho position of X, or are connected to the ortho position of Y and the ortho position of X respectively, preferably both are connected to the ortho position of Y, preferably R1 and R2 are C 1-6 alkyl, more preferably R1 and R2 are -CH3, both connected to the ortho position of Y, or both connected to the ortho position of X, or respectively connected to the ortho position of Y and the ortho position of X, preferably both connected to the ortho position of Y; or R1 and R2 connected to, preferably simultaneously connected to the ortho position of Y and the ortho position of X are connected together to form C 1-3 Alkylene bridge, for example -CH2-, -CH2CH2-, -CH2CH2CH2-.
[0185] In the aforementioned preferred implementations of this embodiment, R1 and / or R2 may be in R or S configuration, preferably R configuration, where chemically feasible.
[0186] It should be noted that the compounds of the present invention encompass embodiments constituted by any combination of any of the above preferred or exemplary embodiments.
[0187] Specific embodiments of the compounds of the present invention include the following specific compounds, their stereoisomers, tautomers, stable isotopic variants, pharmaceutically acceptable salts or solvates,
[0188]
[0189]
[0190] For the compounds of the invention for use as medicines, the methods of prevention or treatment of the invention, the pharmaceutical compositions, the pharmaceutical combinations or the uses described below, the various preferred embodiments of the compounds of formula (I) defined herein are preferred, and the specific compounds listed are more preferred.
[0191] Advantageous Effects of the Invention
[0192] As mentioned above, ATR kinase is known to play a role in tumorigenesis and a variety of other diseases. We have surprisingly found that the above-mentioned compounds of formula (I) are able to potently inhibit ATR kinase, thereby having value as anti-proliferative, apoptotic and / or anti-invasive drugs in the containment and / or treatment of solid and / or liquid tumor diseases. In particular, it is expected that the compounds of the present invention can be used to prevent or treat tumors that are sensitive to the inhibition of ATR. In addition, it is expected that the compounds of the present invention are useful for preventing or treating tumors that are mediated solely or in part by ATR.
[0193] Specifically, it has been found through research that the compounds of the present invention can effectively inhibit the activity of ATR kinase and tumor cell lines, and can achieve one or more of the following technical effects:
[0194] High ATR kinase inhibitory activity: in the kinase ATR inhibition assay, the IC50 is in the range of 0.1 nM to 1 μM, preferably in the range of 0.1 nM to 0.5 μM, preferably in the range of 0.1 nM to 0.1 μM, more preferably in the range of 0.1 nM to 50 nM, 0.1 nM to 20 nM, as verified in Activity Example 1; and / or
[0195] High LOVO cell line proliferation inhibition activity, as verified in Activity Example 2; and / or
[0196] · Have good pharmacokinetic properties, such as longer t 1 / 2 , so that, for example, the dosing interval can be increased, the half-life can be longer, and the patient has better compliance, as verified in Active Example 3; and / or
[0197] Having improved AUC0-t data, better drugability, and higher bioavailability, as demonstrated in Active Example 4 below; and / or
[0198] Good safety profile, such as membrane permeability, P450 (reduced risk of drug interactions), lower toxicity and / or fewer side effects; and / or
[0199] Excellent physicochemical properties, such as solubility, physical and / or chemical stability, as demonstrated in Active Example 5.
[0200] Based on the beneficial effects of the above compounds of the present invention, the present invention also provides the following technical solutions in various aspects.
[0201] Compounds of the invention for use in therapy or as a medicament
[0202] In one aspect, the present invention provides a compound of the present invention for use as a medicament, particularly as an ATR inhibitor, more particularly as an anticancer or antitumor agent.
[0203] In another aspect, the present invention provides compounds of the present invention for use in the treatment and / or prevention of diseases associated with ATR.
[0204] In a specific embodiment, the present invention provides compounds of the present invention for use in the treatment and / or prevention of diseases in which ATR promotes the onset and progression of the disease or in which inhibition of ATR reduces the incidence of the disease, reduces or eliminates the symptoms of the disease, such as tumors or cancers, including but not limited to: hematological malignancies, such as leukemias (including chronic lymphocytic leukemia, acute lymphocytic leukemia, acute myeloid leukemia and chronic myeloid leukemia), multiple myeloma, lymphatic malignancies (such as lymphoma, Hodgkin's disease, non-Hodgkin's lymphoma), myelodysplastic syndrome, and solid tumors, such as carcinomas and sarcomas and their metastases, such as breast cancer, lung cancer (non-small cell lung cancer, small cell lung cancer, squamous cell carcinoma, bronchoalveolar carcinoma), central nervous system malignancies, such as leukemia ... systemic tumors (e.g., glioma, dysembryoplastic neuroepithelial tumor, glioblastoma multiforme, mixed glioma, medulloblastoma, retinoblastoma, neuroblastoma, germ cell tumor, and teratoma), gastrointestinal cancer (e.g., gastric cancer, esophageal cancer, liver cancer, bile duct cancer, colorectal cancer, small intestine cancer, pancreatic cancer), skin cancer, melanoma, thyroid cancer, bone cancer, head and neck cancer, salivary gland cancer, prostate cancer, testicular cancer, ovarian cancer, cervical cancer, uterine cancer, endometrial cancer, vulvar cancer, bladder cancer, kidney cancer, squamous cell carcinoma, sarcoma (e.g., osteosarcoma, chondrosarcoma, leiomyosarcoma, soft tissue sarcoma, Ewing's sarcoma, gastrointestinal tissue cancer, gastrointestinal stromal tumor, Kaposi's sarcoma), and pediatric cancer (e.g., rhabdomyosarcoma and neuroblastoma).
[0205] The present invention particularly provides compounds of formula (I), stereoisomers, tautomers, stable isotopic variants, pharmaceutically acceptable salts or solvates thereof that can be used to treat patients suffering from lung cancer, prostate cancer, melanoma, ovarian cancer, breast cancer, endometrial cancer, kidney cancer, gastric cancer, sarcoma, head and neck cancer, central nervous system tumors and their metastases, and acute myeloid leukemia.
[0206] Pharmaceutical compositions and their administration
[0207] On the other hand, in order to achieve the purpose of treatment or prevention, the compounds of the present invention can be formulated into pharmaceutical compositions according to standard pharmaceutical practices. At the same time, based on the good pharmacokinetic properties, improved AUC0-last, and good drugability of the compounds of the present invention, drugs with better pharmacokinetic properties and higher bioavailability can be prepared from the compounds of the present invention.
[0208] Therefore, the present invention provides a pharmaceutical composition comprising the above-mentioned compound of the present invention and a pharmaceutically acceptable excipient.
[0209] The excipients selected for inclusion in a particular composition will depend on a variety of factors, such as the mode of administration and the form of the composition provided. Suitable pharmaceutically acceptable excipients are well known to those skilled in the art and are described in, for example, Ansel, Howard C., et al., Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems. Philadelphia: Lippincott, Williams & Wilkins, 2004, including, for example, adjuvants, diluents (e.g., glucose, lactose or mannitol), carriers, pH adjusters, buffers, sweeteners, fillers, stabilizers, surfactants, wetting agents, lubricants, emulsifiers, suspending agents, preservatives, antioxidants, opacifiers, glidants, processing aids, colorants, flavoring agents, flavoring agents, other known additives.
[0210] The pharmaceutical compositions of the present invention can be formulated by techniques known to those skilled in the art, such as those disclosed in Remington's Pharmaceutical Sciences 20th edition.
[0211] The pharmaceutical composition of the present invention can be applied in a standard manner. For example, suitable modes of application include oral, intravenous, rectal, parenteral, topical, transdermal, ophthalmic, nasal, cheek or pulmonary (inhalation) administration, wherein parenteral infusion includes intramuscular, intravenous, intraarterial, intraperitoneal or subcutaneous administration. For these purposes, the compounds of the present invention can be formulated into, for example, tablets, capsules, syrups, powders, granules, aqueous or oily solutions or suspensions, (lipid) emulsions, dispersible powders, suppositories, ointments, creams, drops, aerosols, dry powder preparations and sterile injectable aqueous or oily solutions or suspensions by methods known in the art.
[0212] The size of the preventive or therapeutic dose of the compounds of the present invention will vary according to a series of factors, including the individual treated, the severity of the disease or condition, the rate of administration, the disposal of the compound and the judgment of the prescribing physician. For the treatment of a specific disease, an effective amount is a dose sufficient to improve or alleviate the symptoms associated with the disease. Such a dose can be administered as a single dose, or can be administered according to an effective treatment regimen. In general, the effective dose is about 0.0001 to about 5000 mg per kg body weight per day, for example, about 0.01 to about 1000 mg / kg / day (single or divided administration). For a 70kg person, this will add up to about 0.007 mg / day to about 7000 mg / day, for example, about 0.7 mg / day to about 1500 mg / day. According to the mode of administration, the content or dosage of the compound of the present invention in the pharmaceutical composition can be about 0.01 mg to about 1000 mg, suitably 0.1-500 mg, preferably 0.5-300 mg, more preferably 1-150 mg, particularly preferably 1-50 mg, such as 1.5 mg, 2 mg, 4 mg, 10 mg, 25 mg, etc.; accordingly, the pharmaceutical composition of the present invention will contain 0.05 to 99% w / w (weight percentage), such as 0.05 to 80% w / w, such as 0.10 to 70% w / w, such as 0.10 to 50% w / w of the compound of the present invention, all weight percentages are based on the total composition. It should be understood that it may be necessary to use dosages exceeding these limits in certain circumstances.
[0213] In a specific embodiment, the present invention provides a pharmaceutical composition comprising a compound of the present invention and one or more pharmaceutically acceptable excipients, the composition being formulated for oral administration. The composition can be provided in a unit dosage form, for example in the form of a tablet, capsule or oral liquid preparation. Such a unit dosage form can contain 0.1 mg to 1 g, for example 5 mg to 250 mg of a compound of the present invention as an active ingredient.
[0214] In a specific embodiment, the present invention provides a pharmaceutical composition comprising a compound of the present invention and one or more pharmaceutically acceptable excipients, the composition being formulated for topical administration. Topical administration may be in the form of, for example, a cream, lotion, ointment or transdermal patch, wherein the concentration of the compound of the present invention may be about 0.01 to 100 mg per gram of carrier.
[0215] In a specific embodiment, the present invention provides a pharmaceutical composition comprising a compound of the present invention and one or more pharmaceutically acceptable excipients, the composition being formulated for inhalation administration. Inhalation administration can be by oral inhalation, or by intranasal administration. When administered by oral inhalation, the compound of the present invention can be effectively used in the present invention with a daily dose, for example, up to 500 μg, such as 0.1-50 μg, 0.1-40 μg, 0.1-30 μg, 0.1-20 μg or 0.1-10 μg of the compound of the present invention. The pharmaceutical composition of the present invention for oral inhalation can be formulated into a dry powder, a suspension (in a liquid or gas) or a solution (in a liquid), and can be administered in any suitable form and using any suitable inhaler device known in the art, including, for example, a metered dose inhaler (MDI), a dry powder inhaler (DPI), a nebulizer and a soft mist inhaler. Multi-chamber devices can be used to deliver the compound of the present specification and one or more other active ingredients (when present).
[0216] In a specific embodiment, the pharmaceutical composition of the present invention may further comprise additional therapeutically active ingredients suitable for use in combination with the compounds of the present invention.
[0217] Other therapeutically active ingredients suitable for combined administration with the compounds of the present invention may be known anticancer drugs, in particular other anticancer drugs related to DNA damage and repair mechanisms, including PARP inhibitors, HDAC inhibitors, etc. Other therapeutically active ingredients suitable for combined administration with the compounds of the present invention may also be selected from anticancer drugs related to cell division checkpoints, including ChK1 / 2 inhibitors, CDK4 / 6 inhibitors, ATM / ATR inhibitors. Other known anticancer drugs that can be used in combination include alkylating agents, topoisomerase I / II inhibitors, RNA / DNA anti-metabolites, anti-mitotic agents, antibody drugs, kinase inhibitors, etc. For combined administration, the compounds of the present invention and at least one known anticancer drug may be administered as a single pharmaceutical composition, or may be administered separately, simultaneously or sequentially as separate entities, for example, as a kit.
[0218] The compounds of the present invention can also be administered as bioconjugates. The bioconjugates are composed of the compounds of the present invention and at least one known therapeutically active antibody such as Herceptin or Rituximab, or growth factors such as EGF or FGF, or cytokines such as interleukin 2 or 4, or any molecule that can bind to the cell surface. The antibodies and other molecules can deliver the compounds of the present invention to their target sites to exert their effects, and can also enhance the therapeutic activity of the antibodies or other molecules.
[0219] The compounds of the invention may also be used in combination with radiation therapy, the two being administered at the same or different times.
[0220] The pharmaceutical composition provided by the present invention can be used to prevent or treat the ATR-related diseases defined above in mammals such as human subjects.
[0221] Treatments and uses
[0222] Based on the beneficial effects of the compounds of the present invention, the compounds of the present invention can be used in methods for treating ATR-related diseases in animals, especially mammals such as humans.
[0223] Therefore, in another aspect, the present invention provides a method for modulating, especially inhibiting ATR kinase activity, which method comprises contacting a cell with a compound of the present invention as described above to modulate, especially inhibit the activity of ATR in the cell.
[0224] Based on the same properties, the present invention also provides a method for inhibiting abnormal cell growth in a mammal, comprising administering a therapeutically effective amount of the compound of the present invention, or a pharmaceutical composition comprising the compound of the present invention, to the mammal.
[0225] On the other hand, the present invention provides a method for preventing or treating a disease associated with ATR (e.g., a disease treatable or preventable by ATR inhibition), which comprises administering to an individual in need thereof an effective amount of a compound of the present invention as described above or a pharmaceutical composition of the present invention comprising the same.
[0226] In another aspect, the present invention provides use of the compound of the present invention as described above or a pharmaceutical composition comprising the same for inhibiting ATR activity, or for treating and / or preventing diseases associated with ATR, such as diseases treatable or preventable by ATR inhibition.
[0227] On the other hand, the present invention also provides the use of the above-mentioned compound of the present invention or a pharmaceutical composition comprising the same in the preparation of a drug, especially in a drug having ATR kinase inhibitor activity.
[0228] On the other hand, the present invention provides the use of a compound of the present invention as described above or a pharmaceutical composition comprising the same in the preparation of a medicament for treating or preventing a disease associated with ATR, such as a disease treatable or preventable by ATR kinase inhibition, wherein the compound or pharmaceutical composition is optionally combined with one or more chemotherapies or immunotherapies.
[0229] Preparation method of the compound of the present invention
[0230] The present invention also provides a method for preparing the compound of formula (I), and the following illustrates a general synthetic scheme for synthesizing the compounds of the present invention. For each reaction step, appropriate reaction conditions are known to those skilled in the art or can be routinely determined. If not otherwise specified, the raw materials and reagents used in the preparation of these compounds are generally commercially available, or can be prepared by the following method, a method similar to the method given below, or a method known in the art. If necessary, the raw materials and intermediates in the synthetic reaction flow can be separated and purified using conventional techniques, including but not limited to filtration, distillation, crystallization, chromatography, etc. The materials can be characterized using conventional methods including physical constants and spectral data. Synthetic Scheme 1:
[0231]
[0232] As illustrated in Scheme 1, the compounds of the present invention can be synthesized by a method comprising the following steps:
[0233] Step 1: reacting a compound of formula (I-1) with an amine in the presence of a base such as DIEA in a solvent such as NMP by heating to obtain a compound of formula (I-2);
[0234] Step 2: The compound of formula (I-2) reacts with an amine in the presence of a base such as DIEA and in a solvent such as NMP by heating to obtain a compound of formula (I-3);
[0235] Step 3: The compound of formula (I-3) reacts with an iodination agent such as NIS in a solvent such as ACN at room temperature to obtain a compound of formula (I-4);
[0236] Step 4: The compound of formula (I-4) is subjected to Suzuki coupling in the presence of a coupling agent such as Pd(dtbpf)Cl2 / H3PO4 and heated in a solvent such as dioxane / water to obtain a compound of formula (I-5); and
[0237] Step 5: The compound of formula (I-5) is deprotected under the action of an acid to obtain a compound of formula (I).
[0238] Synthesis Scheme 2:
[0239]
[0240] As illustrated in Scheme 2, the compounds of the present invention can be synthesized by a method comprising the following steps:
[0241] Step 1: The compound of formula (II-1) reacts with an iodination agent such as NIS in the presence of an acid such as TFA in a solvent such as CHCl3 at room temperature to obtain a compound of formula (II-2);
[0242] Step 2: The compound of formula (II-2) reacts with an amine in the presence of a base such as DIEA and in a solvent such as THF by heating to obtain a compound of formula (II-3);
[0243] Step 3: The compound of formula (II-3) is subjected to Suzuki coupling in the presence of a coupling agent such as Pd(dtbpf)Cl2 / H3PO4, heated in a solvent such as dioxane / water or reacted at room temperature to obtain a compound of formula (II-4);
[0244] Step 4: The compound of formula (II-4) reacts with an amine in the presence of a catalyst such as RuPhos-G2, in the presence of a base such as cesium carbonate, and in a solvent such as toluene by heating to obtain a compound of formula (II-5);
[0245] Step 5: Deprotecting the compound of formula (II-5) under the action of an acid such as HCl to obtain a compound of formula (II);
[0246] Synthesis Scheme 3:
[0247]
[0248] Wherein R1, R2, and X are as defined above for general formula (I):
[0249] As illustrated in Scheme 3, the compounds of the present invention can be synthesized by a method comprising the following steps:
[0250] Step 1: heating the compound of formula (III-1) with a chlorination agent such as POCl3 to obtain a compound of formula (III-2);
[0251] Step 2: The compound of formula (III-2) reacts with an amine in the presence of a base such as K2CO3 in a solvent such as DMF at about room temperature to obtain a compound of formula (III-3);
[0252] Step 3: The compound of formula (III-3) reacts with an amine in the presence of a base such as DIEA and in a solvent such as DMF under heating to obtain a compound of formula (III-4);
[0253] Step 4: heating the compound of formula (III-4) with a cyaniding agent such as Zn(CN)2 in the presence of a catalyst such as Pd2(dba)3 / DPPF and in the presence of a solvent such as DMF to obtain a compound of formula (III-5);
[0254] Step 5: The compound of formula (III-5) is subjected to a reduction reaction in the presence of a catalyst such as Raney nickel / ammonia water in a solvent such as MeOH / THF to obtain a compound of formula (III-6);
[0255] Step 6: The compound of formula (III-6) is reacted by condensation reaction in the presence of a condensing agent such as HATU / DIEA in a solvent such as DME to obtain a compound of formula (III-7);
[0256] Step 7: The compound of formula (III-7) is heated in the presence of POCl3, such as at 100-150°C, to close the ring to obtain the compound of formula (III). Synthesis Scheme 4:
[0257]
[0258] As illustrated in Scheme 4, the compounds of the present invention can be synthesized by a method comprising the following steps:
[0259] Step 1: The compound of formula (IV-1) reacts with a formate ester such as ethyl formate in a solvent such as THF at low temperature under the action of a base such as LDA to obtain a compound of formula (IV-2);
[0260] Step 2: reacting the compound of formula (IV-2) with 3-hydrazine-1H-pyrazole in a solvent such as ethanol at room temperature to obtain a compound of formula (IV-3);
[0261] Step 3: The compound of formula (IV-3) undergoes a ring-closure reaction in a solvent such as NMP at an elevated temperature such as reflux to obtain a compound of formula (IV-4);
[0262] Step 4: The compound of formula (IV-4) reacts with an amine in a solvent such as DMSO under heating to obtain a compound of formula (IV-5);
[0263] Step 5: Add a protecting group to the compound of formula (IV-5) using a protecting agent such as DHP / TsOH in a solvent such as DCM at room temperature to obtain a compound of formula (IV-6);
[0264] Step 6: The compound of formula (IV-6) is heated in the presence of a coupling agent such as Pd(dtbpf)Cl2 / CsCO3 in a solvent such as NMP and coupled with an amine to obtain a compound of formula (IV-7);
[0265] Step 7: Deprotecting the compound of formula (IV-7) to obtain the compound of formula (IV).
[0266] The above synthesis schemes only list the preparation methods of some compounds in the present invention. The compounds of the present invention or their stereoisomers, tautomers, stable isotope derivatives, pharmaceutically acceptable salts or solvates can be prepared by various methods, including the methods given above, the methods given in the examples or similar methods, by ordinary technicians in the field on the basis of the above synthesis schemes, combined with conventional techniques in the field, and appropriately modified to obtain. DETAILED DESCRIPTION
[0267] The technical solution of the present invention is further described below in conjunction with specific embodiments, but the protection scope of the present invention is not limited to these embodiments. Any changes or equivalent substitutions that do not deviate from the concept of the present invention are included in the protection scope of the present invention.
[0268] The experimental methods in the following examples where specific conditions are not specified are generally carried out under conventional conditions for such reactions or under conditions recommended by the manufacturer. When the chiral center configuration is not specified in the following examples, it means that it can exist as a single enantiomer or a mixture of enantiomers, and those skilled in the art can determine the stable and feasible isomeric forms of the compound. Unless otherwise specified, percentages and parts are weight percentages and weight parts, respectively. Unless otherwise specified, the ratio of liquids is volume ratio, and the temperatures used in the present invention are all degrees Celsius.
[0269] The experimental materials and reagents used in the following examples can be obtained from commercial channels, prepared according to the methods of the prior art, or prepared according to methods similar to those disclosed in the present application unless otherwise specified. Unless otherwise specified, the raw materials used in the present invention are all commercially available raw materials and can be used directly without further purification. 5,7-dichloropyrazolo[1,5-A]pyrimidine used in the following examples was purchased from Shanghai Haohong Biopharmaceutical Technology Co., Ltd. (Leyan, CAS: 57489-77-7, batch number: Ld102321002), 8-bromo-6-chloroimidazo[1,2-B]pyridazine was purchased from Shaoyuan Technology (Shanghai) Co., Ltd. (CAS: 933190-51-3, batch number: J140-1157-27), and 8-oxa-3-azabicyclo[3.2.1]octane hydrochloride was purchased from Shanghai Bid Pharmaceutical Technology Co., Ltd. (CAS: 54745-74-3, batch number: BGX458).
[0270] The abbreviations used in this application have the meanings commonly understood in the art, unless otherwise clearly defined in the specification. The meanings of the abbreviations used in the specification are listed below:
[0271] <![CDATA[Pd2(dba)3]]> Tris(dibenzylideneacetone)dipalladium <![CDATA[Pd(dtbpf)Cl2]]> Dichloro[1,1'-bis(di-tert-butylphosphino)ferrocenepalladium(II) DPPF 1,1'-Bis(diphenylphosphino)ferrocene RuPhosPdG2 Chloro(2-dicyclohexylphosphino-2',6'-diisopropoxy-1,1'-biphenyl)(2-amino-1,1'-biphenyl-2-yl)palladium(II) HATU 2-(7-Azobenzotriazole)-N,N,N',N',-tetramethyluronium hexafluorophosphate DIEA N,N-Diisopropylethylamine DCM Dichloromethane EA Ethyl acetate PE Petroleum ether NIS N-Iodosuccinimide DMF N,N-Dimethylformamide ACN Acetonitrile DHP 3,4-Dihydro-2H-pyran NMP N-Methylpyrrolidone LC-MS Liquid chromatography-mass spectrometry ESI Electrospray ionization m / z Mass-to-charge ratio HPLC High performance liquid chromatography
[0272] Synthesis Example
[0273] In the preparation method of the target compound provided by the present invention, the column chromatography uses silica gel (300-400 mesh) produced by Rushan Sun Desiccant Co., Ltd.; the thin layer chromatography uses GF254 (0.25 mm); the nuclear magnetic resonance chromatography (NMR) uses a Varian-400 nuclear magnetic resonance instrument for determination; and the liquid chromatography-mass spectrometry (LC / MS) uses an Agilent TechnologiESI 6120 liquid chromatography-mass spectrometer.
[0274] In addition, all operations involving easily oxidized or hydrolyzed raw materials were carried out under nitrogen protection.
[0275] When the structure of a compound of the present invention is inconsistent with the compound name, the structural formula shall prevail unless the compound name can be determined to be correct from the context.
[0276] Example 1: 3-(7-((R)-3-methylmorpholino)-3-(1H-pyrazol-3-yl)pyrazolo[1,5-a]pyrimidine-5- 1-(2-(2-nitrophenyl)-8-oxa-3-azabicyclo[3.2.1]octane
[0277]
[0278] Step 1: Synthesis of (R)-4-(5-chloropyrazolo[1,5-a]pyrimidin-7-yl)-3-methylmorpholine
[0279]
[0280] A solution of 5,7-dichloropyrazolo[1,5-a]pyrimidine (5.0 g, 26.6 mmol), (R)-3-methylmorpholine (8.07 g, 79.8 mmol) and DIEA (10.31 g, 79.8 mmol) in NMP (30.0 mL) was stirred at 100°C for 0.5 hours before the reaction was stopped. The reaction mixture was cooled to room temperature and diluted with DCM (150 mL), washed with saturated brine (30.0 mL × 5), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was separated and purified by column chromatography (PE:EA=3:1-1:2) to obtain the target compound (6.50 g, yield 96.7%, yellow solid). LC-MS (ESI) m / z 253.1[M+H] + . 1 H NMR(400MHz, CDCl3)δ8.01(d,J=2.3Hz,1H),6.50(d,J=2.3Hz,1H),6.04(s,1H),5.22–5.08(m,1H),4.13–3.9 5(m,2H),3.89–3.80(m,1H),3.80–3.75(m,1H),3.74–3.68(m,1H),3.67–3.62(m,1H),1.30(d,J=6.8Hz,3H).
[0281] Step 2: Synthesis of 3-(7-((R)-3-methylmorpholino)pyrazolo[1,5-a]pyrimidin-5-yl)-8-oxa-3-azabicyclo[3.2.1]octane
[0282]
[0283] DIEA (306 mg, 2.37 mmol) was added to a solution of (R)-4-(5-chloropyrazolo[1,5-a]pyrimidin-7-yl)-3-methylmorpholine (200 mg, 0.791 mmol) and 8-oxa-3-azabicyclo[3.2.1]octane hydrochloride (268 mg, 1.79 mmol) in NMP (15.0 mL). The reaction mixture was reacted in a microwave reactor at 140°C under nitrogen protection for 2 hours to stop the reaction. EA (35.0 mL) was then added to the reaction solution, which was washed with saturated brine (30.0 mL×3), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was separated and purified by column chromatography (PE:EA=3:1) to obtain the target compound (120 mg, yield 46.0%, yellow oil). LC-MS (ESI) m / z 330.1 [M+H] + .
[0284] Step 3: Synthesis of 3-(3-iodo-7-((R)-3-methylmorpholino)pyrazolo[1,5-a]pyrimidin-5-yl)-8-oxa-3-azabicyclo[3.2.1]octane
[0285]
[0286] NIS (82 mg, 0.364 mmol) was added to a solution of 3-(7-((R)-3-methylmorpholino)pyrazolo[1,5-a]pyrimidin-5-yl)-8-oxa-3-azabicyclo[3.2.1]octane (120 mg, 0.364 mmol) in acetonitrile (5.00 mL). The reaction mixture was stirred at room temperature for 0.5 hours and the reaction was stopped. Water (10.0 mL) was then added and extracted with EA (20.0 mL×3). The organic phases were combined, washed with saturated brine (20.0 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was separated and purified by column chromatography (PE:EA=3:1) to obtain the target compound (100 mg, yield 60.3%, yellow solid). LC-MS (ESI) m / z 456.0 [M+H] + . 1 H NMR(400MHz, CDCl3)δ7.85(s,1H),5.38(s,1H),5.10(s,1H),4.51(s,2H),4.08–3.91(m,3H),3.90–3.80(m,2H),3.7 4(d,J=11.6Hz,1H),3.68–3.57(m,1H),3.40–3.15(m,3H),2.03–1.96(m,2H),1.93–1.83(m,2H),1.25–1.14(m,3H).
[0287] Step 4: Synthesis of 3-(7-((R)-3-methylmorpholino)-3-(1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)pyrazolo[1,5-a]pyrimidin-5-yl)-8-oxa-3-azabicyclo[3.2.1]octane
[0288]
[0289] Under nitrogen protection, Pd(dtbpf)Cl2 (14.0 mg, 0.0219 mmol) and potassium phosphate (139 mg, 0.658 mmol) were added to a solution of 3-(3-iodo-7-((R)-3-methylmorpholino)pyrazolo[1,5-a]pyrimidin-5-yl)-8-oxa-3-azabicyclo[3.2.1]octane (100 mg, 0.219 mmol) and 1-(tetrahydro-2H-pyran-2-yl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (91.6 mg, 0.329 mmol) in 1,4-dioxane (5.00 mL) and water (1.00 mL). The reaction mixture was stirred at 60°C for 16 hours and then the reaction was stopped. Then water (30.0 mL) was added, and then extracted with EA (20.0 mL × 3). The combined organic phases were washed with saturated brine (25.0 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was separated and purified by column chromatography (PE: EA = 1: 1) to obtain the target compound (100 mg, yield 94.9%, yellow solid). LC-MS (ESI) m / z 480.1 [M+H] + .
[0290] Step 5: Synthesis of 3-(7-((R)-3-methylmorpholino)-3-(1H-pyrazol-3-yl)pyrazolo[1,5-a]pyrimidin-5-yl)-8-oxa-3-azabicyclo[3.2.1]octane
[0291]
[0292] At room temperature, 3-(7-((R)-3-methylmorpholino)-3-(1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)pyrazolo[1,5-a]pyrimidin-5-yl)-8-oxa-3-azabicyclo[3.2.1]octane (100 mg, 0.208 mmol) and hydrochloric acid ethyl acetate solution (5.00 mL, 3 M) were added to the reaction bottle. The reaction mixture was stirred at room temperature for 2 hours and the reaction was stopped. The mixture was concentrated under reduced pressure and the obtained residue was purified by reverse phase preparative chromatography (acetonitrile / water containing 0.05% formic acid) to obtain the target compound (75.8 mg, yield 91.9%, light yellow solid). LC-MS (ESI) m / z 396.2 [M+H]+ . 1 H NMR(400MHz,DMSO-d6)δ12.62(Brs,1H),8.23(s,1H),7.64–7.47(m,1H),6.77–6.63(m,1 H),5.77(s,1H),5.15–5.07(m,1H),4.49–4.44(m,2H),4.19–4.10(m,1H),4.09–4.01(m,1 H),3.96–3.91(m,1H),3.85–3.80(m,1H),3.70–3.63(m,2H),3.57–3.50(m,1H),3.40–3.3 4(m,1H),3.14–3.07(m,2H),1.88–1.81(m,2H),1.79–1.72(m,2H),1.10(d,J=6.8Hz,3H).
[0293] Example 2: 3-(8-((R)-3-methylmorpholino)-3-(1H-pyrazol-3-yl)imidazo[1,2-b]pyridazine-6- 1-(2-(2-nitrophenyl)-8-oxa-3-azabicyclo[3.2.1]octane
[0294]
[0295] Step 1: Synthesis of (8-bromo-6-chloro-3-iodoimidazo[1,2-b]pyridazine
[0296]
[0297] NIS (484 mg, 2.15 mmol) was added to a solution of 8-bromo-6-chloroimidazo[1,2-b]pyridazine (500 mg, 2.15 mmol) in chloroform (10.0 mL) and trifluoroacetic acid (1.00 mL). The reaction mixture was stirred at room temperature for 2 hours to stop the reaction. Saturated sodium bicarbonate solution (25.0 mL) was then added, and the mixture was extracted with EA (30.0 mL × 3). The combined organic phases were washed with saturated brine (20.0 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was separated and purified by column chromatography (PE:EA=5:1) to obtain the target compound (500 mg, yield 64.8%, yellow solid). LC-MS (ESI) m / z 357.7, 359.7 [M+H] + . 1 H NMR (400MHz, CDCl3) δ8.07 (s, 1H), 7.56 (s, 1H).
[0298] Step 2: Synthesis of (R)-4-(6-chloro-3-iodoimidazo[1,2-b]pyridazin-8-yl)-3-methylmorpholine
[0299]
[0300] DIEA (541 mg, 4.19 mmol) was added to a solution of 8-bromo-6-chloro-3-iodoimidazo[1,2-b]pyridazine (500 mg, 1.40 mmol) and (R)-3-methylmorpholine (211 mg, 2.09 mmol) in tetrahydrofuran (10.0 mL). The reaction mixture was stirred at 100 °C for 2 hours under nitrogen protection to stop the reaction. The reaction solution was then added to EA (35.0 mL), washed with saturated brine (35 mL × 3), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was separated and purified by column chromatography (PE:EA=5:1) to obtain the target compound (500 mg, yield 94.6%, yellow oil). LC-MS (ESI) m / z 378.8 [M+H] + .
[0301] Step 3: Synthesis of (3R)-4-(6-chloro-3-(1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)imidazo[1,2-b]pyridazin-8-yl)-3-methylmorpholine
[0302]
[0303] Under nitrogen protection, Pd(dtbpf)Cl2 (67.3 mg, 0.105 mmol) and potassium phosphate (448 mg, 2.11 mmol) were added to a solution of (R)-4-(6-chloro-3-iodoimidazo[1,2-b]pyridazin-8-yl)-3-methylmorpholine (400 mg, 1.06 mmol) and 1-(tetrahydro-2H-pyran-2-yl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (293 mg, 1.06 mmol) in 1,4-dioxane (10.0 mL) and water (2.00 mL). The reaction mixture was stirred at room temperature for 16 hours and the reaction was stopped. Then water (25.0 mL) was added, and then extracted with EA (30.0 mL × 3). The combined organic phases were washed with saturated brine (25.0 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was separated and purified by column chromatography (PE: EA = 1: 1) to obtain the target compound (320 mg, yield 75.1%, yellow solid). LC-MS (ESI) m / z 403.1 [M+H] + .
[0304] Step 4: Synthesis of 3-(8-((R)-3-methylmorpholino)-3-(1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)imidazo[1,2-b]pyridazin-6-yl)-8-oxa-3-azabicyclo[3.2.1]octane
[0305]
[0306] Under nitrogen protection, to a solution of (3R)-4-(6-chloro-3-(1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)imidazo[1,2-b]pyridazin-8-yl)-3-methylmorpholine (300 mg, 0.744 mmol) and RuPhosPdG2 (58.1 mg, 0.0744 mmol) in toluene (15.0 mL) were added cesium carbonate (727 mg, 2.23 mmol) and 8-oxa-3-azabicyclo[3.2.1]octane hydrochloride (168 mg, 1.12 mmol), and the reaction mixture was stirred at 110 ° C for 16 hours to stop the reaction. Then water (25.0 mL) was added, and then extracted with EA (25.0 mL × 3). The combined organic phases were washed with saturated brine (25.0 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was separated and purified by column chromatography (PE: EA = 1: 1) to obtain the target compound (100 mg, yield 28.0%, yellow solid). LC-MS (ESI) m / z 480.2 [M+H] + .
[0307] Step 5: Synthesis of 3-(8-((R)-3-methylmorpholino)-3-(1H-pyrazol-3-yl)imidazo[1,2-b]pyridazin-6-yl)-8-oxa-3-azabicyclo[3.2.1]octane
[0308]
[0309] At room temperature, 3-(8-((R)-3-methylmorpholino)-3-(1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)imidazo[1,2-b]pyridazine-6-yl)-8-oxa-3-azabicyclo[3.2.1]octane (100 mg, 0.208 mmol) and EA solution of hydrochloric acid (10.0 mL, 3 M) were added to the reaction bottle. The reaction mixture was stirred at room temperature for 2 hours and the reaction was stopped. The residue was concentrated under reduced pressure and purified by reverse phase preparative chromatography (acetonitrile / water containing 0.05% formic acid) to obtain the target compound (38.7 mg, yield 47.0%, white solid). LC-MS (ESI) m / z 396.3 [M+H] + . 1H NMR (400MHz, DMSO-d6) δ13.33–12.85(m,1H),7.84–7.72(m,1H),7.14–6.86(m ,1H),5.98(s,1H),5.63–5.33(m,1H),4.51–4.43(m,2H),4.15–3.99(m,1H),4 .00–3.93(m,1H),3.81–3.71(m,4H),3.66–3.57(m,1H),3.39–3.34(m,1H),3. 30–3.25(m,1H),3.07–2.99(m,2H),1.90–1.81(m,4H),1.15(d,J=6.7Hz,3H).
[0310] Example 3: 3-(4-((R)-3-methylmorpholino)-7-(1H-pyrazol-3-yl)imidazo[1,5-b]pyridazine-2-yl 1-(2-(2-nitrophenyl)-8-oxa-3-azabicyclo[3.2.1]octane
[0311]
[0312] Step 1: Synthesis of 4-bromo-3,6-dichloropyridazine
[0313]
[0314] 4-Bromo-1,2-dihydropyridazine-3,6-dione (5.50 g, 28.8 mmol) was dissolved in phosphorus oxychloride (35.0 mL), and the reaction mixture was heated to 100 ° C for 16 hours to stop the reaction. After the reaction solution was cooled to room temperature, it was slowly poured into ice water, and then the pH was adjusted to about 7, and then extracted with EA (100 mL × 3). The organic phase was washed with saturated brine (50.0 mL × 3), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was separated and purified by column chromatography (PE: EA = 20: 1-5: 1) to obtain the target compound (5.00 g, yield 76.2%, light yellow solid). LC-MS (ESI) m / z 227.0 [M + H] + .
[0315] Step 2: Synthesis of (R)-4-(3,6-dichloropyridazin-4-yl)-3-methylmorpholine
[0316]
[0317] Potassium carbonate (6.59 g, 47.7 mmol) was added to a DMF (37.0 mL) solution of 4-bromo-3,6-dichloropyridazine (2.73 g, 12.0 mmol) and (R)-3-methylmorpholine (2.40 g, 23.7 mmol). The reaction mixture was stirred at 30°C for 16 hours under nitrogen protection, and then the reaction was stopped. Water (45.0 mL) was added, and then extracted with EA (60.0 mL × 3). The organic phase was washed with saturated brine (45.0 mL × 3), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was separated and purified by column chromatography (PE: EA = 5: 1-2: 1) to obtain the target compound (2.36 g, yield 79.4%, white solid). LC-MS (ESI) m / z 248.1 [M+H] + .
[0318] Step 3: Synthesis of 3-(6-chloro-5-((R)-3-methylmorpholino)pyridazin-3-yl)-8-oxa-3-azabicyclo[3.2.1]octane
[0319]
[0320] DIEA (2.26 g, 17.5 mmol) was added to a solution of (R)-4-(3,6-dichloropyridazin-4-yl)-3-methylmorpholine (1.44 g, 5.80 mmol) and 8-oxa-3-azabicyclo[3.2.1]octane hydrochloride (1.30 g, 8.68 mmol) in NMP (26.0 mL). The reaction mixture was stirred at 145°C for 16 hours and then the reaction was stopped. After the reaction mixture was cooled to room temperature, water (25.0 mL) was added and extracted with EA (30.0 mL×2). The organic phase was washed with saturated brine (25.0 mL×3), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was separated and purified by column chromatography (PE:EA=5:1-1:1) to obtain the target compound (1.50 g, yield 79.6%, brown solid). LC-MS (ESI) m / z 325.2 [M+H] + .
[0321] Step 4: Synthesis of 6-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-4-((R)-3-methylmorpholino)pyridazine-3-carbonitrile
[0322]
[0323] Zinc cyanide (1.08 g, 9.18 mmol), DPPF (510 mg, 0.918 mmol) and Pd2(dba)3 (421 mg, 0.459 mmol) were added to a mixed solution of 3-(6-chloro-5-((R)-3-methylmorpholino)pyridazin-3-yl)-8-oxa-3-azabicyclo[3.2.1]octane (1.49 g, 4.59 mmol) in water (8 drops) and DMF (40.0 mL) in sequence. The reaction mixture was stirred at 145°C overnight under nitrogen protection, and then the reaction was stopped. After the reaction solution was cooled to room temperature, water (30.0 mL) was added, and then extracted with EA (35.0 mL × 3). The organic phase was washed with saturated brine (30.0 mL × 3) and dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The obtained residue was separated and purified by column chromatography (PE: EA = 5: 1-1: 2) to obtain the target compound (1.10 g, yield 76.0%, brown solid). LC-MS (ESI) m / z 316.3 [M + H] + .
[0324] Step 5: Synthesis of (6-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-4-((R)-3-methylmorpholino)pyridazin-3-yl)methanamine
[0325]
[0326] Ammonia (5.00 mL) and Raney nickel (~1.15 g) were added to a solution of 6-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-4-((R)-3-methylmorpholino)pyridazine-3-carbonitrile (1.03 g, 3.27 mmol) in tetrahydrofuran (30.0 mL) in sequence. After hydrogen replacement three times, the reaction mixture was reacted at room temperature under a hydrogen atmosphere overnight to stop the reaction. The reaction mixture was filtered to remove the solid residue, and the filtrate was concentrated under reduced pressure to obtain the target compound (1.00 g, yield 95.9%, brown solid). LC-MS (ESI) m / z 320.3 [M+H] + Step 6: Synthesis of N-((6-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-4-((R)-3-methylmorpholino)pyridazin-3-yl)methyl)-1H-pyrazole 5-carboxamide
[0327]
[0328] To a solution of (6-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-4-((R)-3-methylmorpholino)pyridazin-3-yl)methanamine (1.20 g, 3.74 mmol) and 1H-pyrazole-5-carboxylic acid (505 mg, 4.49 mmol) in DMF (28.0 mL) were added HATU (2.85 g, 7.48 mmol) and DIEA (1.19 g, 9.35 mmol), and the reaction mixture was reacted at room temperature for 4 hours, and the reaction was stopped. The reaction mixture was diluted with water (15.0 mL), then extracted with DCM: methanol = 10: 1 (20.0 mL × 3), the organic phases were combined, washed with saturated brine (15.0 mL × 4), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The resulting residue was separated and purified by column chromatography (DCM: methanol = 50: 1-10: 1) to obtain the target compound (660 mg, yield 42.7%, white solid). LC-MS (ESI) m / z 414.2 [M+H] + .
[0329] Step 7: Synthesis of 3-(4-((R)-3-methylmorpholino)-7-(1H-pyrazol-3-yl)imidazo[1,5-b]pyridazin-2-yl)-8-oxa-3-azabicyclo[3.2.1]octane
[0330]
[0331] N-((6-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-4-((R)-3-methylmorpholino)pyridazin-3-yl)methyl)-1H-pyrazole 5-carboxamide (660 mg, 1.60 mmol) was dissolved in phosphorus oxychloride (23.0 mL) solution. The reaction mixture was reacted at 145°C for 3 hours and then the reaction was stopped. After the reaction solution was cooled to room temperature, the reaction solution was concentrated under reduced pressure to remove excess phosphorus oxychloride. The resulting residue was separated and purified by reverse phase preparative chromatography (acetonitrile / water containing 0.05% formic acid) to obtain the target compound (36.8 mg, yield 5.83%, white solid). LC-MS (ESI) m / z 396.3 [M+H] + . 1H NMR(400MHz,DMSO-d6)δ13.22(brs,1H),7.76–7.54(m,2H),7.11-7.04(m,1H),5.79(s,1H),4.50–4.42(m,2H),4.38–4.30(m,1H),3.99–3.92(m ,1H),3.85–3.75(m,3H),3.74–3.68(m,1H),3.65–3.57(m,1H),3.50–3. 38(m,2H),3.11–3.00(m,2H),1.90–1.78(m,4H),1.15(d,J=6.6Hz,3H).
[0332] Example 4: 3-(3-chloro-4-((R)-3-methylmorpholino)-7-(1H-pyrazol-3-yl)imidazo[1,5-b]pyridazin-2-yl)-8-oxa-3-nitrogen Heterobicyclo[3.2.1]octane
[0333]
[0334] Phosphorus oxychloride (25.0 mL) was added to a solution of N-((6-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-4-((R)-3-methylmorpholino)pyridazin-3-yl)methyl)-1H-pyrazole 5-carboxamide (6.50 g, 15.72 mmol) in acetonitrile (100 mL). The reaction mixture was reacted at 90° C. for 1.5 hours and then the reaction was stopped. After the reaction mixture was cooled to room temperature, the reaction solution was slowly added dropwise to a saturated sodium bicarbonate solution at 0°C, and then the pH was adjusted to 9 with a saturated sodium bicarbonate solution at 0°C, and then extracted with EA (200mL×3), the combined organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was separated and purified by two reverse phase preparative chromatography (acetonitrile / water containing 0.05% ammonia water) and (acetonitrile / water containing 0.05% formic acid) to obtain the target compound (1.50 g, yield 22.2%, green solid). LC-MS (ESI) m / z 430.2 [M+H] + . 1H NMR(400MHz,MeOD-d4)δ7.74(s,1H),7.64(s,1H),7.17(s,1H),4.50–4.40( m,2H),4.10–4.01(m,1H),4.00–3.91(m,2H),3.84–3.71(m,3H),3.66–3.60 (m,1H),3.42–3.35(m,2H),3.34-3.32(m,1H),2.97(d,J=11.8Hz,1H),2.38 –2.31(m,1H),2.16–2.08(m,1H),2.01–1.91(m,2H),1.23(d,J=6.5Hz,3H).
[0335] Example 5: 3-(4-((R)-3-methylmorpholino)-1-(1H-pyrazol-3-yl)-1H-pyrazolo[3,4-b]pyridine- 6-yl)-8-oxa-3-azabicyclo[3.2.1]octane
[0336]
[0337] Synthesis of Intermediate 3-Hydrazino-1H-pyrazole
[0338]
[0339] 3-Aminopyrazole (1.00 g, 12.0 mmol) was added to a 6 mol / L aqueous hydrochloric acid solution (7 mL), the mixture was cooled to -5 °C, a 1 mol / L aqueous sodium nitrite solution (12 mL, 12.0 mmol) was added to the reaction mixture, and the reaction solution was stirred at room temperature for 2 hours. A concentrated hydrochloric acid solution (24 mL) of stannous chloride dihydrate (5.43 g, 24.1 mmol) was added to the reaction mixture, the reaction solution was stirred at room temperature for 1 hour, and then concentrated under reduced pressure to obtain a crude product of the target compound (9.00 g, crude product, bright yellow solid).
[0340] Step 1: Synthesis of 2,6-difluoro-4-iodo-3-pyridinecarboxaldehyde
[0341]
[0342] 2,6-difluoro-4-iodopyridine (5.00 g, 20.7 mmol) was added to a three-necked flask containing anhydrous tetrahydrofuran (75 mL). The resulting mixture was cooled to -78°C under nitrogen protection, and lithium diisopropylamide (2 mol / L tetrahydrofuran solution) (12.5 mL, 24.9 mmol) was added. After stirring for 1 hour, ethyl formate (2.31 g, 31.1 mmol) was slowly added. After continuing to stir at -78°C for 30 minutes, TLC spot plate detection showed that the raw material reaction was complete. Formic acid (1.91 g, 41.5 mmol) was added to the reaction solution. After stirring at -78°C for 10 minutes, EA (25 mL) was added, and then the temperature was raised to 0°C and water (30 mL) was added. The stirring was stopped and additional EA (25 mL) was added for extraction. The product was washed with saturated brine and dried over anhydrous sodium sulfate. The solvent was removed under reduced pressure and the residue was purified by silica gel column separation (PE:EA=5:1) to obtain the target compound (3.54 g, yield 63.4%, yellow solid).
[0343] Step 2: Synthesis of 3-((2-(1H-pyrazol-3-yl)hydrazine)methyl)-2,6-difluoro-4-iodopyridine
[0344]
[0345] 2,6-difluoro-4-iodo-3-pyridinecarboxaldehyde (1.00 g, 3.72 mmol) and 3-hydrazino-1H-pyrazole (9.00 g, crude product) were added to 95% ethanol aqueous solution (20 mL). The resulting mixture was stirred at room temperature for 3 hours under nitrogen protection, and the solvent was removed under reduced pressure. EA (30 mL) was added to the residue and stirred evenly. Saturated sodium bicarbonate solution was slowly added to the stirred suspension and stirred vigorously to make the mixture alkaline. After stirring for 15 minutes, it was extracted with EA, washed with saturated brine, dried over anhydrous sodium sulfate, and purified by silica gel column separation (PE: EA = 1: 2) after reduced pressure distillation to obtain the target compound (1.40 g, crude product, yellow solid). LC-MS (ESI) m / z: 349.9 [M + H] + .
[0346] Step 3: Synthesis of 6-fluoro-4-iodo-1-(1H-pyrazol-3-yl)-1H-pyrazolo[3,4-b]pyridine
[0347]
[0348] 3-((2-(1H-pyrazol-3-yl)hydrazine)methyl)-2,6-difluoro-4-iodopyridine (1.40 g, 4.01 mmol) was dissolved in NMP (19 mL). The reaction mixture was stirred under heating reflux for 1 hour. After the reaction was completed, the reaction mixture was added dropwise to water (50 mL) to precipitate a brown solid. The mixed solution was stirred at room temperature for 10 minutes and then cooled to 0°C. Stirring was continued for 10 minutes. The suspension was filtered with a suction funnel to collect the solid. The aqueous phase was extracted with EA (10 mL × 2). The combined organic phases were washed with saturated brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure to obtain a crude product. The target compound (838 mg, two-step yield 68.5%, brown solid) was obtained by separation and purification on a preparative plate (silica gel, EA:PE=1:1). LC-MS (ESI) m / z: 329.9 [M+H] + . 1 H NMR (400MHz, DMSO-d6) δ13.09(s,1H),8.27(s,1H),7.93(t,J=2.0Hz,1H),7.68(d,J=1.2Hz,1H),6.66(t,J=2.2Hz,1H).
[0349] Step 4: Synthesis of 3-(4-iodo-1-(1H-pyrazol-3-yl)-1H-pyrazolo[3,4-b]pyridin-6-yl)-8-oxa-3-azabicyclo[3.2.1]octane
[0350]
[0351] 6-Fluoro-4-iodo-1-(1H-pyrazol-3-yl)-1H-pyrazolo[3,4-b]pyridine (538 mg, 1.63 mmol) was dissolved in dimethyl sulfoxide (3 mL). The resulting mixture was stirred at room temperature under nitrogen protection, and 8-oxa-3-azabicyclo[3.2.1]octane hydrochloride (367 mg, 2.45 mmol) was added. The reaction solution was heated to 120°C and stirred for 45 minutes. After the reaction was completed by LC-MS monitoring, the reaction mixture was added dropwise to water (30 mL) to precipitate a brown-yellow solid. The mixed solution was stirred at room temperature for 10 minutes and then cooled to 0°C. Stirring was continued for 10 minutes. The suspension was filtered with a suction funnel to collect the solid, and the aqueous phase was extracted with EA (10 mL×2). The residue was separated and purified by silica gel column (PE:EA=1:2) to obtain the target compound (300 mg, yield 43.5%, yellow solid). LC-MS (ESI) m / z: 423.0 [M+H] + .
[0352] Step 5: Synthesis of 3-(4-iodo-1-(1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-1H-pyrazolo[3,4-b]pyridin-6-yl)-8-oxa-3-azabicyclo[3.2.1]octane
[0353]
[0354] 3-(4-iodo-1-(1H-pyrazol-3-yl)-1H-pyrazolo[3,4-b]pyridin-6-yl)-8-oxa-3-azabicyclo[3.2.1]octane (300 mg, 0.711 mmol), DHP (120 mg, 1.42 mmol), p-toluenesulfonic acid monohydrate (14 mg, 0.071 mmol) were added to DCM (5 mL) in sequence. The reaction mixture was stirred at room temperature for 16 hours. After the reaction was completed by LC-MS monitoring, water (10 mL) was added to the reaction mixture and extracted with EA (10 mL×2). The combined organic phases were washed with saturated brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure to obtain a crude product. The target compound (330 mg, yield 91.7%, colorless oil) was obtained by separation and purification on a preparative plate (silica gel, EA:PE=1:2). LC-MS (ESI) m / z 507.0 [M+H] + .
[0355] Step 6: Synthesis of 3-(4-((R)-3-methylmorpholino)-1-(1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-1H-pyrazolo[3,4-b]pyridin-6-yl)-8-oxa-3-azabicyclo[3.2.1]octane
[0356]
[0357] 3-(4-iodo-1-(1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-1H-pyrazolo[3,4-b]pyridin-6-yl)-8-oxa-3-azabicyclo[3.2.1]octane (160 mg, 0.316 mmol), (R)-3-methylmorpholine (64 mg, 0.632 mmol), RuPhosPdG2 (25 mg, 0.032 mmol), cesium carbonate (309 mg, 0.948 mmol) were added to NMP (2 mL). The resulting mixture was stirred at 110 ° C for 2 hours under nitrogen protection. After the reaction was completed by LC-MS monitoring, water (10 mL) was added to the reaction mixture and extracted with EA (10 mL×2). The combined organic phases were washed with saturated brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure to obtain a crude product, which was separated and purified by silica gel column (PE:EA=1:2) to obtain the target compound (110 mg, yield 72.6%, colorless oil). LC-MS (ESI) m / z: 480.2 [M+H] + .
[0358] Step 7: Synthesis of 3-(4-((R)-3-methylmorpholino)-1-(1H-pyrazol-3-yl)-1H-pyrazolo[3,4-b]pyridin-6-yl)-8-oxa-3-azabicyclo[3.2.1]octane
[0359]
[0360] 4 mol / L hydrochloric acid 1,4-dioxane solution (2 mL) was added to a solution of 3-(4-((R)-3-methylmorpholino)-1-(1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-1H-pyrazolo[3,4-b]pyridin-6-yl)-8-oxa-3-azabicyclo[3.2.1]octane (110 mg, 2.4 mmol) in methanol (2 mL). The resulting mixture was stirred at room temperature for 2 hours under nitrogen protection, the solvent was removed under reduced pressure, and the residue was separated and purified by prep-HPLC column to obtain the target compound (12.2 mg, yield 13.4%, white solid). LC-MS (ESI) m / z: 396.2 [M+H] + . 1H NMR(400MHz, DMSO-d6)δ8.20(s,1H),7.80(d,J=2.3Hz,1H),6.80(d,J=2.2Hz,1H),5.82(s,1H),4.52–4.42(m,2H),4.42–4.26(m,1H),4.01–3.84 (m,3H),3.80–3.69(m,2H),3.65–3.55(m,2H),3.39–3.27(m,1H),3.07–2 .97(m,2H),1.87–1.79(m,2H),1.80–1.70(m,2H),1.16(d,J=6.6Hz,3H).
[0361] Example 6: 3-(4-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-7-(1H-pyrazol-3-yl)imidazole [1,5-b]pyridazin-2-yl)-8-oxa-3-azabicyclo[3.2.1]octane
[0362]
[0363] Step 1: Synthesis of 3-(3,6-dichloropyridazin-4-yl)-8-oxa-3-azabicyclo[3.2.1]octane
[0364]
[0365] Potassium carbonate (1.21 g, 8.78 mmol) was added to a DMF (15.0 mL) solution of 4-bromo-3,6-dichloropyridazine (1.00 g, 4.39 mmol) and 8-oxa-3-azabicyclo[3.2.1]octane hydrochloride (745 mg, 4.98 mmol). The reaction mixture was stirred at room temperature for 16 hours under nitrogen protection to stop the reaction. The reaction solution was then added to EA (35.0 mL), washed with saturated brine (35.0 mL × 3), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was separated and purified by column chromatography (PE: EA = 5: 1) to obtain the target compound (700 mg, yield 61.3%, yellow oil). LC-MS (ESI) m / z 260.1 [M+H] + Step 2: Synthesis of 3-(6-(8-oxa-3-azabicyclo[3.2.1]octane-3-yl)-3-chloropyridin-4-yl)-8-oxa-3-azabicyclo[3.2.1]octane
[0366]
[0367] DIEA (1.04 g, 8.07 mmol) was added to a solution of 3-(3,6-dichloropyridazin-4-yl)-8-oxa-3-azabicyclo[3.2.1]octane (700 mg, 2.69 mmol) and 8-oxa-3-azabicyclo[3.2.1]octane hydrochloride (609 mg, 4.07 mmol) in NMP (15.0 mL). The reaction mixture was stirred at 145°C for 16 hours under nitrogen protection to stop the reaction. The reaction solution was then added to EA (35.0 mL), washed with saturated brine (25.0 mL×3), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was separated and purified by column chromatography (PE:EA=1:1) to obtain the target compound (550 mg, yield 60.7%, yellow solid). LC-MS(ESI)m / z 337.0[M+H] + .
[0368] Step 3: Synthesis of 4-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-6-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)pyridazine-3-carbonitrile
[0369]
[0370] DPPF (181 mg, 0.326 mmol) and Pd2(dba)3 (149 mg, 0.163 mmol) were added to a DMF (10.0 mL) solution of 3-(6-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-3-chloropyridin-4-yl)-8-oxa-3-azabicyclo[3.2.1]octane (550 mg, 1.63 mmol) and zinc cyanide (383 mg, 3.27 mmol). The reaction mixture was stirred at 140°C for 16 hours under nitrogen protection to stop the reaction. The reaction solution was then washed with EA (25.0 mL), saturated brine (20.0 mL×3), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was separated and purified by column chromatography (PE:EA=1:1) to obtain the target compound (350 mg, yield 65.5%, yellow solid). LC-MS (ESI) m / z 328.2 [M+H] + .
[0371] Step 4: Synthesis of (4-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-6-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)pyridazin-3-yl)methanamine
[0372]
[0373] To a solution of 4-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-6-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)pyridazine-3-carbonitrile (350 mg, 1.07 mmol) in tetrahydrofuran (10.0 mL) was added Raney nickel (~314 mg, 5.35 mmol). The reaction mixture was reacted at room temperature under hydrogen atmosphere for 16 hours, and the reaction was stopped. The reaction solution was then filtered and concentrated under reduced pressure. The residue obtained was the target compound (300 mg, yield 84.7%, yellow oil). LC-MS (ESI) m / z 332.2 [M+H] + .
[0374] Step 5: Synthesis of N-((4-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-6-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)pyridazin-3-yl)methyl)-1H-pyrazole-5-carboxamide
[0375]
[0376] HATU (413 mg, 1.09 mmol) and DIEA (351 mg, 2.72 mmol) were added to a solution of (4-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-6-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)pyridazin-3-yl)methylamine (300 mg, 0.905 mmol) and 1H-pyrazole-5-carboxylic acid (101 mg, 0.905 mmol) in tetrahydrofuran (10.0 mL). The reaction mixture was reacted at room temperature for 1 hour to stop the reaction. The reaction solution was then filtered and concentrated under reduced pressure. The residue was separated and purified by column chromatography (PE:EA=0:1) to obtain the target compound (200 mg, yield 51.9%, yellow oil). LC-MS (ESI) m / z 426.0 [M+H] + . 1 H NMR (400MHz, DMSO-d6) δ13.27(s,1H),8.30(s,1H),7.83(s,1H),6.65(s,1H),6.46(s,1H),4.60(d,J=5.1Hz,2H), 4.46–4.37(m,4H),3.93–3.86(m,2H),3.00–2.96(m,6H),2.05–2.02(m,2H),1.89–1.80(m,4H),1.76–1.73(m,2H).
[0377] Step 6: Synthesis of 3-(4-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-7-(1H-pyrazol-3-yl)imidazo[1,5-b]pyridazin-2-yl)-8-oxa-3-azabicyclo[3.2.1]octane
[0378]
[0379] N-((4-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-6-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)pyridazin-3-yl)methyl)-1H-pyrazole-5-carboxamide (200 mg, 0.470 mmol) and phosphorus oxychloride (10.0 mL) were added to the reaction bottle at room temperature. The reaction mixture was reacted at 100°C for 1 hour to stop the reaction. The reaction solution was slowly added to a saturated sodium bicarbonate aqueous solution and the pH was adjusted to 7 with a saturated sodium bicarbonate aqueous solution. The mixture was then extracted with EA (20.0 mL×3). The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by reverse phase preparative chromatography (acetonitrile / water containing 0.05% formic acid) to obtain the target compound (21.3 mg, yield 11.1%, white solid). LC-MS (ESI) m / z 408.3 [M+H] + . 1 H NMR (400MHz, DMSO-d6) δ13.39–12.85(s,1H),7.72–7.55(m,2H),7.07(d,J=1.6Hz,1H),5.72(s,1H) ),4.49-4.42(m,4H),3.81–3.71(m,4H),3.23–3.19(m,2H),3.07–3.01(m,2H),1.91–1.80(m,8H).
[0380] Example 7: 3-(4-morpholino-7-(1 H -pyrazol-3-yl)imidazo[1,5-b]pyridazin-2-yl)-8-oxa-3- Azabicyclo[3.2.1]octane
[0381]
[0382] Step 1: Synthesis of 4-(3,6-dichloropyridazin-4-yl)morpholine
[0383]
[0384] Potassium carbonate (1.69 g, 12.3 mmol) was added to a DMF (15.0 mL) solution of 4-bromo-3,6-dichloropyridazine (700 mg, 3.07 mmol) and morpholine (535 mg, 6.14 mmol). The reaction mixture was stirred at 30°C for 12 hours under nitrogen protection, and then the reaction was stopped. Water (10.0 mL) was added, and then extracted with EA (15.0 mL × 3). The organic phase was washed with saturated brine (15.0 mL × 4), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was separated and purified by column chromatography (PE: EA = 5: 1-1: 1) to obtain the target compound (700 mg, yield 97.3%, white solid). LC-MS (ESI) m / z 234.0 [M+H] + .
[0385] Step 2: Synthesis of 3-(6-chloro-5-morpholinopyridin-3-yl)-8-oxa-3-azabicyclo[3.2.1]octane
[0386]
[0387] DIEA (1.16 g, 8.97 mmol) was added to a solution of 4-(3,6-dichloropyridazin-4-yl)morpholine (700 mg, 2.99 mmol) and 8-oxa-3-azabicyclo[3.2.1]octane hydrochloride (671 mg, 4.49 mmol) in NMP (10.0 mL). The reaction mixture was stirred at 145°C for 16 hours and then the reaction was stopped. After the reaction mixture was cooled to room temperature, water (15.0 mL) was added and extracted with EA (20.0 mL×3). The organic phases were combined, washed with water (15.0 mL×2) and saturated brine (15.0 mL×3), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was separated and purified by column chromatography (PE:EA=3:1-1:2) to obtain the target compound (800 mg, yield 86.1%, white solid). LC-MS (ESI) m / z 311.2 [M+H] + .
[0388] Step 3: Synthesis of 6-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-4-morpholinopyridazine-3-carbonitrile
[0389]
[0390] Zinc cyanide (453 mg, 3.86 mmol), DPPF (214 mg, 0.386 mmol) and Pd2(dba)3 (177 mg, 0.193 mmol) were added to a mixed solution of 3-(6-chloro-5-morpholinopyridazine-3-yl)-8-oxa-3-azabicyclo[3.2.1]octane (600 mg, 1.93 mmol) in water (5 drops) and DMF (10.0 mL) in sequence. The reaction mixture was stirred at 145°C for 16 hours under nitrogen protection, and then the reaction was stopped. After the reaction solution was cooled to room temperature, water (15.0 mL) was added, and then extracted with EA (20.0 mL × 3). The combined organic phases were washed with water (15.0 mL × 2) and saturated brine (10.0 mL × 2), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The obtained residue was separated and purified by column chromatography (PE: EA = 5: 1-1: 3) to obtain the target compound (360 mg, yield 61.9%, brown solid). LC-MS (ESI) m / z 302.3 [M + H] + .
[0391] Step 4: Synthesis of (6-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-4-morpholinopyridazin-3-yl)methanamine
[0392]
[0393] Ammonia (2.00 mL) and Raney nickel (~300 mg) were added to a solution of 6-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-4-morpholinopyridazine-3-carbonitrile (360 mg, 1.19 mmol) in tetrahydrofuran (20.0 mL) in sequence. After hydrogen replacement three times, the reaction mixture was reacted at room temperature overnight under a hydrogen atmosphere to stop the reaction. The reaction mixture was filtered to remove the solid residue, and the filtrate was concentrated under reduced pressure to obtain the target compound (320 mg, yield 87.7%, brown solid). LC-MS (ESI) m / z 306.1 [M+H] + .
[0394] Step 5: Synthesis of N-((6-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-4-morpholinopyridazin-3-yl)methyl)-1H-pyrazole-5-carboxamide
[0395]
[0396] HATU (599 mg, 1.58 mmol) and DIEA (271 mg, 2.10 mmol) were added to a solution of (6-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-4-morpholinopyridazin-3-yl)methylamine (320 mg, 1.05 mmol) and 1H-pyrazole-5-carboxylic acid (118 mg, 1.05 mmol) in tetrahydrofuran (13.0 mL). The reaction mixture was reacted at room temperature for 2 hours and the reaction was stopped. The reaction mixture was concentrated under reduced pressure and the obtained residue was separated and purified by column chromatography (DCM: methanol = 100: 1-30: 1) to obtain the target compound (170 mg, yield 40.6%, brown solid). LC-MS (ESI) m / z 400.3 [M+H] + .
[0397] Step 6: Synthesis of 3-(3-chloro-4-morpholino-7-(1H-pyrazol-3-yl)imidazo[1,5-b]pyridazin-2-yl)-8-oxa-3-azabicyclo[3.2.1]octane
[0398]
[0399] Phosphorus oxychloride (1.00 mL) was added to a solution of N-((6-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-4-morpholinopyridin-3-yl)methyl)-1H-pyrazole-5-carboxamide (170 mg, 0.426 mmol) in acetonitrile (4.00 mL). The reaction mixture was reacted at 90°C for 1 hour, and then the reaction was stopped. After the reaction mixture was cooled to room temperature, the reaction solution was slowly added dropwise to a saturated sodium bicarbonate solution at 0°C, and then the pH was adjusted to 9 with a saturated sodium bicarbonate solution at 0°C, and then extracted with EA (15.0 mL×3). The combined organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was separated and purified on a silica gel plate (DCM: methanol = 20:1) to obtain the target compound (80.0 mg, yield 45.2%, yellow solid). LC-MS (ESI) m / z 416.1 [M+H] + .
[0400] Step 7: Synthesis of 3-(4-morpholino-7-(1H-pyrazol-3-yl)imidazo[1,5-b]pyridazin-2-yl)-8-oxa-3-azabicyclo[3.2.1]octane
[0401]
[0402] Palladium carbon (50.0 mg) was added to a mixed solution of 3-(3-chloro-4-morpholino-7-(1H-pyrazol-3-yl)imidazo[1,5-b]pyridazine-2-yl)-8-oxa-3-azabicyclo[3.2.1]octane (80.0 mg, 0.192 mmol) in methanol (3.00 mL) and tetrahydrofuran (3.00 mL). After hydrogen replacement three times, the reaction mixture was reacted at 50°C under a hydrogen atmosphere overnight and the reaction was stopped. The reaction mixture was filtered to remove the solid residue, and the filtrate was concentrated under reduced pressure. The obtained residue was separated and purified by reverse phase preparative chromatography (acetonitrile / water containing 0.05% formic acid) to obtain the target compound (4.60 mg, yield 6.27%, white solid). LC-MS (ESI) m / z 382.1 [M+H] + . 1 H NMR(400MHz,MeOD-d4)δ7.83–7.64(m,1H),7.60–7.43(m,1H),7.25–7.02(m,1H),5.84(s,1H), 4.55-4.45(m,2H),3.94-3.79(m,6H),3.51-3.43(m,4H),3.23-3.14(m,2H),2.03-1.93(m,4H).
[0403] Example 8: 8-(2-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-7-(1H-pyrazol-3-yl)imidazole [1,5-b]pyridazin-4-yl)-3-oxa-8-azabicyclo[3.2.1]octane
[0404]
[0405] Step 1: Synthesis of 8-(3,6-dichloropyridazin-4-yl)-3-oxa-8-azabicyclo[3.2.1]octane
[0406]
[0407] Potassium carbonate (1.82 g, 13.2 mmol) was added to a DMF (15.0 mL) solution of 4-bromo-3,6-dichloropyridazine (1.00 g, 4.39 mmol) and 3-oxa-8-azabicyclo[3.2.1]octane hydrochloride (985 mg, 6.58 mmol). The reaction mixture was stirred at room temperature for 16 hours under nitrogen protection to stop the reaction. The reaction solution was then diluted with EA (45.0 mL), washed with saturated brine (35.0 mL × 3), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was separated and purified by column chromatography (PE: EA = 5: 1) to obtain the target compound (1.00 g, yield 87.6%, yellow oil). LC-MS (ESI) m / z 259.9 [M+H] + ,261.9[M+2+H] + . 1H NMR (400MHz, CDCl3) δ6.72(s,1H),4.44–4.33(m,2H),3.91–3.82(m,2H),3.72–3.62(m,2H),2.21–2.12(m,2H),2.06–1.95(m,2H).
[0408] Step 2: Synthesis of 8-(6-(8-oxa-3-azabicyclo[3.2.1]octane-3-yl)-3-chloropyridazin-4-yl)-3-oxa-8-azabicyclo[3.2.1]octane
[0409]
[0410] DIEA (1.49 g, 11.5 mmol) was added to a solution of 8-(3,6-dichloropyridazin-4-yl)-3-oxa-8-azabicyclo[3.2.1]octane (1.00 g, 3.84 mmol) and 8-oxa-3-azabicyclo[3.2.1]octane hydrochloride (1.15 g, 7.69 mmol) in NMP (15.0 mL). The reaction mixture was stirred at 145°C for 16 hours under nitrogen protection to stop the reaction. The reaction solution was then diluted with EA (45.0 mL), washed with saturated brine (35.0 mL×3), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was separated and purified by column chromatography (PE:EA=1:1) to obtain the target compound (770 mg, yield 59.5%, yellow solid). LC-MS(ESI)m / z 337.0[M+H] + .
[0411] Step 3: Synthesis of 6-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-4-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)pyridazine-3-carbonitrile
[0412]
[0413] DPPF (247 mg, 0.445 mmol) and Pd2(dba)3 (204 mg, 0.222 mmol) were added to a DMF (15.0 mL) solution of 8-(6-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-3-chloropyridazin-4-yl)-3-oxa-8-azabicyclo[3.2.1]octane (750 mg, 2.23 mmol) and zinc cyanide (523 mg, 4.45 mmol). The reaction mixture was stirred at 140°C for 16 hours under nitrogen protection to stop the reaction. The reaction solution was then diluted with EA (35.0 mL), washed with saturated brine (30.0 mL×3), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was separated and purified by column chromatography (PE:EA=1:1) to obtain the target compound (600 mg, yield 82.3%, yellow solid). LC-MS (ESI) m / z 328.0 [M+H] + .
[0414] Step 4: Synthesis of (6-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-4-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)pyridazin-3-yl)methanamine
[0415]
[0416] To a solution of 6-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-4-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)pyridazine-3-carbonitrile (600 mg, 1.83 mmol) in tetrahydrofuran (10.0 mL) was added Raney nickel (~323 mg, 5.50 mmol). The reaction mixture was reacted at room temperature for 16 hours under a hydrogen atmosphere, and the reaction was stopped. The reaction solution was then filtered and concentrated under reduced pressure. The residue obtained was the target compound (480 mg, yield 79.0%, yellow oil). LC-MS (ESI) m / z 332.1 [M+H] + .
[0417] Step 5: Synthesis of N-((6-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-4-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)pyridazin-3-yl)methyl)-1H-pyrazole-5-carboxamide
[0418]
[0419] HATU (661 mg, 1.74 mmol) and DIEA (562 mg, 4.34 mmol) were added to a solution of (6-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-4-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)pyridazin-3-yl)methanamine (480 mg, 1.45 mmol) and 1H-pyrazole-5-carboxylic acid (146 mg, 1.30 mmol) in tetrahydrofuran (10.0 mL). The reaction mixture was reacted at room temperature for 1 hour to stop the reaction. The reaction solution was then filtered and concentrated under reduced pressure. The residue was separated and purified by column chromatography (PE:EA=0:1) to obtain the target compound (400 mg, yield 64.9%, yellow oil). LC-MS (ESI) m / z 426.0 [M+H] + .
[0420] Step 6: Synthesis of 8-(2-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-7-(1H-pyrazol-3-yl)imidazo[1,5-b]pyridazin-4-yl)-3-oxa-8-azabicyclo[3.2.1]octane
[0421]
[0422] At room temperature, N-((6-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-4-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)pyridazin-3-yl)methyl)-1H-pyrazole-5-carboxamide (100 mg, 0.235 mmol) and phosphorus oxychloride (5.00 mL) were added to the reaction bottle. The reaction mixture was reacted at 100°C for 1 hour to stop the reaction. The reaction solution was added to a saturated sodium bicarbonate aqueous solution under ice bath until pH = 7, and then the mixture was extracted with EA (20.0 mL×3), the organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by reverse phase preparative chromatography (acetonitrile / water containing 0.05% formic acid) to obtain the target compound (10.5 mg, yield 11.0%, white solid). LC-MS (ESI) m / z 408.3 [M+H] + . 1 HNMR(400MHz,MeOD-d4)δ7.70(s,1H),7.58(s,1H),7.13(s,1H),5.78(s,1H),4.56–4.48(m,4H) ,3.90–3.80(m,4H),3.67–3.61(m,2H),3.23–3.14(m,2H),2.18–2.09(m,4H),2.01–1.94(m,4H).
[0423] Example 9: 3-(4-((R)-2-methylpiperazin-1-yl)-7-(1H-pyrazol-3-yl)imidazo[1,5-b]pyridazine- 2-yl)-8-oxa-3-azabicyclo[3.2.1]octanecarboxylate
[0424]
[0425] Step 1: Synthesis of (R)-tert-butyl 4-(3,6-dichloropyridazin-4-yl)-3-methylpiperazine-1-carboxylate
[0426]
[0427] Potassium carbonate (2.43 g, 17.6 mmol) was added to a DMF (25.0 mL) solution of 4-bromo-3,6-dichloropyridazine (2.00 g, 8.78 mmol) and (R)-3-methylpiperazine-1-carboxylic acid tert-butyl ester (2.64 g, 13.2 mmol). The reaction mixture was stirred at room temperature under nitrogen protection for 16 hours to stop the reaction. The reaction solution was then diluted with EA (55.0 mL), washed with saturated brine (35.0 mL × 3), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was separated and purified by column chromatography (PE: EA = 5: 1) to obtain the target compound (1.60 g, yield 52.5%, yellow solid). LC-MS (ESI) m / z 346.9 [M+H] + . 1 H NMR (400MHz, CDCl3) δ6.83 (s, 1H), 4.25–4.08 (m, 2H), 3.89–3.79 (m, 1H), 3.46–3.28 (m, 2H), 3.23–3.02 (m, 2H), 1.48 (s, 9H), 1.12 (d, J = 6.6Hz, 3H).
[0428] Step 2: Synthesis of tert-butyl (3R)-4-(6-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-3-chloropyridazin-4-yl)-3-methylpiperazine-1-carboxylate
[0429]
[0430] DIEA (1.79 g, 13.8 mmol) was added to a solution of (R)-4-(3,6-dichloropyridazin-4-yl)-3-methylpiperazine-1-carboxylic acid tert-butyl ester (1.60 g, 4.61 mmol) and 8-oxa-3-azabicyclo[3.2.1]octane hydrochloride (1.38 g, 9.22 mmol) in NMP (15.0 mL). The reaction mixture was stirred at 145°C for 16 hours under nitrogen protection to stop the reaction. The reaction solution was then diluted with EA (55.0 mL), washed with saturated brine (35.0 mL×3), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was separated and purified by column chromatography (PE:EA=1:1) to obtain the target compound (1.20 g, yield 61.4%, yellow solid). LC-MS(ESI)m / z 424.2[M+H] + . 1 H NMR(400MHz, CDCl3)δ6.11(s,1H),4.54–4.49(m,2H),4.14–3.93(m,2H),3.86–3.81(m,1H),3.77–3.65(m,2H),3.44–3.3 1(m,2H),3.26–3.10(m,3H),2.90–2.84(m,1H),2.03–1.95(m,2H),1.90–1.82(m,2H),1.48(s,9H),1.02(d,J=6.5Hz,3H).
[0431] Step 3: Synthesis of tert-butyl (3R)-4-(6-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-3-cyanopyridazin-4-yl)-3-methylpiperazine-1-carboxylate
[0432]
[0433] DPPF (314 mg, 0.556 mmol) and Pd2(dba)3 (259 mg, 0.283 mmol) were added to a solution of (3R)-4-(6-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-3-chloropyrazin-4-yl)-3-methylpiperazine-1-carboxylic acid tert-butyl ester (1.20 g, 2.83 mmol) and zinc cyanide (665 mg, 5.66 mmol) in DMF (20.0 mL). The reaction mixture was stirred at 140°C for 16 hours under nitrogen protection to stop the reaction. The reaction solution was then diluted with EA (45.0 mL), washed with saturated brine (30.0 mL×3), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was separated and purified by column chromatography (PE:EA=1:1) to obtain the target compound (1.00 g, yield 85.2%, yellow solid). LC-MS (ESI) m / z 415.0 [M+H] + .
[0434] Step 4: Synthesis of tert-butyl (3R)-4-(3-(aminomethyl)-6-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)pyridazin-4-yl)-3-methylpiperazine-1-carboxylate
[0435]
[0436] To a solution of (3R)-4-(6-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-3-cyanopyridazin-4-yl)-3-methylpiperazine-1-carboxylic acid tert-butyl ester (500 mg, 1.21 mmol) in tetrahydrofuran (10.0 mL) was added Raney nickel (~212 mg, 3.62 mmol). The reaction mixture was reacted at room temperature for 16 hours under a hydrogen atmosphere to stop the reaction. The reaction solution was then filtered and concentrated under reduced pressure to obtain the target compound (400 mg, yield 79.2%, yellow oil). LC-MS (ESI) m / z 419.1 [M+H] + .
[0437] Step 5: Synthesis of tert-butyl (3R)-4-(3-((1H-pyrazole-5-carboxamido)methyl)-6-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)pyridazin-4-yl)-3-methylpiperazine-1-carboxylate
[0438]
[0439] HATU (436 mg, 1.15 mmol) and DIEA (371 mg, 2.87 mmol) were added to a solution of (3R)-4-(3-(aminomethyl)-6-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)pyridazin-4-yl)-3-methylpiperazine-1-carboxylic acid tert-butyl ester (400 mg, 0.956 mmol) and 1H-pyrazole-5-carboxylic acid (96.4 mg, 0.860 mmol) in tetrahydrofuran (10.0 mL). The reaction mixture was reacted at room temperature for 1 hour to stop the reaction. The reaction solution was then filtered and concentrated under reduced pressure. The residue was separated and purified by column chromatography (PE:EA=0:1) to obtain the target compound (300 mg, yield 61.2%, yellow oil). LC-MS (ESI) m / z 513.1 [M+H] + .
[0440] Step 6: Synthesis of 3-(4-((R)-2-methylpiperazin-1-yl)-7-(1H-pyrazol-3-yl)imidazo[1,5-b]pyridazin-2-yl)-8-oxa-3-azabicyclo[3.2.1]octanecarboxylate
[0441]
[0442] At room temperature, (3R)-4-(3-((1H-pyrazole-5-carboxamide)methyl)-6-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)pyridazin-4-yl)-3-methylpiperazine-1-carboxylic acid tert-butyl ester (100 mg, 0.195 mmol) and phosphorus oxychloride (5.00 mL) were added to the reaction bottle. The reaction mixture was reacted at 100°C for 1 hour to stop the reaction. The reaction solution was added to a saturated sodium bicarbonate aqueous solution under ice bath until pH = 7, and then the mixture was extracted with EA (20.0 mL×3), the organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by reverse phase preparative chromatography (acetonitrile / water containing 0.05% formic acid) to obtain the target compound (8.50 mg, yield 11.0%, white solid). LC-MS (ESI) m / z 395.3 [M+H] + . 1H NMR(400MHz,MeOD-d4)δ7.72(s,1H),7.59(s,1H),7.14(s,1H),5.93(s,1H),4.54–4.49(m,2H),3.93–3.86(m,4H),3 .84–3.81(m,1H),3.73–3.59(m,2H),3.53–3.44(m,2H),3.23–3.17(m,2H),2.01–1.93(m,4H),1.32(d,J=6.9Hz,3H).
[0443] Example 10: 3-(4-(piperazin-1-yl)-7-(1H-pyrazol-3-yl)imidazo[1,5-b]pyridazin-2-yl)-8- Oxa-3-azabicyclo[3.2.1]octane formate
[0444]
[0445] Step 1: Synthesis of tert-butyl 4-(3,6-dichloropyridazin-4-yl)piperazine-1-carboxylate
[0446]
[0447] Potassium carbonate (1.82 g, 13.2 mmol) was added to a DMF solution (12.0 mL) of 4-bromo-3,6-dichloropyridazine (1.00 g, 4.39 mmol) and tert-butylpiperazine-1-carboxylate (1.23 g, 6.58 mmol). The reaction mixture was stirred at room temperature for 16 hours to stop the reaction. Water (35.0 mL) was then added, and the mixture was extracted with EA (30.0 mL × 3). The combined organic phases were washed with saturated brine (30.0 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was separated and purified by column chromatography (PE:EA=5:1) to obtain the target compound (1.50 g, yield 100%, yellow solid). LC-MS (ESI) m / z 334.5 [M+2+H] + .
[0448] Step 2: Synthesis of tert-butyl 4-(6-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-3-chloropyridazin-4-yl)piperazine-1-carboxylate
[0449]
[0450] DIEA (1.72 g, 13.3 mmol) was added to a solution (20.0 mL) of tert-butyl 4-(3,6-dichloropyridazin-4-yl)piperazine-1-carboxylate (1.48 g, 4.44 mmol) and 8-oxa-3-azabicyclo[3.2.1]octane hydrochloride (997 mg, 6.66 mmol) in NMP. The reaction mixture was stirred at 145°C for 16 hours to stop the reaction. Water (35.0 mL) was then added, and the mixture was extracted with EA (30.0 mL×3). The combined organic phases were washed with saturated brine (30.0 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was separated and purified by chromatography (PE:EA=5:1) to obtain the target compound (1.20 g, yield 65.9%, yellow solid). LC-MS (ESI) m / z 410 [M+H] + .
[0451] Step 3: Synthesis of tert-butyl 4-(6-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-3-cyanopyridazin-4-yl)piperazine-1-carboxylate
[0452]
[0453] DPPF (297 mg, 0.537 mmol) and Pd2(dba)3 (246 mg, 0.268 mmol) were added to a DMF (20.0 mL) solution of tert-butyl 4-(6-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-3-chloropyridazine-4-yl)piperazine-1-carboxylate (1.10 g, 2.68 mmol) and zinc cyanide (630 mg, 5.37 mmol). The reaction mixture was stirred at 140°C for 16 hours under nitrogen protection to stop the reaction. The reaction solution was then diluted with EA (30.0 mL), washed with saturated brine (25.0 mL×3), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was separated and purified by column chromatography (PE:EA=1:1) to obtain the target compound (600 mg, yield 55.8%, yellow solid). LC-MS (ESI) m / z 401.1 [M+H] + . 1 H NMR(400MHz, CDCl3)δ5.89(s,1H),4.54–4.50(m,2H),4.01–3.93(m,2H),3.64–3. 61(m,4H),3.35–3.26(m,6H),2.04–1.99(m,2H),1.85–1.79(m,2H),1.48(s,9H).
[0454] Step 4: Synthesis of tert-butyl 4-(3-(aminomethyl)-6-(8-oxa-3-azabicyclo[3.2.1]oct-3-yl)pyridazin-4-yl)piperazine-1-carboxylate
[0455]
[0456] To a solution of tert-butyl 4-(6-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-3-cyanopyridazin-4-yl)piperazine-1-carboxylate (600 mg, 1.50 mmol) in tetrahydrofuran (12.0 mL) was added Raney nickel (439 mg, 7.49 mmol) and aqueous ammonia (5 drops). The reaction mixture was reacted at room temperature for 16 hours under a hydrogen atmosphere, and the reaction was stopped. The reaction solution was then filtered and concentrated under reduced pressure. The residue obtained was the target compound (530 mg, yield 87.5%, yellow oil). LC-MS (ESI) m / z 405.1 [M+H] + .
[0457] Step 5: Synthesis of tert-butyl 4-(3-((1H-pyrazole-5-carboxamido)methyl)-6-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)pyridazin-4-yl)piperazine-1-carboxylate
[0458]
[0459] Under nitrogen protection, HATU (541 mg, 1.42 mmol) and DIEA (306 mg, 2.37 mmol) were added to a tetrahydrofuran solution (10.0 mL) of tert-butyl 4-(3-(aminomethyl)-6-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)pyridazin-4-yl)piperazine-1-carboxylate (480 mg, 1.19 mmol) and 1H-pyrazole-5-carboxylic acid (119 mg, 1.07 mmol), and the reaction mixture was stirred at room temperature for 1 hour to stop the reaction. Then water (25.0 mL) was added, and then extracted with EA (20.0 mL×3). The combined organic phases were washed with saturated brine (20.0 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was separated and purified by chromatography (DCM: methanol = 10:1) to obtain the target compound (500 mg, yield 84.5%, yellow solid). LC-MS (ESI) m / z 499.2 [M+H] + .
[0460] Step 6: Synthesis of 3-(4-(piperazin-1-yl)-7-(1H-pyrazol-3-yl)imidazo[1,5-b]pyridazin-2-yl)-8-oxa-3-azabicyclo[3.2.1]octanecarboxylate
[0461]
[0462] 4-(3-((1H-pyrazole-5-carboxamide)methyl)-6-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)pyridazin-4-yl)piperazine-1-carboxylic acid tert-butyl ester (150 mg, 0.301 mmol) and phosphorus oxychloride (15.0 mL) were added to the reaction bottle at room temperature. The reaction mixture was reacted at 100°C for 1 hour to stop the reaction. The reaction solution was added to a saturated sodium bicarbonate aqueous solution under ice bath until pH = 7, and then the mixture was extracted with EA (25.0 mL × 3), the organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The obtained residue was purified by reverse phase preparative chromatography (acetonitrile / water containing 0.05% formic acid) to obtain the target compound (5.66 mg, yield 4.94%, white solid). LC-MS (ESI) m / z 381.0 [M+H] + . 1 H NMR(400MHz,MeOD-d4)δ7.72(s,1H),7.55(s,1H),7.14(s,1H),5.94(s,1H),4.53–4.48(m,2H), 3.88–3.82(m,2H),3.70–3.63(m,4H),3.41–3.36(m,4H),3.23–3.17(m,2H),2.01–1.92(m,4H).
[0463] Example 11: 3-(4-((R)-2,4-dimethylpiperazin-1-yl)-7-(1H-pyrazol-3-yl)imidazo[1,5-b] Pyridazin-2-yl)-8-oxa-3-azabicyclo[3.2.1]octanecarboxylate
[0464]
[0465] Step 1: Synthesis of 6-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-4-((R)-2-methylpiperazin-1-yl)pyridazine-3-carbonitrile
[0466]
[0467] At room temperature, (3R)-4-(6-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-3-cyanopyridazin-4-yl)-3-methylpiperazine-1-carboxylic acid tert-butyl ester (500 mg, 1.21 mmol) and EA hydrochloride (10.0 mL, 3 M) were added to the reaction bottle. The reaction mixture was stirred at room temperature for 2 hours to stop the reaction. The mixture was concentrated under reduced pressure to obtain the target compound (400 mg, yield 94.5%, white solid). LC-MS (ESI) m / z 315.1 [M+H] + .
[0468] Step 2: Synthesis of 6-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-4-((R)-2,4-dimethylpiperazin-1-yl)pyridazine-3-carbonitrile
[0469]
[0470] Sodium borohydride (115 mg, 3.82 mmol) was added to a solution of 6-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-4-((R)-2-methylpiperazin-1-yl)pyridazine-3-carbonitrile (400 mg, 1.27 mmol) and paraformaldehyde (144 mg, 3.82 mmol) in methanol (10.0 mL). The reaction mixture was stirred at room temperature for 1 hour to stop the reaction. Water (20.0 mL) was then added, and the mixture was extracted with EA (20.0 mL×3). The combined organic phases were washed with saturated brine (20.0 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was separated and purified by column chromatography (PE:EA=1:1) to obtain the target compound (400 mg, yield 95.7%, white solid). LC-MS (ESI) m / z 329.2 [M+H] + .
[0471] Step 3: Synthesis of (6-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-4-((R)-2,4-dimethylpiperazin-1-yl)pyridazin-3-yl)methanamine
[0472]
[0473] To a solution of 6-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-4-((R)-2,4-dimethylpiperazin-1-yl)pyridazine-3-carbonitrile (400 mg, 1.22 mmol) in tetrahydrofuran (10.0 mL) was added Raney nickel (214 mg, 3.65 mmol). The reaction mixture was reacted at room temperature for 16 hours under a hydrogen atmosphere, and the reaction was stopped. The reaction solution was then filtered and concentrated under reduced pressure. The residue obtained was the target compound (300 mg, yield 74.1%, yellow oil). LC-MS (ESI) m / z 333.1 [M+H] + .
[0474] Step 4: Synthesis of N-((6-(8-oxy-3-azabicyclo[3.2.1]octan-3-yl)-4-((R)-2,4-dimethylpiperazin-1-yl)pyrazin-3-yl)methyl)-1H-pyrazole-5-carboxamide
[0475]
[0476] HATU (412 mg, 1.08 mmol) and DIEA (350 mg, 2.71 mmol) were added to a solution of (6-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-4-((R)-2,4-dimethylpiperazin-1-yl)pyridazin-3-yl)methanamine (300 mg, 0.902 mmol) and 1H-pyrazole-5-carboxylic acid (91.0 mg, 0.812 mmol) in tetrahydrofuran (10.0 mL). The reaction mixture was reacted at room temperature for 1 hour to stop the reaction. The reaction solution was then filtered and concentrated under reduced pressure. The residue was separated and purified by column chromatography (EA = 100%) to obtain the target compound (200 mg, yield 51.9%, yellow oil). LC-MS (ESI) m / z 427.2 [M+H] + .
[0477] Step 5: Synthesis of 3-(3-chloro-4-((R)-2,4-dimethylpiperazin-1-yl)-7-(1H-pyrazol-3-yl)imidazo[1,5-b]pyridazin-2-yl)-8-oxa-3-azabicyclo[3.2.1]octane
[0478]
[0479] N-((6-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-4-((R)-2,4-dimethylpiperazin-1-yl)pyrazin-3-yl)methyl)-1H-pyrazole-5-carboxamide (100 mg, 0.234 mmol) and phosphorus oxychloride (5.00 mL) were added to the reaction bottle at room temperature. The reaction mixture was reacted at 100°C for 1 hour to stop the reaction. Under ice bath, the reaction solution was added to saturated sodium bicarbonate aqueous solution until pH = 7, and then the mixture was extracted with EA (20.0 mL×3), the organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue obtained was the target compound (100 mg, yield 96.3%, white solid). LC-MS (ESI) m / z 443.3 [M+H] + .
[0480] Step 6: Synthesis of 3-(4-((R)-2,4-dimethylpiperazin-1-yl)-7-(1H-pyrazol-3-yl)imidazo[1,5-b]pyridazin-2-yl)-8-oxa-3-azabicyclo[3.2.1]octanecarboxylate
[0481]
[0482] Palladium on carbon (53.5 mg, 5%) was added to a solution of 3-(3-chloro-4-((R)-2,4-dimethylpiperazin-1-yl)-7-(1H-pyrazol-3-yl)imidazo[1,5-b]pyridazin-2-yl)-8-oxa-3-azabicyclo[3.2.1]octane (100 mg, 0.226 mmol) in methanol (10.0 mL). The reaction mixture was reacted at 60°C for 16 hours under a hydrogen atmosphere to stop the reaction. The reaction solution was then filtered and concentrated under reduced pressure. The resulting residue was purified by reverse phase preparative chromatography (acetonitrile / water containing 0.05% formic acid) to obtain the target compound (12.5 mg, yield 13.6%, white solid). LC-MS (ESI) m / z 409.3 [M+H] + . 1 H NMR(400MHz,MeOD-d4)δ7.72(s,1H),7.63–7.44(m,1H),7.26–6.99(m,1H),5.84(s,1H),4.52–4.49(m,2H),3.95–3.75(m,3H),3.63–3.49( m,2H),3.22–3.11(m,3H),3.06–2.98(m,1H),2.81–2.73(m,1H),2.62–2.54(m,1H),2.52(s,3H),2.00–1.91(m,4H),1.28(d,J=6.4Hz,3H).
[0483] Example 12: 3-(6-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-1-(1H-pyrazol-3-yl)- 1H-pyrazolo[3,4-b]pyridin-4-yl)-8-oxa-3-azabicyclo[3.2.1]octane
[0484]
[0485] Synthesis of Intermediate 6-fluoro-4-iodo-1-(1H-pyrazol-3-yl)-1H-pyrazolo[3,4-b]pyridine Reference Example 5
[0486] Step 1: Synthesis of 3-(4-iodo-1-(1H-pyrazol-3-yl)-1H-pyrazolo[3,4-b]pyridin-6-yl)-8-oxa-3-azabicyclo[3.2.1]octane
[0487]
[0488] 6-Fluoro-4-iodo-1-(1H-pyrazol-3-yl)-1H-pyrazolo[3,4-b]pyridine (718 mg, 2.18 mmol) was dissolved in dimethyl sulfoxide (7 mL). The resulting mixture was stirred at room temperature under nitrogen protection, 8-oxa-3-azabicyclo[3.2.1]octane hydrochloride (326 mg, 2.18 mmol) was added, the reaction solution was heated to 120°C and stirred for 45 minutes, and after the reaction was completed by LC-MS monitoring, the reaction mixture was added dropwise to water (30 mL) to precipitate a brown-yellow solid, the mixed solution was stirred at room temperature for 10 minutes and then cooled to 0°C, and continued to stir for 10 minutes, the suspension was filtered with a suction funnel, the solid was collected, and the aqueous phase was extracted with EA (10 mL×2), and the crude product was separated and purified by silica gel column (PE:EA=1:2) to obtain the target compound (215 mg, yield 23.3%, yellow solid). LC-MS (ESI) m / z: 423.0 [M+H] + .
[0489] Step 2: Synthesis of 3-(4-iodo-1-(1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-1H-pyrazolo[3,4-b]pyridin-6-yl)-8-oxa-3-azabicyclo[3.2.1]octane
[0490]
[0491] 3-(4-iodo-1-(1H-pyrazol-3-yl)-1H-pyrazolo[3,4-b]pyridin-6-yl)-8-oxa-3-azabicyclo[3.2.1]octane (215 mg, 0.509 mmol), DHP (86 mg, 1.02 mmol), p-toluenesulfonic acid monohydrate (10 mg, 0.051 mmol) were added to DCM (2 mL) in sequence. The reaction mixture was stirred at room temperature for overnight reaction. After the reaction was completed by LC-MS monitoring, water (5 mL) was added to the reaction mixture and extracted with EA (10 mL×2). The combined organic phases were washed with saturated brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure to obtain a crude product. The target compound (210 mg, yield 81.4%, yellow solid) was obtained by separation and purification on a preparative plate (silica gel, EA:PE=1:2). LC-MS (ESI) m / z: 507.1 [M+H] + .
[0492] Step 3: Synthesis of 3-(6-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-1-(1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-1H-pyrazolyl[3,4-b]pyridin-4-yl)-8-oxa-3-azabicyclo[3.2.1]octane
[0493]
[0494] 3-(4-iodo-1-(1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-1H-pyrazolo[3,4-b]pyridin-6-yl)-8-oxa-3-azabicyclo[3.2.1]octane (210 mg, 0.415 mmol), 8-oxa-3-azabicyclo[3.2.1]octane hydrochloride (124 mg, 0.829 mmol), RuPhosPdG2 (32 mg, 0.042 mmol), cesium carbonate (405 mg, 1.24 mmol) were added to 1,4-dioxane (2 mL). The resulting mixture was stirred at 110 °C for 2 hours under nitrogen protection. After the reaction was completed by LC-MS monitoring, water (10 mL) was added to the reaction mixture and extracted with EA (10 mL×2). The combined organic phases were washed with saturated brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure to obtain a crude product, which was separated and purified by silica gel column (PE:EA=1:1) to obtain the target compound (55 mg, yield 27.0%, brown oil). LC-MS (ESI) m / z: 492.2 [M+H] + .
[0495] Step 4: Synthesis of 3-(6-(8-oxa-3-azabicyclo[3.2.1]octane-3-yl)-1-(1H-pyrazol-3-yl)-1H-pyrazolo[3,4-b]pyridin-4-yl)-8-oxa-3-azabicyclo[3.2.1]octane
[0496]
[0497] 4 mol / L hydrochloric acid 1,4-dioxane solution (2 mL) was added to a solution of 3-(6-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-1-(1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-1H-pyrazolyl[3,4-b]pyridin-4-yl)-8-oxa-3-azabicyclo[3.2.1]octane (55 mg, 0.112 mmol) in methanol (2 mL). The resulting mixture was stirred at room temperature for 2 hours under nitrogen protection, the solvent was removed under reduced pressure, and the residue was separated and purified by prep-HPLC preparation column to obtain the target compound (3.3 mg, yield 7.24%, white solid). LC-MS (ESI) m / z: 408.2 [M+H] + . 1H NMR (400MHz, MeOD) δ8.31-8.23(m,1H),7.90-7.77(m,1H),6.80(s,1H),4.63–4.49(m,4H),3.92(d,J=12.2Hz,2H ),3.81(d,J=11.9Hz,2H),3.48(d,J=11.8Hz,2H),3.35(d,J=12.0Hz,2H),2.09–1.99(m,4H),1.99–1.89(m,4H).
[0498] Example 13: 3-(7-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-1-methyl-3-(1H-pyrazole- 3-yl)-1H-pyrazolo[4,3- b ]pyridin-5-yl)-8-oxa-3-azabicyclo[3.2.1]octane
[0499]
[0500] Synthesis of Intermediate 1-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)ethan-1-one
[0501]
[0502] 8-Oxa-3-azabicyclo[3.2.1]octane hydrochloride (3.20 g, 32.6 mmol) was added to a DCM solution (60 mL), and the mixture was cooled to 0°C. Potassium carbonate (28.2 g, 204 mmol) was added to the reaction mixture. The reaction mixture was stirred at 0°C for 30 minutes, and acetyl chloride (8 mL, 114 mmol) was added to the reaction mixture. After the reaction mixture was stirred at room temperature for 16 hours, the reaction was completed as monitored by TLC spot plate (EA:PE=1:1, phosphomolybdic acid color development). After the solid was removed by suction, the mixture was concentrated under reduced pressure to obtain the target compound (3.50 g, crude product, yellow oil).
[0503] Step 1: Synthesis of methyl 4-amino-1-methyl-1H-pyrazole-5-carboxylate
[0504]
[0505] 1-Methyl-4-nitro-1H-pyrazole-5-carboxylic acid methyl ester (5.00 g, 27.0 mmol) was added to methanol (200 mL), and 10% palladium carbon (100 mg) was added to the reaction mixture. After the reaction solution was replaced with hydrogen three times, it was stirred at room temperature in a hydrogen atmosphere to react overnight. LC-MS monitored the completion of the reaction, and the filtrate was filtered through diatomaceous earth. The filtrate was concentrated under reduced pressure to obtain the crude target compound (4.50 g, crude product, blue-purple solid). LC-MS (ESI) m / z: 156.2 [M+H] + .
[0506] Step 2: Synthesis of methyl 4-((1-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)ethylidene)amino)-1-methyl-1H-pyrazole-5-carboxylate
[0507]
[0508] 4-Amino-1-methyl-1H-pyrazole-5-carboxylic acid methyl ester (3.48 g, 22.4 mmol) was added to 1,2-dichloroethane solution (35 mL), the mixture was cooled to 0°C, 1-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)ethane-1-one (3.48 g, 22.4 mmol) was added to the reaction mixture, the reaction mixture was stirred at 0°C for 10 minutes, phosphorus oxychloride (6.25 mL, 67.3 mmol) was added to the reaction mixture, the reaction mixture was stirred at 80°C for 0.5 hours, LC-MS monitored the completion of the reaction, the mixture was concentrated under reduced pressure and separated by silica gel column (PE:EA=1:1), and the target compound (3.56 g, yield 54.3%, yellow oil) was obtained. LC-MS (ESI) m / z: 293.1 [M+H] + .
[0509] Step 3: Synthesis of 5-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-1-methyl-1H-pyrazolo[4,3-b]pyridin-7-ol
[0510]
[0511] Dissolve 4-((1-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)ethylidene)amino)-1-methyl-1H-pyrazole-5-carboxylic acid methyl ester (3.56 g, 12.2 mmol) in DMF (70 mL), and slowly add 1M lithium bistrimethylsilylamide tetrahydrofuran solution (36.5 mL) at 0°C. The resulting mixture was stirred at 0°C for 1 hour under nitrogen protection. After LC-MS monitoring of the reaction, an appropriate amount of ammonium chloride aqueous solution was added to quench the reaction. After reduced pressure distillation, the reaction was separated and purified on a silica gel column (DCM:MeOH=20:1-10:1) to obtain the target compound (2.16 g, yield 68.1%, yellow oil). LC-MS (ESI) m / z: 261.2 [M+H] + .
[0512] Step 4: Preparation of 3-(7-chloro-1-methyl-1H-pyrazolo[4,3-b]pyridin-5-yl)-8-oxa-3-azabicyclo[3.2.1]octane
[0513]
[0514] 5-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-1-methyl-1H-pyrazolo[4,3-b]pyridine-7-ol (2.16 g, 8.30 mmol) was dissolved in acetonitrile (22 mL). After stirring at room temperature for half an hour, phosphorus oxychloride (2.3 mL, 24.9 mmol) was added to the reaction mixture, and the reaction was stirred at 80 ° C overnight. After the reaction was completed, the reaction mixture was dried and purified by silica gel column separation (silica gel, EA: PE = 1: 2) to obtain the target compound (2.28 g, yield 98.6%, yellow solid). LC-MS (ESI) m / z: 279.1 [M + H] + . 1 H NMR(400MHz,DMSO-d6)δ7.89(s,1H),7.10(s,1H),4.43-4.39(m,2H),4.17(s,3H),3 .82(d,J=12.2Hz,2H),2.95(d,J=12.2Hz,2H),1.85–1.76(m,2H),1.79–1.69(m,2H).
[0515] Step 5: Synthesis of 3-(7-(8-oxa-3-azabicyclo[3.2.1]octane-3-yl)-1-methyl-1H-pyrazolo[4,3-b]pyridin-5-yl)-8-oxa-3-azabicyclo[3.2.1]octane
[0516]
[0517] 3-(7-chloro-1-methyl-1H-pyrazolo[4,3-b]pyridin-5-yl)-8-oxa-3-azabicyclo[3.2.1]octane (1.20 g, 4.50 mmol) was dissolved in N-methylpyrrolidone (5 mL), and 8-oxabicyclo[3.2.1]octane 8-oxa-3-azabicyclo[3.2.1]octane hydrochloride (537 mg, 3.59 mmol), RuphosPdG2 (139 mg, 0.179 mmol), and cesium carbonate (1.75 g, 5.38 mmol) were added. The resulting mixture was stirred at 110°C for 2 hours under nitrogen protection. After the reaction was completed under LC-MS monitoring, the reaction mixture was added into water (50 mL), the aqueous phase was extracted with EA (20 mL×2), and washed with saturated brine (10 mL). The organic phase was dried and purified by silica gel column separation (DCM: MeOH = 20: 1) to obtain the target compound (245 mg, yield 38.4%, brown solid). LC-MS (ESI) m / z: 356.2 [M+H] + . 1H NMR (400MHz, DMSO-d6) δ7.78(s,1H),6.43(s,1H),4.46–4.30(m,4H),4.15(s,3H),3.79(d,J=12.1Hz,2H),3.10(d,J= 11.4Hz,2H),2.99(d,J=11.4Hz,2H),2.90(d,J=11.7Hz,2H),2.13–2.03(m,2H),1.94–1.86(m,2H),1.83–1.71(m,4H).
[0518] Step 6: Synthesis of 3-(7-(8-oxa-3-azabicyclo[3.2.1]octane-3-yl)-3-bromo-1-methyl-1H-pyrazolo[4,3-b]pyridin-5-yl)-8-oxa-3-azabicyclo[3.2.1]octane
[0519]
[0520] 3-(7-(8-oxa-3-azabicyclo[3.2.1]octane-3-yl)-1-methyl-1H-pyrazolo[4,3-b]pyridin-5-yl)-8-oxa-3-azabicyclo[3.2.1]octane (95 mg, 0.267 mmol) was dissolved in DCM (5 mL). N-bromosuccinimide (48 mg, 0.267 mmol) was added to the reaction mixture under nitrogen protection, and the reaction solution was stirred at room temperature for 10 minutes. After the reaction was completed by LC-MS monitoring, water (5 mL) was added to the reaction mixture and extracted with DCM (5 mL×3). The combined organic phases were washed with saturated brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure to obtain a crude product. The target compound 3-(7-(8-oxa-3-azabicyclo[3.2.1]octane-3-yl)-3-bromo-1-methyl-1H-pyrazolo[4,3-b]pyridin-5-yl)-8-oxa-3-azabicyclo[3.2.1]octane (67 mg, yield 57.7%, yellow solid) was separated and purified on a preparative silica gel plate (EA:PE=1:2). LC-MS (ESI) m / z: 434.1 [M+H] + . 1 H NMR(400MHz,DMSO-d6)δ6.49(s,1H),4.46–4.36(m,4H),4.12(s,3H),3.87(d,J=12.3Hz,2H),3.1 0(d,J=11.5Hz,2H),3.04–2.89(m,4H),2.11–2.02(m,2H),1.97–1.85(m,2H),1.83–1.71(m,4H).
[0521] Step 7: Synthesis of 3-(7-(8-oxa-3-azabicyclo[3.2.1]octyl)-1-methyl-3-(1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-1H-pyrazolyl[4,3-b]pyridin-5-yl)-8-oxa-3-azabicyclo[3.2.1]octane
[0522]
[0523] 3-(7-(8-Oxa-3-azabicyclo[3.2.1]octan-3-yl)-3-bromo-1-methyl-1H-pyrazolo[4,3-b]pyridin-5-yl)-8-oxa-3-azabicyclo[3.2.1]octane (67 mg, 0.154 mmol) was dissolved in 1,4-dioxane (1 mL) and water (0.2 mL), and 1-(tetrahydro-2H-pyran-2-yl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (215 mg, 0.772 mmol), Pd(dtbpf)Cl2 (10 mg, 0.015 mmol) and potassium phosphate (98 mg, 0.463 mmol) were added. The resulting mixture was stirred at 110°C for 2 hours under nitrogen protection. After the reaction was completed as monitored by LC-MS, water (5 mL) was added to the reaction mixture and extracted with EA (10 mL × 2). The combined organic phases were washed with saturated brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure to obtain a crude product, which was separated and purified by silica gel column (PE: EA = 1: 2) to obtain the target compound (53 mg, yield 67.9%, brown oil). LC-MS (ESI) m / z: 506.2 [M + H] + .
[0524] Step 8: Synthesis of 3-(7-(8-oxa-3-azabicyclo[3.2.1]octane-3-yl)-1-methyl-3-(1H-pyrazol-3-yl)-1H-pyrazolo[4,3-b]pyridin-5-yl)-8-oxa-3-azabicyclo[3.2.1]octane
[0525]
[0526] 4 mol / L hydrochloric acid 1,4-dioxane solution (2 mL) was added to a solution of 3-(7-(8-oxa-3-azabicyclo[3.2.1]octyl)-1-methyl-3-(1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-1H-pyrazolyl[4,3-b]pyridin-5-yl)-8-oxa-3-azabicyclo[3.2.1]octane (53 mg, 0.105 mmol) in methanol (2 mL). The resulting mixture was stirred at room temperature for 2 hours under nitrogen protection. After the reaction was completed as monitored by LC-MS, the solvent was removed under reduced pressure, and the residue was separated and purified by prep-HPLC column to obtain the target compound (2.9 mg, yield 6.57%, white solid). LC-MS (ESI) m / z: 422.2 [M+H] + . 1 H NMR(400MHz,MeOD)δ7.91-7.75(m,1H),6.90-6.77(m,1H),6.41(s,1H),4.67–4.57(m,2H),4.57–4.49(m,2H),4.27(s,3H),3.81 (d,J=11.8Hz,2H),3.58(d,J=12.3Hz,2H),3.48(d,J=11.8Hz,2H),3.37(d,J=12.2Hz,2H),2.22–2.04(m,4H),2.04–1.91(m,4H).
[0527] Example 14: 3-(4-(4,4-difluoropiperidin-1-yl)-7-(1H-pyrazol-3-yl)imidazo[1,5-b]pyridazine- 2-yl)-8-oxa-3-azabicyclo[3.2.1]octane
[0528]
[0529] Step 1: Synthesis of 3,6-dichloro-4-(4,4-difluoropiperidin-1-yl)pyridazine
[0530]
[0531] Potassium carbonate (1.82 g, 13.2 mmol) was added to a DMF (15.0 mL) solution of 4-bromo-3,6-dichloropyridazine (1.00 g, 4.39 mmol) and 4,4-difluoropiperidine (797 mg, 6.58 mmol). The reaction mixture was stirred at room temperature for 16 hours under nitrogen protection, and then the reaction was stopped. Water (20.0 mL) was added, and then extracted with EA (25.0 mL × 3). The combined organic phases were washed with water (20.0 mL × 2) and saturated brine (20.0 mL × 3), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was separated and purified by column chromatography (PE: EA = 10: 1-3: 1) to obtain the target compound (1.10 g, yield 93.5%, white solid). LC-MS (ESI) m / z 268.0 [M+H] + .
[0532] Step 2: Synthesis of 3-(6-chloro-5-(4,4-difluoropiperidin-1-yl)pyridazin-3-yl)-8-oxa-3-azabicyclo[3.2.1]octane
[0533]
[0534] DIEA (1.59 g, 12.3 mmol) was added to a solution of 3,6-dichloro-4-(4,4-difluoropiperidin-1-yl)pyridazine (1.10 g, 4.10 mmol) and 8-oxa-3-azabicyclo[3.2.1]octane hydrochloride (921 mg, 6.16 mmol) in NMP (23.0 mL). The reaction mixture was stirred at 145°C for 16 hours and then the reaction was stopped. After the reaction mixture was cooled to room temperature, water (25.0 mL) was added and extracted with EA (30.0 mL×3). The organic phases were combined, washed with water (30.0 mL×2) and saturated brine (30.0 mL×2), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was separated and purified by column chromatography (PE:EA=10:1-1:1) to obtain the target compound (1.20 g, yield 84.8%, white solid). LC-MS (ESI) m / z 345.0 [M+H] + .
[0535] Step 3: Synthesis of 6-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-4-(4,4-difluoropiperidin-1-yl)pyridazine-3-carbonitrile
[0536]
[0537] Zinc cyanide (476 mg, 4.05 mmol), DPPF (225 mg, 0.406 mmol) and Pd2(dba)3 (186 mg, 0.203 mmol) were added to a mixed solution of 3-(6-chloro-5-(4,4-difluoropiperidin-1-yl)pyridazin-3-yl)-8-oxa-3-azabicyclo[3.2.1]octane (700 mg, 2.03 mmol) in water (3 drops) in DMF (15.0 mL) in sequence. The reaction mixture was stirred at 145°C for 16 hours under nitrogen protection, and then the reaction was stopped. After the reaction solution was cooled to room temperature, water (20.0 mL) was added, and then extracted with EA (25.0 mL × 3). The combined organic phases were washed with water (20.0 mL × 2) and saturated brine (20.0 mL × 2), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The obtained residue was separated and purified by column chromatography (PE: EA = 3: 1-1: 3) to obtain the target compound (450 mg, yield 66.1%, brown solid). LC-MS (ESI) m / z 336.3 [M + H] + .
[0538] Step 4: Synthesis of (6-(8-oxa-3-azabicyclo[3.2.1]oct-3-yl)-4-(4,4-difluoropiperidin-1-yl)pyridazin-3-yl)methanamine
[0539]
[0540] Ammonia (2.00 mL) and Raney nickel (400 mg) were added to a solution of 6-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-4-(4,4-difluoropiperidin-1-yl)pyridazine-3-carbonitrile (450 mg, 1.34 mmol) in tetrahydrofuran (20.0 mL) in sequence. After hydrogen replacement three times, the reaction mixture was reacted at room temperature under a hydrogen atmosphere overnight to stop the reaction. The reaction mixture was filtered to remove the solid residue, and the filtrate was concentrated under reduced pressure and dried in vacuo to obtain the target compound (450 mg, yield 98.8%, brown solid). LC-MS (ESI) m / z 340.2 [M+H] + .
[0541] Step 5: Synthesis of N-((6-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-4-(4,4-difluoropiperidin-1-yl)pyridazin-3-yl)methyl)-1H-pyrazole-5-carboxamide
[0542]
[0543] To a solution of (6-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-4-(4,4-difluoropiperidin-1-yl)pyridazin-3-yl)methanamine (450 mg, 1.33 mmol) and 1H-pyrazole-5-carboxylic acid (134 mg, 1.20 mmol) in tetrahydrofuran (20.0 mL) were added HATU (605 mg, 1.60 mmol) and DIEA (343 mg, 2.66 mmol). After the reaction mixture was reacted at room temperature for 1 hour, sodium hydroxide (1.60 mL, 1 M) solution was added to the reaction solution, and the reaction was continued to stir for 1 hour to stop the reaction. The reaction mixture was diluted with water (25.0 mL), then extracted with (DCM: methanol) = 10:1 (30.0 mL × 3), the organic phase was washed with saturated brine (30.0 mL) and dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The resulting residue was separated and purified by column chromatography (DCM: methanol = 100: 1-30: 1) to obtain the target compound (330 mg, yield 57.4%, brown solid). LC-MS (ESI) m / z 434.3 [M+H] + Step 6: Synthesis of 3-(4-(4,4-difluoropiperidin-1-yl)-7-(1H-pyrazol-3-yl)imidazo[1,5-b]pyridazin-2-yl)-8-oxa-3-azabicyclo[3.2.1]octane
[0544]
[0545] N-((6-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-4-(4,4-difluoropiperidin-1-yl)pyridazin-3-yl)methyl)-1H-pyrazole-5-carboxamide (330 mg, 0.761 mmol) was dissolved in phosphorus oxychloride (12.0 mL) solution, and the reaction mixture was reacted at 120°C for 1 hour, and then the reaction was stopped. After the reaction mixture was cooled to room temperature, the reaction solution was slowly added dropwise to a saturated sodium bicarbonate solution at 0°C, and then the pH was adjusted to 9 with a saturated sodium bicarbonate solution at 0°C, and then extracted with EA (40.0 mL×3), the combined organic layer was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The obtained residue was separated and purified by reverse phase preparative chromatography (acetonitrile / water containing 0.05% formic acid) to obtain the target compound (127.46 mg, yield 40.3%, gray solid). LC-MS (ESI) m / z 416.1 [M+H] + . 1H NMR(400MHz,DMSO-d6)δ13.16(Brs,1H),7.71–7.64(m,1H),7.62(s,1H),7.12-7.03(m,1H),5.93(s,1H),4.47( s,2H),3.82(d,J=12.2Hz,2H),3.65–3.59(m,4H),3.06(d,J=11.1Hz,2H),2.22–2.11(m,4H),1.87–1.81(m,4H).
[0546] Example 15: 3-(4-((S)-3-methylmorpholino)-7-(1H-pyrazol-3-yl)imidazo[1,5-b]pyridazine-2-yl 1-(2-(2-nitrophenyl)-8-oxa-3-azabicyclo[3.2.1]octane
[0547]
[0548] Step 1: (S)-4-(3,6-dichloropyridinium Oxazine Synthesis of 4-(4-yl)-3-methylmorpholine
[0549]
[0550] Potassium carbonate (4.52 g, 32.7 mmol) was added to a solution of 3,4,6-trichloropyridazine (2.00 g, 10.9 mmol) and (S)-3-methylmorpholine (1.65 g, 16.3 mmol) in NMP (20.0 mL). The reaction mixture was stirred at room temperature for 16 hours under nitrogen protection, and then the reaction was stopped. Water (25.0 mL) was added, and then extracted with EA (30.0 mL × 3). The combined organic phases were washed with water (20.0 mL × 2) and saturated brine (20.0 mL × 3), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was separated and purified by column chromatography (PE: EA = 10: 1-3: 1) to obtain the target compound (1.70 g, yield 62.8%, light yellow solid). LC-MS (ESI) m / z 247.9 [M+H] + .
[0551] Step 2: Synthesis of 3-(6-chloro-5-((S)-3-methylmorpholino)pyridazin-3-yl)-8-oxa-3-azabicyclo[3.2.1]octane
[0552]
[0553] DIEA (1.41 g, 10.9 mmol) was added to a solution of (S)-4-(3,6-dichloropyridazin-4-yl)-3-methylmorpholine (900 mg, 3.63 mmol) and 8-oxa-3-azabicyclo[3.2.1]octane hydrochloride (814 mg, 5.44 mmol) in NMP (15.0 mL). The reaction mixture was stirred at 145°C for 16 hours and then the reaction was stopped. After the reaction mixture was cooled to room temperature, water (20.0 mL) was added and extracted with EA (25.0 mL×3). The organic phases were combined, washed with water (20.0 mL×2) and saturated brine (20.0 mL×2), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was separated and purified by column chromatography (PE:EA=5:1-1:1) to obtain the target compound (770 mg, yield 65.4%, white solid). LC-MS (ESI) m / z 325.3 [M+H] + .
[0554] Step 3: Synthesis of 6-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-4-((S)-3-methylmorpholino)pyridazine-3-carbonitrile
[0555]
[0556] Zinc cyanide (557 mg, 4.74 mmol), DPPF (263 mg, 0.474 mmol) and Pd2(dba)3 (217 mg, 0.237 mmol) were added to a mixed solution of 3-(6-chloro-5-((S)-3-methylmorpholino)pyridazin-3-yl)-8-oxa-3-azabicyclo[3.2.1]octane (770 mg, 2.37 mmol) in water (3 drops) and DMF (15.0 mL) in sequence. The reaction mixture was stirred at 145°C for 16 hours under nitrogen protection, and then the reaction was stopped. After the reaction solution was cooled to room temperature, water (20.0 mL) was added, and then extracted with EA (25.0 mL × 3). The combined organic phases were washed with water (20.0 mL × 2) and saturated brine (20.0 mL × 2), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The obtained residue was separated and purified by column chromatography (PE: EA = 3: 1-1: 4) to obtain the target compound (670 mg, yield 89.6%, brown solid). LC-MS (ESI) m / z 316.1 [M + H] + .
[0557] Step 4: Synthesis of (6-(8-oxa-3-azabicyclo[3.2.1]oct-3-yl)-4-((S)-3-methylmorpholino)pyridazin-3-yl)methanamine
[0558]
[0559] Ammonia (1.50 mL) and Raney nickel (500 mg) were added to a solution of 6-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-4-((S)-3-methylmorpholino)pyridazine-3-carbonitrile (670 mg, 2.12 mmol) in tetrahydrofuran (15.0 mL) in sequence. After hydrogen replacement three times, the reaction mixture was reacted at room temperature under a hydrogen atmosphere overnight to stop the reaction. The reaction mixture was filtered to remove the solid residue, and the filtrate was concentrated under reduced pressure and dried in vacuo to obtain the target compound (630 mg, yield 92.8%, brown solid). LC-MS (ESI) m / z 320.3 [M+H] + .
[0560] Step 5: Synthesis of N-((6-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-4-((S)-3-methylmorpholino)pyridazin-3-yl)methyl)-1H-pyrazole 5-carboxamide
[0561]
[0562] To a solution of (6-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-4-((S)-3-methylmorpholino)pyridazin-3-yl)methanamine (330 mg, 1.03 mmol) and 1H-pyrazole-5-carboxylic acid (116 mg, 1.03 mmol) in tetrahydrofuran (15.0 mL) were added HATU (471 mg, 1.24 mmol) and DIEA (267 mg, 2.06 mmol). After the reaction mixture was reacted at room temperature for 1 hour, sodium hydroxide (1 mol / L) solution was added to the reaction solution, and the reaction was continued to stir for 1 hour to stop the reaction. The reaction mixture was diluted with water (20.0 mL), then extracted with (DCM: methanol) = 10:1 (25.0 mL × 2), the organic phase was washed with saturated brine (20.0 mL) and dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The resulting residue was separated and purified by column chromatography (DCM: methanol = 100: 1-20: 1) to obtain the target compound (275 mg, yield 64.4%, brown solid). LC-MS (ESI) m / z 414.3 [M+H] + .
[0563] Step 6: Synthesis of 3-(4-((S)-3-methylmorpholino)-7-(1H-pyrazol-3-yl)imidazo[1,5-b]pyridazin-2-yl)-8-oxa-3-azabicyclo[3.2.1]octane
[0564]
[0565] N-((6-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-4-((S)-3-methylmorpholino)pyridazin-3-yl)methyl)-1H-pyrazole 5-carboxamide (275 mg, 0.665 mmol) was dissolved in phosphorus oxychloride (12.0 mL) solution, and the reaction mixture was reacted at 120°C for 1 hour, and then the reaction was stopped. After the reaction mixture was cooled to room temperature, the reaction solution was slowly added dropwise to a saturated sodium bicarbonate solution at 0°C, and then the pH was adjusted to 9 with a saturated sodium bicarbonate solution at 0°C, and then extracted with EA (30.0 mL×3), the combined organic layer was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The obtained residue was separated and purified by reverse phase preparative chromatography (acetonitrile / water containing 0.05% formic acid) to obtain the target compound (112.12 mg, yield 42.6%, white solid). LC-MS (ESI) m / z 396.2 [M+H] + . 1 H NMR(400MHz,DMSO-d6)δ13.20(Brs,1H),7.72–7.61(m,2H),7.08(s,1H),5.78(s,1H),4.49–4.43(m,2H),4.38–4.31(m,1H),3.99–3.92(m,1 H),3.84–3.75(m,3H),3.74–3.68(m,1H),3.65–3.57(m,1H),3.49–3.3 9(m,2H),3.10–3.02(m,2H),1.88–1.80(m,4H),1.15(d,J=6.6Hz,3H).
[0566] Example 16: 3-(4-cis-2,6-dimethylmorpholino)-7-(1H-pyrazol-3-yl)imidazo[1,5-b]pyridazine- 2-yl)-8-oxa-3-azabicyclo[3.2.1]octane
[0567]
[0568] Step 1: Synthesis of 4-(3,6-dichloropyridazin-4-yl)-cis-2,6-dimethylmorpholine
[0569]
[0570] Potassium carbonate (6.78 g, 49.1 mmol) was added to a solution of 3,4,6-trichloropyridazine (3.00 g, 16.4 mmol) and cis-2,6-dimethylmorpholine (3.01 g, 26.1 mmol) in NMP (30.0 mL). The reaction mixture was stirred at room temperature for 16 hours under nitrogen protection, and then the reaction was stopped. Water (35.0 mL) was added, and then extracted with EA (40.0 mL × 3). The combined organic phases were washed with water (30.0 mL × 2) and saturated brine (30.0 mL × 2), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was separated and purified by column chromatography (PE: EA = 10: 1-3: 1) to obtain the target compound (3.70 g, yield 86.3%, white solid). LC-MS (ESI) m / z 262.2 [M+H] + .
[0571] Step 2: Synthesis of 3-(6-chloro-5-(cis-2,6-dimethylmorpholino)pyridazin-3-yl)-8-oxa-3-azabicyclo[3.2.1]octane
[0572]
[0573] DIEA (1.48 g, 11.4 mmol) was added to a solution of 4-(3,6-dichloropyridin-4-yl)-cis-2,6-dimethylmorpholine (1.00 g, 3.81 mmol) and 8-oxa-3-azabicyclo[3.2.1]octane hydrochloride (913 mg, 6.10 mmol) in NMP (15.0 mL). The reaction mixture was stirred at 145°C for 16 hours and then the reaction was stopped. After the reaction mixture was cooled to room temperature, water (25.0 mL) was added and extracted with EA (30.0 mL×3). The organic phases were combined, washed with water (25.0 mL×2) and saturated brine (25.0 mL×2), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was separated and purified by column chromatography (PE:EA=5:1-1:1) to obtain the target compound (1.00 g, yield 77.3%, brown solid). LC-MS (ESI) m / z 339.3 [M+H] + .
[0574] Step 3: Synthesis of 6-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-4-(cis-2,6-dimethylmorpholino)pyridazine-3-carbonitrile
[0575]
[0576] Zinc cyanide (695 mg, 5.92 mmol), DPPF (328 mg, 0.592 mmol) and Pd2(dba)3 (271 mg, 0.295 mmol) were added to a mixed solution of 3-(6-chloro-5-(cis-2,6-dimethylmorpholino)pyridazin-3-yl)-8-oxa-3-azabicyclo[3.2.1]octane (1.00 g, 2.95 mmol) in water (5 drops) in DMF (20.0 mL) in sequence. The reaction mixture was stirred at 145°C for 16 hours under nitrogen protection, and then the reaction was stopped. After the reaction solution was cooled to room temperature, water (20.0 mL) was added, and then extracted with EA (25.0 mL × 3). The combined organic phases were washed with saturated brine (20.0 mL × 4) and dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The obtained residue was separated and purified by column chromatography (PE: EA = 5: 1-1: 3) to obtain the target compound (860 mg, yield 88.5%, brown solid). LC-MS (ESI) m / z 330.3 [M + H] + .
[0577] Step 4: Synthesis of (6-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-4-(cis-2,6-dimethylmorpholino)pyridazin-3-yl)methanamine
[0578]
[0579] Ammonia (2.00 mL) and Raney nickel (~600 mg) were added to a solution of 6-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-4-(cis-2,6-dimethylmorpholino)pyridazine-3-carbonitrile (860 mg, 2.61 mmol) in tetrahydrofuran (20.0 mL) in sequence. After hydrogen replacement three times, the reaction mixture was reacted at room temperature under a hydrogen atmosphere overnight to stop the reaction. The reaction mixture was filtered to remove the solid residue, and the filtrate was concentrated under reduced pressure and dried in vacuo to obtain the target compound (710 mg, yield 81.6%, brown solid). LC-MS (ESI) m / z 334.3 [M+H] + .
[0580] Step 5: Synthesis of N-((6-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-4-(cis-2,6-dimethylmorpholino)pyridazin-3-yl)methyl)-1H-pyrazole-5-carboxamide
[0581]
[0582] To a solution of (6-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-4-(cis-2,6-dimethylmorpholino)pyridazin-3-yl)methanamine (350 mg, 1.05 mmol) and 1H-pyrazole-5-carboxylic acid (118 mg, 1.05 mmol) in tetrahydrofuran (15.0 mL) were added HATU (479 mg, 1.26 mmol) and DIEA (271 mg, 2.10 mmol). After the reaction mixture was reacted at room temperature for 1 hour, sodium hydroxide (1 mol / L) solution was added to the reaction solution, and the reaction was continued to stir for 1 hour to stop the reaction. The reaction mixture was diluted with water (20.0 mL), then extracted with (DCM: methanol) = 10:1 (25.0 mL × 3), the organic phase was washed with saturated brine (20.0 mL × 2) and dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The obtained residue was separated and purified by column chromatography (methanol: DCM = 5%) to obtain the target compound (280 mg, yield 62.4%, brown solid). LC-MS (ESI) m / z 428.4 [M+H] + .
[0583] Step 6: Synthesis of 3-(4-(cis-2,6-dimethylmorpholino)-7-(1H-pyrazol-3-yl)imidazo[1,5-b]pyridazin-2-yl)-8-oxa-3-azabicyclo[3.2.1]octane
[0584]
[0585] N-((6-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-4-(cis-2,6-dimethylmorpholino)pyridazin-3-yl)methyl)-1H-pyrazole-5-carboxamide (150 mg, 0.351 mmol) was dissolved in phosphorus oxychloride (6.00 mL) solution, and the reaction mixture was reacted at 120°C for 1 hour, and then the reaction was stopped. After the reaction mixture was cooled to room temperature, the reaction solution was slowly added dropwise to a saturated sodium bicarbonate solution at 0°C, and then the pH was adjusted to 9 with a saturated sodium bicarbonate solution at 0°C, and then extracted with EA (30.0 mL×3), the combined organic layer was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The obtained residue was separated and purified by reverse phase preparative chromatography (acetonitrile / water containing 0.05% formic acid) to obtain the target compound (54.42 mg, yield 37.9%, white solid). LC-MS (ESI) m / z 410.4 [M+H] + . 1H NMR (400MHz, DMSO-d6) δ13.12(Brs,1H),7.68-7.62(m,2H),7.07(d,J=1.8Hz,1H),5.85(s,1H),4.47(s, 2H),3.90–3.74(m,6H),3.09–3.02(m,2H),2.66–2.57(m,2H),1.88–1.81(m,4H),1.19(d,J=6.2Hz,6H).
[0586] Example 17: 3-(4-(piperidin-1-yl)-7-(1H-pyrazol-3-yl)imidazo[1,5-b]pyridazin-2-yl)-8- Oxa-3-azabicyclo[3.2.1]octane
[0587]
[0588] Step 1: Synthesis of 3,6-dichloro-4-(piperidin-1-yl)pyridazine
[0589]
[0590] Potassium carbonate (3.01 g, 21.8 mmol) was added to a solution of 3,4,6-trichloropyridazine (2.00 g, 10.9 mmol) and piperidine (1.39 g, 16.4 mmol) in NMP (25.0 mL). The reaction mixture was stirred at room temperature for 16 hours under nitrogen protection to stop the reaction. The reaction solution was then diluted with EA (45.0 mL), washed with saturated brine (45.0 mL × 3), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was separated and purified by column chromatography (PE: EA = 5: 1) to obtain the target compound (2.30 g, yield 90.9%, yellow solid). LC-MS (ESI) m / z 232.1 [M+H] + .
[0591] Step 2: Synthesis of 3-(6-chloro-5-(piperidin-1-yl)pyridazin-3-yl)-8-oxa-3-azabicyclo[3.2.1]octane
[0592]
[0593] DIEA (6.75 mL, 38.7 mmol) was added to a NMP solution (60.0 mL) of 3,6-dichloro-4-(piperidin-1-yl)pyridazine (3.00 g, 12.9 mmol) and 8-oxa-3-azabicyclo[3.2.1]octane hydrochloride (3.87 g, 25.8 mmol). The reaction mixture was stirred at 145°C for 16 hours to stop the reaction. Water (50.0 mL) was then added, and the mixture was extracted with EA (40.0 mL×3). The combined organic phases were washed with saturated brine (30.0 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was separated and purified by chromatography (PE:EA=5:1) to obtain the target compound (1.20 g, yield 30.1%, yellow solid). LC-MS(ESI)m / z 309.1[M+H] + . 1 H NMR(400MHz, CDCl3)δ6.12(s,1H),4.52–4.46(m,2H),3.82–3.75(m,2H),3.20–3.18(m,1H),3.18–3.15 (m,1H),3.13–3.07(m,4H),2.01–1.94(m,2H),1.88–1.82(m,2H),1.76–1.71(m,4H),1.66–1.58(m,2H).
[0594] Step 3: Synthesis of 6-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-4-(piperidin-1-yl)pyridazine-3-carbonitrile
[0595]
[0596] DPPF (431 mg, 0.777 mmol) and Pd2(dba)3 (356 mg, 0.388 mmol) were added to a solution of 3-(6-chloro-5-(piperidin-1-yl)pyridazin-3-yl)-8-oxa-3-azabicyclo[3.2.1]octane (1.20 g, 3.89 mmol) and zinc cyanide (912 mg, 7.77 mmol) in DMF (25.0 mL). The reaction mixture was stirred at 140 °C for 16 hours under nitrogen protection to stop the reaction. The reaction solution was then diluted with EA (40.0 mL), washed with saturated brine (35.0 mL × 3), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was separated and purified by column chromatography (PE:EA=1:1) to obtain the target compound (1.20 g, yield 100%, yellow solid). LC-MS (ESI) m / z 300.2 [M+H] + .
[0597] Step 4: Synthesis of (6-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-4-(piperidin-1-yl)pyridazin-3-yl)methanamine
[0598]
[0599] To a solution of 6-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-4-(piperidin-1-yl)pyridazine-3-carbonitrile (1.2 g, 4.01 mmol) in tetrahydrofuran (20.0 mL) was added Raney nickel (~1.18 g, 20.0 mmol) and aqueous ammonia (5 drops). The reaction mixture was reacted at room temperature under a hydrogen atmosphere for 16 hours, and the reaction was stopped. The reaction solution was then filtered and concentrated under reduced pressure. The residue obtained was the target compound (1.10 g, yield 90.4%, yellow oil). LC-MS (ESI) m / z 304.1 [M+H] + .
[0600] Step 5: Synthesis of N-((6-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-4-(piperidin-1-yl)pyridazin-3-yl)methyl)-1H-pyrazole-5-carboxamide
[0601]
[0602] HATU (752 mg, 1.98 mmol) and DIEA (639 mg, 4.94 mmol) were added to a tetrahydrofuran solution (12.0 mL) of (6-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-4-(piperidin-1-yl)pyridazin-3-yl)methylamine (500 mg, 1.65 mmol) and 1H-pyrazole-5-carboxylic acid (166 mg, 1.48 mmol). The reaction mixture was stirred at room temperature for 45 minutes to stop the reaction. Sodium hydroxide solution was added dropwise to the reaction solution and stirred for 2 minutes. The mixture was concentrated under reduced pressure and the residue was separated and purified by column chromatography (DCM: methanol = 10:1) to obtain the target compound (300 mg, yield 45.8%, yellow solid). LC-MS (ESI) m / z 398.2 [M+H] + .
[0603] Step 6: Synthesis of 3-(4-(piperidin-1-yl)-7-(1H-pyrazol-3-yl)imidazo[1,5-b]pyridazin-2-yl)-8-oxa-3-azabicyclo[3.2.1]octane
[0604]
[0605] N-((6-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-4-(piperidin-1-yl)pyridazin-3-yl)methyl)-1H-pyrazole-5-carboxamide (150 mg, 0.327 mmol) and phosphorus oxychloride (9.00 mL) were added to the reaction bottle at room temperature. The reaction mixture was reacted at 100°C for 1 hour, and the reaction was stopped. The reaction solution was added dropwise to a saturated sodium bicarbonate aqueous solution and the pH was adjusted to 7. The mixture was then extracted with EA (20.0 mL×3). The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by reverse phase preparative chromatography (acetonitrile / water containing 0.05% formic acid) to obtain the target compound (51.7 mg, yield 36.1%, white solid). LC-MS (ESI) m / z 380.1 [M+H] + . 1 H NMR(400MHz,MeOD-d4)δ7.69(s,1H),7.47(s,1H),7.10(s,1H),5.77(s,1H),4.51–4.48(m,2H), 3.83–3.79(m,2H),3.52–3.48(m,4H),3.21–3.16(m,2H),1.99–1.95(m,4H),1.79–1.74(m,6H).
[0606] Example 18: 3-(4-(2-methylmorpholino)-7-(1H-pyrazol-3-yl)imidazo[1,5-b]pyridazine-2-yl 1-(2-(2-nitrophenyl)-8-oxa-3-azabicyclo[3.2.1]octane
[0607]
[0608] Step 1: Synthesis of 4-(3,6-dichloropyridazin-4-yl)-2-methylmorpholine
[0609]
[0610] Potassium carbonate (3.01 g, 21.8 mmol) was added to a solution of 3,4,6-trichloropyridazine (2.00 g, 10.9 mmol) and 2-methylmorpholine (1.32 g, 13.1 mmol) in NMP (25.0 mL). The reaction mixture was stirred at room temperature for 16 hours under nitrogen protection to stop the reaction. The reaction solution was then diluted with EA (45.0 mL), washed with saturated brine (45.0 mL × 3), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was separated and purified by column chromatography (PE: EA = 5: 1) to obtain the target compound (2.30 g, yield 85.0%, yellow solid). LC-MS (ESI) m / z 248.1 [M+H] + .
[0611] Step 2: Synthesis of 3-(6-chloro-5-(2-methylmorpholino)pyridazin-3-yl)-8-oxa-3-azabicyclo[3.2.1]octane
[0612]
[0613] DIEA (2.40 g, 18.5 mmol) was added to a solution of 4-(3,6-dichloropyridazin-4-yl)-2-methylmorpholine (2.30 g, 9.27 mmol) and 8-oxa-3-azabicyclo[3.2.1]octane hydrochloride (2.08 g, 13.9 mmol) in NMP (25.0 mL). The reaction mixture was stirred at 145°C for 16 hours under nitrogen protection to stop the reaction. The reaction solution was then diluted with EA (45.0 mL), washed with saturated brine (45.0 mL×3), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was separated and purified by column chromatography (PE:EA=1:1) to obtain the target compound (2.00 g, yield 76.4%, yellow solid). LC-MS(ESI)m / z 225.1[M+H] + . 1 H NMR(400MHz, CDCl3)δ6.13(s,1H),4.55–4.48(m,2H),4.01–3.94(m,1H),3.89–3.80(m,4H),3.50–3.43(m,2H),3.2 5–3.19(m,2H),2.89–2.80(m,1H),2.57–2.49(m,1H),2.04–1.96(m,2H),1.91–1.82(m,2H),1.24(d,J=6.3Hz,3H).
[0614] Step 3: Synthesis of 6-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-4-(2-methylmorpholino)pyridazine-3-carbonitrile
[0615]
[0616] DPPF (614 mg, 1.11 mmol) and Pd2(dba)3 (507 mg, 0.554 mmol) were added to a DMF (35.0 mL) solution of 3-(6-chloro-5-(2-methylmorpholino)pyridazin-3-yl)-8-oxa-3-azabicyclo[3.2.1]octane (1.80 g, 5.54 mmol) and zinc cyanide (1.30 g, 11.1 mmol). The reaction mixture was stirred at 140°C for 16 hours under nitrogen protection to stop the reaction. The reaction solution was then diluted with EA (55.0 mL), washed with saturated brine (40.0 mL×3), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was separated and purified by column chromatography (PE:EA=1:1) to obtain the target compound (1.50 g, yield 85.8%, yellow solid). LC-MS (ESI) m / z 316.0 [M+H] + .
[0617] Step 4: Synthesis of (6-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-4-(2-methylmorpholino)pyridazin-3-yl)methanamine
[0618]
[0619] To a solution of 6-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-4-(2-methylmorpholino)pyridazine-3-carbonitrile (1.50 g, 4.76 mmol) in tetrahydrofuran (30.0 mL) was added Raney nickel (~1.40 g, 23.8 mmol). The reaction mixture was reacted at room temperature for 16 hours under a hydrogen atmosphere, and the reaction was stopped. The reaction solution was then filtered and concentrated under reduced pressure. The residue was separated and purified by column chromatography (DCM: methanol = 10: 1) to obtain the target compound (1.50 g, yield 98.7%, yellow solid). LC-MS (ESI) m / z 320.0 [M+H] + Step 5: Synthesis of N-((6-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-4-(2-methylmorpholino)pyridazin-3-yl)methyl)-1H-pyrazole-5-carboxamide
[0620]
[0621] HATU (714 mg, 1.88 mmol) and DIEA (607 mg, 4.70 mmol) were added to a solution of (6-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-4-(2-methylmorpholino)pyridazin-3-yl)methanamine (500 mg, 1.57 mmol) and 1H-pyrazole-5-carboxylic acid (158 mg, 1.41 mmol) in tetrahydrofuran (10.0 mL). The reaction mixture was reacted at room temperature for 1 hour to stop the reaction. The reaction solution was then filtered and concentrated under reduced pressure. The residue was separated and purified by column chromatography (PE:EA=0:1) to obtain the target compound (500 mg, yield 77.2%, yellow solid). LC-MS (ESI) m / z 414.0 [M+H] + .
[0622] Step 6: Synthesis of 3-(4-(2-methylmorpholino)-7-(1H-pyrazol-3-yl)imidazo[1,5-b]pyridazin-2-yl)-8-oxa-3-azabicyclo[3.2.1]octane
[0623]
[0624] At room temperature, N-((6-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-4-(2-methylmorpholino)pyridazin-3-yl)methyl)-1H-pyrazole-5-carboxamide (200 mg, 0.484 mmol) and phosphorus oxychloride (6.00 mL) were added to the reaction bottle. The reaction mixture was reacted at 100°C for 1 hour, and the reaction was stopped. The reaction solution was added dropwise to a saturated sodium bicarbonate aqueous solution and the pH was adjusted to 7, and then the mixture was extracted with EA (30.0 mL×3), the organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by reverse phase preparative chromatography (acetonitrile / water containing 0.05% formic acid) to obtain the target compound (82.0 mg, yield 42.9%, white solid). LC-MS (ESI) m / z 396.1 [M+H] + . 1 H NMR(400MHz,MeOD-d4)δ7.86–7.63(m,1H),7.62–7.41(m,1H),7.13(s,1H),5.84(s,1H),4.54–4.47(m,2H),4.04–3.98(m, 1H),3.87–3.78(m,6H),3.22–3.16(m,2H),3.13–3.04(m,1H),2.79–2.70(m,1H),2.01–1.93(m,4H),1.25(d,J=6.1Hz,3H).
[0625] Example 19: 3-(1-methyl-7-((R)-3-methylmorpholino)-3-(1H-pyrazol-3-yl)-1H-pyrazolo[4, 3-b]pyridin-5-yl)-8-oxa-3-azabicyclo[3.2.1]octane
[0626]
[0627] Synthesis of Intermediate 3-(7-chloro-1-methyl-1H-pyrazolo[4,3-b]pyridin-5-yl)-8-oxa-3-azabicyclo[3.2.1]octane Reference Example 13
[0628] Step 1: Synthesis of 3-(3-bromo-7-chloro-1-methyl-1H-pyrazolo[4,3-b]pyridin-5-yl)-8-oxa-3-azabicyclo[3.2.1]octane
[0629]
[0630] 3-(7-chloro-1-methyl-1H-pyrazolo[4,3-b]pyridin-5-yl)-8-oxa-3-azabicyclo[3.2.1]octane (200 mg, 0.718 mmol) was dissolved in DCM (5 mL). N-bromosuccinimide (128 mg, 0.718 mmol) was added to the reaction mixture under nitrogen protection, and the reaction solution was stirred at room temperature for 10 minutes. After the reaction was completed, water (5 mL) was added to the reaction mixture and extracted with DCM (5 mL×3). The combined organic phases were washed with saturated brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure to obtain a crude product. The target compound (241 mg, yield 93.9%, yellow solid) was obtained by separation and purification on a silica gel column (EA:PE=1:4). LC-MS (ESI) m / z: 357.1 [M+H] + . 1 H NMR(400MHz,DMSO-d6)δ7.20(s,1H),4.45–4.36(m,2H),4.20(s,3H),3.87(d, J=12.4Hz,2H),2.99(d,J=12.4Hz,2H),1.86–1.76(m,2H),1.75–1.69(m,2H).
[0631] Step 2: Synthesis of 3-(7-chloro-1-methyl-3-(1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-1H-pyrazolo[4,3-b]pyridin-5-yl)-8-oxa-3-azabicyclo[3.2.1]octane
[0632]
[0633] 3-(3-bromo-7-chloro-1-methyl-1H-pyrazolo[4,3-b]pyridin-5-yl)-8-oxa-3-azabicyclo[3.2.1]octane (201 mg, 0.562 mmol) was dissolved in 1,4-dioxane (2 mL) and water (0.2 mL), and 1-(tetrahydro-2H-pyran-2-yl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolane-2-yl)-1H-pyrazole (313 mg, 1.12 mmol), Pd(dtbpf)Cl2 (36.3 mg, 0.056 mmol) and potassium phosphate (358 mg, 1.69 mmol) were added. The resulting mixture was stirred at 40°C for 2 hours under nitrogen protection. After the reaction was completed by LC-MS monitoring, water (5 mL) was added to the reaction mixture, and it was extracted with EA (10 mL×2). The combined organic phases were washed with saturated brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure to obtain a crude product, which was separated and purified by silica gel column (PE:EA=1:2) to obtain the target compound (102 mg, yield 42.3%, brown oil). LC-MS (ESI) m / z: 429.2 [M+H] + .
[0634] Step 3: Synthesis of 3-(1-methyl-7-((R)-3-methylmorpholino)-3-(1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-1H-pyrazolo[4,3-b]pyridin-5-yl)-8-oxa-3-azabicyclo[3.2.1]octane
[0635]
[0636] 3-(7-Chloro-1-methyl-3-(1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-1H-pyrazolo[4,3-b]pyridin-5-yl)-8-oxa-3-azabicyclo[3.2.1]octane (80 mg, 0.187 mmol) was dissolved in N-methylpyrrolidone (1 mL), and (3R)-3-methylmorpholine (37.7 mg, 0.373 mmol), RuphosPdG2 (14.5 mg, 0.019 mmol), cesium carbonate (182 mg, 0.560 mmol) and cuprous iodide (35.5 mg, 0.187 mmol) were added. The resulting mixture was stirred at 110°C for 2 hours under nitrogen protection. After the reaction was completed, the reaction mixture was added to water (10 mL), the aqueous phase was extracted with EA (20 mL × 2), and washed with saturated brine (10 mL). The organic phase was dried and then separated and purified by silica gel column (PE: EA = 1: 1) to obtain the target compound (39 mg, yield 42.4%, brown solid). LC-MS (ESI) m / z: 494.3 [M + H] + .
[0637] Step 4: Synthesis of 3-(1-methyl-7-((R)-3-methylmorpholino)-3-(1H-pyrazol-3-yl)-1H-pyrazolo[4,3-b]pyridin-5-yl)-8-oxa-3-azabicyclo[3.2.1]octane
[0638]
[0639] 4 mol / L hydrochloric acid 1,4-dioxane solution (2 mL) was added to a solution of 3-(1-methyl-7-((R)-3-methylmorpholino)-3-(1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-1H-pyrazolo[4,3-b]pyridin-5-yl)-8-oxa-3-azabicyclo[3.2.1]octane (39.0 mg, 0.079 mmol) in methanol (2 mL). The resulting mixture was stirred at room temperature for 2 hours under nitrogen protection. After the reaction was completed as monitored by LC-MS, the solvent was removed under reduced pressure, and the residue was separated and purified by prep-HPLC column to obtain the target compound (4.2 mg, yield 13.0%, white solid). LC-MS (ESI) m / z: 410.2 [M+H] + . 1 HNMR(400MHz,CD3OD)δ7.82-7.73(m,1H),6.89-6.85(m,1H),6.50(s,1H),4.26(s,3H),4.07–3.94(m,2H),3.91–3.78(m,4H),3.74– 3.64(m,1H),3.65–3.55(m,1H),3.51–3.37(m,3H),3.17–3.02(m,2H),2.09–2.00(m,2H),2.02–1.93(m,2H),1.17(d,J=6.4Hz,3H).
[0640] Example 20: 3-(4-(3,3-dimethylmorpholino)-7-(1H-pyrazol-3-yl)imidazo[1,5-b]pyridazine-2-yl 1-(2-(2-nitrophenyl)-8-oxa-3-azabicyclo[3.2.1]octane
[0641]
[0642] Step 1: Synthesis of 4-(3,6-dichloropyridazin-4-yl)-3,3-dimethylmorpholine
[0643]
[0644] 3,3-Dimethylmorpholine (4.00 g, 34.7 mmol) and DIEA (13.5 g, 104 mmol) were added to a solution of 3,4,6-trichloropyridazine (7.64 g, 41.7 mmol) in N-methylpyrrolidone (30.0 mL). The reaction mixture was stirred at 100 °C for 16 hours under nitrogen protection to stop the reaction. The reaction solution was then diluted with EA (70.0 mL), washed with saturated brine (50.0 mL × 3), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was separated and purified by column chromatography (PE: EA = 3: 1) to obtain the target compound (2.00 g, yield 22.0%, yellow solid). LC-MS (ESI) m / z 262.1 [M+H] + . 1 H NMR (400MHz, CDCl3) δ7.13(s,1H),3.90–3.86(m,2H),3.47(s,2H),3.32–3.29(m,2H),1.32(s,6H).
[0645] Step 2: Synthesis of 3-(6-chloro-5-(3,3-dimethylmorpholino)pyridazin-3-yl)-8-oxa-3-azabicyclo[3.2.1]octane
[0646]
[0647] DIEA (3.70 g, 28.6 mmol) was added to a solution of 4-(3,6-dichloropyridazin-4-yl)-3,3-dimethylmorpholine (2.50 g, 9.54 mmol) and (1R,5S)-8-oxa-3-azabicyclo[3.2.1]octane hydrochloride (2.14 g, 14.3 mmol) in N-methylpyrrolidone (30.0 mL). The reaction mixture was stirred at 145°C for 16 hours under nitrogen protection to stop the reaction. The reaction solution was then diluted with water (50.0 mL) and extracted with ethyl acetate (40.0 mL×3). The combined organic phases were washed with saturated brine (30.0 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was separated and purified by chromatography (petroleum ether: ethyl acetate = 1:1) to obtain the target compound (2.50 g, yield 77.4%, yellow solid). LC-MS (ESI) m / z 339.1 [M+H] + . 1H NMR (400MHz, CDCl3) δ6.49 (s, 1H), 4.54–4.51 (m, 2H), 3.87–3.84 (m, 2H), 3.79 (d, J = 12.1Hz, 2H), 3. 47(s,2H),3.26–3.24(m,1H),3.23–3.19(m,3H),2.04–1.99(m,2H),1.90–1.85(m,2H),1.27(s,6H).
[0648] Step 3: Synthesis of 6-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-4-(3,3-dimethylmorpholino)pyridazine-3-carbonitrile
[0649]
[0650] 2-(Diphenylphosphonyl)cyclopentadienyl iron (458 mg, 0.826 mmol) and tris dibenzylideneacetone dipalladium (378 mg, 0.413 mmol) were added to a solution of 3-(6-chloro-5-(3,3-dimethylmorpholino)pyridazin-3-yl)-8-oxa-3-azabicyclo[3.2.1]octane (1.40 g, 4.13 mmol) and zinc cyanide (970 mg, 8.26 mmol) in N,N-dimethylformamide (30.0 mL). The reaction mixture was stirred at 135°C for 16 hours under nitrogen protection, and the reaction was stopped. The reaction solution was then diluted with ethyl acetate (50.0 mL), washed with saturated brine (30.0 mL × 3), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The resulting residue was separated and purified by column chromatography (PE: EA = 1: 1) to obtain the target compound (800 mg, yield 58.8%, yellow solid). LC-MS (ESI) m / z 330.2 [M+H] + .
[0651] Step 4: Synthesis of (6-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-4-(3,3-dimethylmorpholino)pyridazin-3-yl)methanamine
[0652]
[0653] To a solution of 6-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-4-(3,3-dimethylmorpholino)pyridazine-3-carbonitrile (800 mg, 2.43 mmol) in tetrahydrofuran (15.00 mL) was added Raney nickel (428 mg, 7.29 mmol) and aqueous ammonia (1.00 mL). The reaction mixture was reacted at room temperature for 16 hours under hydrogen atmosphere, and the reaction was stopped. The reaction solution was then filtered and concentrated under reduced pressure. The residue obtained was the target compound (500 mg, yield 61.7%, yellow oil). LC-MS (ESI) m / z 334.1 [M+H] + .
[0654] Step 5: Synthesis of N-((6-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-4-(3,3-dimethylmorpholino)pyridazin-3-yl)methyl)-1H-pyrazole-5-carboxamide
[0655]
[0656] To a solution (15.0 mL) of (6-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-4-(3,3-dimethylmorpholino)pyridazin-3-yl)methanamine (500 mg, 1.50 mmol) and 1H-pyrazole-5-carboxylic acid (151 mg, 1.35 mmol) were added 2-(3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (684 mg, 1.80 mmol) and DIEA (581 mg, 4.50 mmol), and the reaction mixture was stirred at room temperature for 1 hour to stop the reaction. Then water (30.0 mL) was added, and then extracted with ethyl acetate (25.0 mL×3). The combined organic phases were washed with saturated brine (20.0 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was separated and purified by column chromatography (DCM: methanol = 10:1) to obtain the target compound (300 mg, yield 46.8%, yellow solid). LC-MS (ESI) m / z 428.4 [M+H] + . 1H NMR(400MHz, CDCl3)δ9.16(s,1H),7.60–7.56(m,1H),6.81–6.77(m,1H),6.65(s,1H),5.29(s,1H),4.91–4.78(m,2H),4.55–4.50(m,2H),3 .97–3.89(m,2H),3.84–3.76(m,2H),3.55(s,2H),3.26–3.21(m,2H), 3.19–3.09(m,2H),2.04–1.99(m,2H),1.91–1.85(m,2H),1.16(s,6H).
[0657] Step 6: Synthesis of 3-(4-(3,3-dimethylmorpholino)-7-(1H-pyrazol-3-yl)imidazo[1,5-b]pyridazin-2-yl)-8-oxa-3-azabicyclo[3.2.1]octane
[0658]
[0659] Phosphorus oxychloride (6.00 mL) was added to a solution of N-((6-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-4-(3,3-dimethylmorpholino)pyridazin-3-yl)methyl)-1H-pyrazole-5-carboxamide (250 mg, 0.585 mmol) in acetonitrile (5.00 mL) at room temperature. The reaction mixture was reacted at 100°C for 1 hour and the reaction was stopped. The reaction solution was concentrated under reduced pressure and the residue was purified by reverse phase preparation (acetonitrile / water containing 0.05% formic acid) to obtain the target compound (58.9 mg, yield 24.6%, white solid). LC-MS (ESI) m / z 410.1 [M+H] + . 1 H NMR (400MHz, CDCl3) δ7.75–7.69(m,1H),7.44(s,1H),7.09–7.05(m,1H),5.99(s,1H),4.60–4.54(m,2H),3.94–3.89(m,2H) ,3.67–3.62(m,2H),3.52(s,2H),3.50–3.46(m,2H),3.36–3.31(m,2H),2.09–2.02(m,2H),1.96–1.89(m,2H),1.35(s,6H).
[0660] Example 23: 4-(5-((1 R ,5 S )-8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-3-(1 H -Pyrazole- 5-yl)pyrazolo[1,5-a]pyrimidin-7-yl)tetrahydro-2H-pyran-4-ol
[0661]
[0662] Step 1: Synthesis of 3-(pyrazolo[1,5-a]pyrimidin-5-yl)-8-oxa-3-azabicyclo[3.2.1]octane
[0663]
[0664] DIEA (12.6 g, 97.7 mmol) was added to a solution of 5-chloropyrazolo[1,5-a]pyrimidine (5.00 g, 32.6 mmol) and 8-oxa-3-azabicyclo[3.2.1]octane hydrochloride (7.31 g, 48.8 mmol) in N-methylpyrrolidone (60.0 mL). The reaction mixture was stirred at 100°C for 1 hour under nitrogen protection to stop the reaction. The reaction solution was then diluted with ethyl acetate (85.0 mL), washed with saturated brine (55 mL × 3), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was separated and purified by column chromatography (PE: EA = 5: 1) to obtain the target compound (3.60 g, yield 48.0%, yellow solid). LC-MS (ESI) m / z 231.1 [M+H] + . 1 H NMR (400MHz, CDCl3) δ8.33(d,J=7.8Hz,1H),7.88(d,J=2.0Hz,1H),6.26(d,J=7.8Hz,1H),6.13(d,J=1.9Hz,1H) ,4.57–4.47(m,2H),3.92(d,J=12.5Hz,2H),3.27(dd,J=12.6,2.4Hz,2H),2.06–1.94(m,2H),1.87–1.74(m,2H).
[0665] Step 2: Synthesis of 4-(5-((1R,5S)-8-oxa-3-azabicyclo[3.2.1]octan-3-yl)pyrazolo[1,5-a]pyrimidin-7-yl)tetrahydro-2H-pyran-4-ol
[0666]
[0667] Under nitrogen atmosphere, a solution of (1R,5S)-3-(pyrazolo[1,5-a]pyrimidin-5-yl)-8-oxa-3-azabicyclo[3.2.1]octane (1.50 g, 6.51 mmol) in tetrahydrofuran (20.0 mL) was cooled to -78°C. Then n-butyl lithium (8.14 mL, 13.0 mmol, 1.6 M) was added dropwise, and the reaction mixture was stirred at -78°C for 1 hour, and then tetrahydro-4H-pyran-4-one (1.30 g, 13.0 mmol) was slowly added dropwise, and the reaction mixture was stirred at room temperature overnight to stop the reaction. Add aqueous ammonium chloride solution (45.0 mL) to dilute, then extract with EA (45.0 mL × 3), wash the combined organic phases with saturated brine (35.0 mL), dry over anhydrous sodium sulfate, filter, and concentrate under reduced pressure. The resulting residue is separated and purified by column chromatography (PE: EA = 1: 1) to obtain the target compound (500 mg, yield 23.2%, yellow solid). LC-MS (ESI) m / z 331.1 [M+H] + . 1 H NMR (400MHz, CDCl3) δ7.86(d,J=2.3Hz,1H),6.21(d,J=2.2Hz,1H),6.15(s,1H),4.56–4.50(m,2H),4.31–4.27(m,2H),4.23–4 .19(m,2H),3.77–3.76(m,2H),3.33–3.26(m,2H),2.27–2.20(m,2H),2.12–2.07(m,2H),2.03–1.96(m,2H),1.88–1.82(m,2H).
[0668] Step 3: Synthesis of 4-(5-((1R,5S)-8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-3-iodopyrazolo[1,5-a]pyrimidin-7-yl)tetrahydro-2H-pyran-4-ol
[0669]
[0670] N-iodosuccinimide (272 mg, 1.21 mmol) was added to a solution of 4-(5-((1R,5S)-8-oxa-3-azabicyclo[3.2.1]octan-3-yl)pyrazolo[1,5-a]pyrimidin-7-yl)tetrahydro-2H-pyran-4-ol (400 mg, 1.21 mmol) in acetonitrile (10.0 mL). The reaction mixture was stirred at room temperature for 1 hour to stop the reaction. Then water (35.0 mL) was added for dilution, and then EA (30.0 mL×3) was used for extraction. The organic phases were combined, washed with saturated brine (30.0 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was separated and purified by column chromatography (PE:EA=1:1) to obtain the target compound (400 mg, yield 72.4%, yellow solid). LC-MS (ESI) m / z 457.1 [M+H] + .
[0671] Step 4: Synthesis of 4-(5-((1R,5S)-8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-3-(1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-5-yl)pyrazolo[1,5-a]pyrimidin-7-yl)tetrahydro-2H-pyran-4-ol
[0672]
[0673] Under nitrogen protection, 4-(5-((1R,5S)-8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-3-iodopyrazolo[1,5-a]pyrimidin-7-yl)tetrahydro-2H-pyran-4-ol (400 mg, 0.877 mmol) and 1-(tetrahydro-2H-pyran-2-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxybenzofuran-2-yl) were added to the mixture. To a solution of 1,4-dioxane (10.0 mL) and water (2.00 mL) of 1,1'-bis(di-tert-butylphosphino)ferrocenepalladium (55.9 mg, 0.0877 mmol) and potassium phosphate (558 mg, 2.63 mmol) were added, and the reaction mixture was stirred at 100°C for 16 hours to stop the reaction. Then water (35.0 mL) was added for dilution, and then EA (35.0 mL×3) was used for extraction. The organic phases were combined, washed with saturated brine (35.0 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was separated and purified by column chromatography (PE:EA=1:1) to obtain the target compound (150 mg, yield 35.6%, yellow solid). LC-MS(ESI)m / z 481.4[M+H] + .
[0674] Step 5: Synthesis of 4-(5-((1R,5S)-8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-3-(1H-pyrazol-5-yl)pyrazolo[1,5-a]pyrimidin-7-yl)tetrahydro-2H-pyran-4-ol
[0675]
[0676] 4-(5-((1R,5S)-8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-3-(1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-5-yl)pyrazolo[1,5-a]pyrimidin-7-yl)tetrahydro-2H-pyran-4-ol (150 mg, 0.312 mmol) and ethyl acetate hydrochloride (10.0 mL, 3 M) were added to the reaction bottle at room temperature. The reaction mixture was stirred at room temperature for 2 hours and the reaction was stopped. The mixture was concentrated under reduced pressure and the obtained residue was purified by reverse phase preparation (acetonitrile / water containing 0.05% formic acid) to obtain the target compound (66.6 mg, yield 53.8%, white solid). LC-MS (ESI) m / z 397.2 [M+H] + . 1 H NMR(400MHz, CDCl3)δ8.21(s,1H),7.64(s,1H),6.56(s,1H),6.20(s,1H),4.59–4.55(m,2H),4.11–4.05(m,2H),4 .04–3.93(m,2H),3.93–3.87(m,2H),3.40–3.34(m,2H),2.26–2.20(m,2H),2.13–2.02(m,4H),1.88–1.80(m,2H).
[0677] Example 26: 3-(7-(1-methyl-1H-pyrazol-5-yl)-3-(1H-pyrazol-3-yl)pyrazolo[1,5-a]pyrimidine pyridine-5-yl)-8-oxa-3-azabicyclo[3.2.1]octane
[0678]
[0679] Step 1: Synthesis of 5-chloro-7-(1-methyl-1H-pyrazol-5-yl)pyrazolo[1,5-a]pyrimidine
[0680]
[0681] At room temperature, sodium carbonate (1.69 g, 16.0 mmol) and [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium (340 mg, 0.532 mmol) were added to a mixed solution of 5,7-dichloropyrazolo[1,5-a]pyrimidine (1.00 g, 5.32 mmol) and 1-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (1.33 g, 6.38 mmol) in water (1.00 mL) and dioxane (4.00 mL) under nitrogen protection. The reaction mixture was stirred at 90°C for 10 hours under nitrogen protection, and then the reaction was stopped. After the reaction solution was cooled, water (20.0 mL) was added, and then extracted with EA (30.0 mL × 2). The organic phases were combined, washed with saturated brine (20.0 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The obtained residue was separated and purified by normal phase chromatography (EA: PE = 1: 1) to obtain a crude product (370 mg, yield 29.7%, yellow solid). LC-MS (ESI) m / z 233.9 [M + H] + .
[0682] Step 2: Synthesis of 3-(7-(1-methyl-1H-pyrazol-5-yl)pyrazolo[1,5-a]pyrimidin-5-yl)-8-oxa-3-azabicyclo[3.2.1]octane
[0683]
[0684] DIEA (613 mg, 4.75 mmol) was added to a solution of 5-chloro-7-(1-methyl-1H-pyrazol-5-yl)pyrazolo[1,5-a]pyrimidine (370 mg, 1.58 mmol) and 8-oxa-3-azabicyclo[3.2.1]octane hydrochloride (358 mg, 2.39 mmol) in NMP (15.0 mL) at room temperature. The reaction mixture was reacted in a microwave reactor at 140°C under nitrogen protection for 2 hours to stop the reaction. The reaction solution was then diluted with EA (35.0 mL), washed with saturated brine (30.0 mL×3), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was separated and purified by column chromatography (PE:EA=1:1) to obtain the target compound (260 mg, yield 52.9%, yellow oil). LC-MS(ESI)m / z 311.2[M+H] + . 1H NMR (400MHz, CDCl3) δ7.92(d,J=2.2Hz,1H),7.61(d,J=1.9Hz,1H),6.63(d,J=1.9Hz,1H),6.30(s,1H),6.23(d,J=2.2 Hz,1H),4.55–4.50(m,2H),3.97–3.90(m,2H),3.88(s,3H),3.33–3.27(m,2H),2.04–1.98(m,2H),1.90–1.82(m,2H).
[0685] Step 3: Synthesis of 3-(3-iodo-7-(1-methyl-1H-pyrazol-5-yl)pyrazolo[1,5-a]pyrimidin-5-yl)-8-oxa-3-azabicyclo[3.2.1]octane
[0686]
[0687] NIS (188 mg, 0.837 mmol) was added to a solution of 3-(7-(1-methyl-1H-pyrazol-5-yl)pyrazolo[1,5-a]pyrimidin-5-yl)-8-oxa-3-azabicyclo[3.2.1]octane (260 mg, 0.837 mmol) in acetonitrile (10.0 mL). The reaction mixture was stirred at room temperature for 3 hours to stop the reaction. Water (15.0 mL) was then added, and the mixture was extracted with EA (20.0 mL×3). The combined organic phases were washed with saturated brine (15.0 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was separated and purified by column chromatography (PE:EA=1:1) to obtain the target compound (300 mg, yield 82.1%, yellow solid). LC-MS(ESI)m / z 436.9[M+H] + , 1 H NMR(400MHz, CDCl3)δ7.90(s,1H),7.62(d,J=1.9Hz,1H),6.61(d,J=1.9Hz,1H),6.30(s,1H),4.57–4 .52(m,2H),4.11–3.89(m,2H),3.85(s,3H),3.37–3.30(m,2H),2.05–1.99(m,2H),1.90–1.82(m,2H).
[0688] Step 4: Synthesis of 3-(7-(1-methyl-1H-pyrazol-5-yl)-3-(1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)pyrazolo[1,5-a]pyrimidin-5-yl)-8-oxa-3-azabicyclo[3.2.1]octane
[0689]
[0690] Under nitrogen protection, Pd(dtbpf)Cl2 (43.8 mg, 0.0687 mmol) and potassium phosphate (437 mg, 0.2.06 mmol) were added to a solution of 3-(3-iodo-7-(1-methyl-1H-pyrazol-5-yl)pyrazolo[1,5-a]pyrimidin-5-yl)-8-oxa-3-azabicyclo[3.2.1]octane (300 mg, 0.687 mmol) and 1-(tetrahydro-2H-pyran-2-yl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (286 mg, 1.03 mmol) in 1,4-dioxane (10.0 mL) and water (2.00 mL). The reaction mixture was stirred at 60°C for 16 hours and the reaction was stopped. Then dilute with water (30.0 mL), extract with EA (30.0 mL × 3), wash the combined organic phases with saturated brine (25.0 mL), dry over anhydrous sodium sulfate, filter, and concentrate under reduced pressure. The residue is separated and purified by column chromatography (PE: EA = 1: 1) to obtain the target compound (150 mg, yield 47.3%, yellow solid). LC-MS (ESI) m / z 461.1 [M+H] + . 1 H NMR (400MHz, CDCl3) δ8.16(s,1H),7.68(d,J=1.5Hz,1H),7.64(d,J=1.9Hz,1H) ,6.71–6.63(m,2H),6.38(s,1H),5.51–5.39(m,1H),4.60–4.51(m,2H),4.09–3 .95(m,2H),3.93(s,3H),3.72–3.61(m,1H),3.39–3.30(m,2H),2.72–2.59(m,1 H),2.16–2.09(m,1H),2.02–1.96(m,2H),1.88–1.77(m,3H),1.64–1.55(m,2H).
[0691] Step 5: Synthesis of 3-(7-(1-methyl-1H-pyrazol-5-yl)-3-(1H-pyrazol-3-yl)pyrazolo[1,5-a]pyrimidin-5-yl)-8-oxa-3-azabicyclo[3.2.1]octane
[0692]
[0693] 3-(7-(1-methyl-1H-pyrazol-5-yl)-3-(1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)pyrazolo[1,5-a]pyrimidin-5-yl)-8-oxa-3-azabicyclo[3.2.1]octane (150 mg, 0.325 mmol) and EA solution of hydrochloric acid (5.00 mL, 3 M) were added to the reaction bottle at room temperature. The reaction mixture was stirred at room temperature for 2 hours and the reaction was stopped. The mixture was concentrated under reduced pressure and the obtained residue was purified by reverse phase preparation (acetonitrile / water containing 0.05% formic acid) to obtain the target compound (82.68 mg, yield 67.4%, light yellow solid). LC-MS (ESI) m / z 377.2 [M+H] + . 1 H NMR (400MHz, DMSO-d6) δ12.89–12.58(m,1H),8.38–8.19(m,1H),7.80–7.45(m,2H),6.89–6.68( m,3H),4.52–4.46(m,2H),4.31–4.03(m,2H),3.85(s,3H),3.23–3.15(m,2H),1.89–1.74(m,4H).
[0694] Example 27: 3-(8-(1-methyl-1H-pyrazol-5-yl)-3-(1H-pyrazol-3-yl)imidazo[1,2-b]pyridinium oxazine-6-yl)-8-oxa-3-azabicyclo[3.2.1]octane
[0695]
[0696] Step 1: Synthesis of 8-bromo-6-chloro-3-iodoimidazo[1,2-b]pyridazine
[0697]
[0698] NIS (1.94 g, 8.60 mmol) was added to a solution of 8-bromo-6-chloroimidazo[1,2-b]pyridazine (2.00 g, 8.60 mmol) in acetonitrile (30.0 mL). The reaction mixture was stirred at room temperature for 2 hours to stop the reaction. Water (45.0 mL) was then added, and the mixture was extracted with EA (40.0 mL × 3). The combined organic phases were washed with saturated brine (40.0 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was separated and purified by column chromatography (PE: EA = 5: 1) to obtain the target compound (3.00 g, yield 97.3%, yellow solid). LC-MS (ESI) m / z 357.8 [M+H] + ,359.8[M+2+H] + .
[0699] Step 2: Synthesis of 8-bromo-6-chloro-3-(1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)imidazo[1,2-b]pyridazine
[0700]
[0701] Under nitrogen protection, tetrakistriphenylphosphine palladium (644 mg, 0.558 mmol) and potassium phosphate (3.55 g, 16.7 mmol) were added to a solution of 8-bromo-6-chloro-3-iodoimidazo[1,2-b]pyridazine (2.00 g, 5.58 mmol) and 1-(tetrahydro-2H-pyran-2-yl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (1.55 g, 5.58 mmol) in 1,4-dioxane (20.0 mL) and water (4.00 mL). The reaction mixture was stirred at room temperature for 16 hours and the reaction was stopped. Then water (45.0 mL) was added, and then extracted with EA (45.0 mL × 3). The combined organic phases were washed with saturated brine (45.0 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was separated and purified by column chromatography (PE: EA = 3: 1) to obtain the target compound (400 mg, yield 18.7%, yellow solid). LC-MS (ESI) m / z 382.0 [M+H] + ,384.0[M+2+H] + . 1 HNMR(400MHz, CDCl3)δ8.10(s,1H),7.73(s,1H),7.46(s,1H),6.91(s,1H),5.32–5.27(m,1H),4.11–4.0 6(m,1H),3.68–3.62(m,1H),2.65–2.56(m,1H),2.02–1.97(m,2H),1.77–1.70(m,1H),1.63–1.57(m,2H).
[0702] Step 3: Synthesis of 6-chloro-8-(1-methyl-1H-pyrazol-5-yl)-3-(1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)imidazo[1,2-b]pyridazine
[0703]
[0704] Under nitrogen protection, 1,1-bis(diphenylphosphino)ferrocenepalladium chloride (76.5 mg, 0.105 mmol) and potassium phosphate (666 mg, 3.14 mmol) were added to a solution of 8-bromo-6-chloro-3-(1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)imidazo[1,2-b]pyridazine (400 mg, 1.05 mmol) and 1-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (217 mg, 1.05 mmol) in 1,4-dioxane (10.0 mL) and water (2.00 mL). The reaction mixture was stirred at 60 ° C for 2 hours to stop the reaction. Then water (25.0 mL) was added, and then extracted with EA (25.0 mL × 3). The combined organic phases were washed with saturated brine (20.0 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was separated and purified by column chromatography (PE: EA = 1: 1) to obtain the target compound (150 mg, yield 37.4%, yellow solid). LC-MS (ESI) m / z 384.0 [M + H] + . 1 H NMR(400MHz, CDCl3)δ8.10(s,1H),7.73(s,1H),7.46(s,1H),6.91(s,1H),5.32–5.27(m,1H),4.11–4.06 (m,1H),3.68–3.62(m,1H),2.65–2.56(m,1H),2.02–1.97(m,2H),1.77–1.70(m,1H),1.63–1.57(m,2H).
[0705] Step 4: Synthesis of 3-(8-(1-methyl-1H-pyrazol-5-yl)-3-(1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)imidazo[1,2-b]pyridazin-6-yl)-8-oxa-3-azabicyclo[3.2.1]octane
[0706]
[0707] Under nitrogen protection, cesium carbonate (382 mg, 1.17 mmol) and 8-oxa-3-azabicyclo[3.2.1]octane hydrochloride (66.3 mg, 0.443 mmol) were added to a solution of 6-chloro-8-(1-methyl-1H-pyrazol-5-yl)-3-(1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)imidazo[1,2-b]pyridazine (150 mg, 0.391 mmol) and (2-amino-2-[1,1'-biphenyl]-2-yl)(dicyclohexyl(2,6-diisopropoxy-2-[1,1'-biphenyl]-2-yl)-phosphonyl)palladium(II) chloride (39.1 mg, 0.0391 mmol) in toluene (6.00 mL), and the reaction mixture was stirred at 110°C for 16 hours to stop the reaction. Then water (15.0 mL) was added, and then extracted with EA (15.0 mL×3). The combined organic phases were washed with saturated brine (20.0 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was separated and purified by column chromatography (PE:EA=1:1) to obtain the target compound (60.0 mg, yield 33.3%, yellow solid). LC-MS (ESI) m / z 461.2[M+H] + .
[0708] Step 5: Synthesis of 3-(8-(1-methyl-1H-pyrazol-5-yl)-3-(1H-pyrazol-3-yl)imidazo[1,2-b]pyridazin-6-yl)-8-oxa-3-azabicyclo[3.2.1]octane
[0709]
[0710] At room temperature, 3-(8-(1-methyl-1H-pyrazol-5-yl)-3-(1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)imidazo[1,2-b]pyridazine-6-yl)-8-oxa-3-azabicyclo[3.2.1]octane (60.0 mg, 0.130 mmol) and EA solution of hydrochloric acid (5.00 mL, 3 M) were added to the reaction bottle. The reaction mixture was stirred at room temperature for 2 hours to stop the reaction. The residue was concentrated under reduced pressure and purified by reverse phase preparation (acetonitrile / water containing 0.05% formic acid) to obtain the target compound (18.0 mg, yield 36.7%, white solid). LC-MS (ESI) m / z 377.2 [M+H] + . 1H NMR(400MHz,MeOD-d4)δ7.98(s,1H),7.82–7.74(m,1H),7.63(d,J=1.9Hz,1H),7.24–7.18(m,1H),7.17(s,1H),6.71(d,J =1.9Hz,1H),4.58–4.52(m,2H),3.93(s,4H),3.90–3.88(m,1H),3.30–3.28(m,1H),3.28–3.25(m,1H),2.04–1.97(m,4H).
[0711] Example 28: 3-(7-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-3-(1H-pyrazol-5-yl)pyrrolidone oxazolidin-5-yl)-8-oxa-3-azabicyclo[3.2.1]octane
[0712]
[0713] Step 1: Synthesis of 3-(7-(8-oxa-3-azabicyclo[3.2.1]octane-3-yl)pyrazolo[1,5-a]pyrimidin-5-yl)-8-oxa-3-azabicyclo[3.2.1]octane
[0714]
[0715] DIEA (2.06 g, 16.0 mmol) was added to a solution of 5,7-dichloropyrazolo[1,5-a]pyrimidine (1.00 g, 5.32 mmol) and (1R,5S)-8-oxa-3-azabicyclo[3.2.1]octane hydrochloride (2.39 g, 16.0 mmol) in N-methylpyrrolidone (15.0 mL). The reaction mixture was stirred at 145°C for 16 hours to stop the reaction. After the reaction mixture was cooled to room temperature, water (20.0 mL) was added to dilute it, and it was extracted with EA (25.0 mL×3). The organic phases were combined and washed with water (20.0 mL×3) and saturated brine (20.0 mL×3), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was separated and purified by column chromatography (PE:EA=10:1-1:1) to obtain the target compound (550 mg, yield 30.3%, white solid). LC-MS (ESI) m / z 342.3 [M+H] + .
[0716] Step 2: Synthesis of 3-(7-(8-oxa-3-azabicyclo[3.2.1]octane-3-yl)-3-iodopyrazolo[1,5-a]pyrimidin-5-yl)-8-oxa-3-azabicyclo[3.2.1]octane
[0717]
[0718] To a solution of 3-(7-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)pyrazolo[1,5-a]pyrimidin-5-yl)-8-oxa-3-azabicyclo[3.2.1]octane (550 mg, 1.61 mmol) in acetonitrile (20.0 mL) was added N-iodosuccinimide (399 mg, 1.77 mmol). The reaction mixture was stirred at room temperature for 2 hours and then the reaction was stopped. The reaction mixture was concentrated under reduced pressure and the residue was purified by column chromatography (PE:EA=5:1-1:1) to obtain the target compound (500 mg, yield 66.4%, yellow solid). LC-MS (ESI) m / z 468.3 [M+H] + . 1 H NMR(400MHz,DMSO-d6)δ7.90(s,1H),5.70(s,1H),4.45–4.38(m,4H),4.08–3.98(m ,4H),3.09–3.00(m,4H),2.07–1.98(m,2H),1.90–1.78(m,4H),1.75–1.65(m,2H).
[0719] Step 3: Synthesis of 3-(7-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-3-(1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-5-yl)pyrazolo[1,5-a]pyrimidin-5-yl)-8-oxa-3-azabicyclo[3.2.1]octane
[0720]
[0721] To a mixed solution of 3-(7-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-3-iodopyrazolo[1,5-a]pyrimidin-5-yl)-8-oxa-3-azabicyclo[3.2.1]octane (300 mg, 0.642 mmol) and 1-(tetrahydro-2H-pyran-2-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxybenzofuran-2-yl)-1H-pyrazole (268 mg, 0.963 mmol) in water (1.00 mL) and 1,4-dioxane (5.00 mL) were added potassium carbonate (177 mg, 1.28 mmol) and [1,1'-bis(di-tert-butylphosphino)ferrocene]palladium dichloride (42.0 mg, 0.0642 mmol). The reaction mixture was stirred at 60°C under nitrogen protection for 8 hours, and then the reaction was stopped. After the reaction solution was cooled to room temperature, water (10.0 mL) was added, and then extracted with EA (15.0 mL×3). The organic phase was washed with saturated brine (15.0 mL×2) and dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was separated and purified by column chromatography (PE:EA=5:1-1:3) to obtain the target compound (150 mg, yield 47.5%, yellow solid). LC-MS (ESI) m / z 492.4[M+H] + .
[0722] Step 4: Synthesis of 3-(7-(8-oxa-3-azabicyclo[3.2.1]octane-3-yl)-3-(1H-pyrazol-5-yl)pyrazolo[1,5-a]pyrimidin-5-yl)-8-oxa-3-azabicyclo[3.2.1]octane
[0723]
[0724] A solution of 3-(7-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-3-(1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-5-yl)pyrazolo[1,5-a]pyrimidin-5-yl)-8-oxa-3-azabicyclo[3.2.1]octane (120 mg, 0.244 mmol) in methanolic hydrogen chloride (3.0 M, 3.00 mL) was stirred at room temperature for 1 hour to stop the reaction. The reaction mixture was concentrated under reduced pressure, and the residue was separated and purified by reverse phase preparation (acetonitrile / water containing 0.05% formic acid) to obtain the target compound (33.96 mg, yield 34.1%, white solid). LC-MS (ESI) m / z 408.2 [M+H] + . 1H NMR(400MHz,DMSO-d6)δ12.64(Brs,1H),8.23(s,1H),7.55(s,1H),6.69(s,1H),5.72(s,1H),4.49–4.41(m ,4H),4.16–4.04(m,4H),3.09(d,J=10.9Hz,4H),2.11–2.01(m,2H),1.92–1.80(m,4H),1.77–1.68(m,2H).
[0725] Example 29: 1-((R)-4-(2-((1R,S)-8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-7- (1H-pyrazol-3-yl)imidazo[1,5-b]pyridazin-4-yl)-3-methylpiperazin-1-yl)ethan-1-one
[0726]
[0727] Step 1: Synthesis of (R)-tert-butyl 4-(3,6-dichloropyridazin-4-yl)-3-methylpiperazine-1-carboxylate
[0728]
[0729] 3,4,6-trichloropyridazine (5.49 g, 29.9 mmol) and DIEA (9.68 g, 74.9 mmol) were added to a solution of (R)-3-methylpiperazine-1-carboxylic acid tert-butyl ester (5.00 g, 24.9 mmol) in N-methylpyrrolidone (35.0 mL). The reaction mixture was stirred at room temperature for 16 hours under nitrogen protection to stop the reaction. Then water (60.0 mL) was added for dilution, and then ethyl acetate (50.0 mL × 3) was used for extraction. The organic phase was washed with saturated brine (40.0 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was separated and purified by column chromatography (petroleum ether: ethyl acetate = 5:1) to obtain the target compound (3.50 g, yield 40.4%, yellow solid). LC-MS (ESI) m / z 346.9 [M+H] + . 1 H NMR(400MHz, CDCl3)δ6.83(s,1H),4.21–4.16(m,1H),4.14–4.08(m,1H),3.83(d,J=1 3.1Hz,1H),3.42–3.29(m,2H),3.13–3.09(m,2H),1.47(s,9H),1.12(d,J=6.6Hz,3H).
[0730] Step 2: Synthesis of (R)-3,6-dichloro-4-(2-methylpiperazin-1-yl)pyridazine
[0731]
[0732] Add tert-butyl (R)-4-(3,6-dichloropyridazin-4-yl)-3-methylpiperazine-1-carboxylate (3.50 g, 10.1 mmol) and hydrochloric acid / ethyl acetate (8.00 mL, 4 M) to the reaction flask, stir the reaction mixture at room temperature for 5 hours, and stop the reaction. Concentrate the reaction mixture under reduced pressure to obtain the target compound (2.30 g, yield 80.5%, yellow solid). LC-MS (ESI) m / z 247.0 [M+H] + Step 3: Synthesis of (R)-1-(4-(3,6-dichloropyridazin-4-yl)-3-methylpiperazin-1-yl)ethan-1-one
[0733]
[0734] Acetyl chloride (0.955 g, 12.2 mmol) and triethylamine (2.46 g, 24.3 mmol) were added to a solution of (R)-3,6-dichloro-4-(2-methylpiperazin-1-yl)pyridazine hydrochloride (2.30 g, 8.11 mmol) in dichloromethane (20.0 mL). The reaction mixture was stirred at room temperature for 16 hours to stop the reaction. Then water (50.0 mL) was added for dilution, and then ethyl acetate (45.0 mL × 3) was used for extraction. The organic phase was washed with saturated brine (30.0 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was separated and purified by chromatography (petroleum ether: ethyl acetate = 5:1) to obtain the target compound (2.00 g, yield 85.2%, yellow solid). LC-MS (ESI) m / z 288.9 [M+H] + . 1 H NMR (400 MHz, CDCl3) δ 6.85 (s, 1H), 4.75–4.49 (m, 1H), 4.36–4.15 (m, 2H), 3.47–3.30 (m, 2H), 3.23–2.94 (m, 2H), 2.17–2.10 (m, 3H), 1.19–1.12 (m, 3H). Step 4: Synthesis of 1-((3R)-4-(6-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-3-chloropyridazin-4-yl)-3-methylpiperazin-1-yl)ethan-1-one
[0735]
[0736] To a solution of (R)-1-(4-(3,6-dichloropyridazin-4-yl)-3-methylpiperazin-1-yl)ethan-1-one (2.00 g, 6.92 mmol) in N-methylpyrrolidone (25.0 mL) were added (1R,5S)-8-oxa-3-azabicyclo[3.2.1]octane hydrochloride (1.55 g, 10.4 mmol) and N,N-diisopropylethylamine (2.68 g, 20.7 mmol). The reaction mixture was stirred at 145 °C for 16 hours and the reaction was stopped. Then water (50.0 mL) was added for dilution, and then ethyl acetate (45.0 mL × 3) was used for extraction. The organic phase was washed with saturated brine (40.0 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was separated and purified by column chromatography (PE: EA = 1: 1) to obtain the target compound (1.80 g, yield 71.1%, yellow solid). LC-MS (ESI) m / z 366.3 [M+H] + . 1 H NMR (400MHz, CDCl3) δ6.15–6.08(m,1H),4.54–4.44(m,3H),3.97–3.82(m,2H),3.78–3.64(m,2H),3.58–3.47(m,2H) ,3.25–3.18(m,2H),2.20–2.13(m,2H),2.13–2.10(m,2H),2.02–1.97(m,2H),1.89–1.81(m,3H),1.06–1.01(m,3H).
[0737] Step 5: Synthesis of 4-((R)-4-acetyl-2-methylpiperazin-1-yl)-6-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)pyridazine-3-carbonitrile
[0738]
[0739] 2-(Diphenylphosphonyl)cyclopentadienyl iron (546 mg, 0.984 mmol) and tris dibenzylideneacetone dipalladium (450 mg, 0.492 mmol) were added to a solution of 1-((3R)-4-(6-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-3-chloropyridazin-4-yl)-3-methylpiperazin-1-yl)ethan-1-one (1.8 g, 4.92 mmol) and zinc cyanide (1.16 g, 9.84 mmol) in DMF (30.0 mL). The reaction mixture was stirred at 135° C. for 16 hours under nitrogen protection, and the reaction was stopped. The reaction solution was then diluted with EA (40.0 mL), washed with saturated brine (35 mL × 3), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The resulting residue was separated and purified by column chromatography (DCM: methanol = 10:1) to obtain the target compound (1.05 g, yield 59.9%, yellow solid). LC-MS (ESI) m / z 357.0 [M+H] + . 1 H NMR (400MHz, CDCl3) δ5.95–5.84(m,1H),4.74–4.61(m,1H),4.53(s,2H),4.30–4.18(m,1H),4.07–3.83(m,2H),3.66(s,1H),3.54 –3.41(m,1H),3.36–3.17(m,4H),3.03–2.89(m,1H),2.18–2.10(m,3H),2.03–1.98(m,2H),1.87–1.79(m,2H),1.19–1.12(m,3H).
[0740] Step 6: Synthesis of 1-((3R)-4-(3-(aminomethyl)-6-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)pyridazin-4-yl)-3-methylpiperazin-1-yl)ethan-1-one
[0741]
[0742] To a solution of 4-((R)-4-acetyl-2-methylpiperazin-1-yl)-6-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)pyridazine-3-carbonitrile (1.10 g, 3.09 mmol) in tetrahydrofuran (15.0 mL) was added Raney nickel (543 mg, 9.26 mmol) and aqueous ammonia (1.00 mL). The reaction mixture was reacted at room temperature for 5 hours under hydrogen atmosphere, and the reaction was stopped. The reaction solution was then filtered and concentrated under reduced pressure. The residue obtained was the target compound (660 mg, yield 59.3%, yellow oil). LC-MS (ESI) m / z 361.0 [M+H] +Step 7: Synthesis of N-((4-((R)-4-acetyl-2-methylpiperazin-1-yl)-6-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)pyridazin-3-yl)methyl)-1H-pyrazole-5-carboxamide
[0743]
[0744] To a solution of 1-((3R)-4-(3-(aminomethyl)-6-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)pyridazin-4-yl)-3-methylpiperazin-1-yl)ethan-1-one (360 mg, 0.999 mmol) and 1H-pyrazole-5-carboxylic acid (101 mg, 0.899 mmol) in tetrahydrofuran (10.0 mL) were added 2-(3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (0.456 mg, 1.20 mmol) and DIEA (387 mg, 3.00 mmol), and the reaction mixture was stirred at room temperature for 1 hour to stop the reaction. Then water (30.0 mL) was added, and then extracted with EA (25.0 mL×3). The combined organic phases were washed with saturated brine (20.0 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was separated and purified by column chromatography (DCM: methanol = 10:1) to obtain the target compound (170 mg, yield 37.4%, yellow solid). LC-MS (ESI) m / z 455.0 [M+H] + .
[0745] Step 8: Synthesis of 1-((R)-4-(2-((1R,5S)-8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-7-(1H-pyrazol-3-yl)imidazo[1,5-b]pyridazin-4-yl)-3-methylpiperazin-1-yl)ethan-1-one
[0746]
[0747] At room temperature, N-((4-((R)-4-acetyl-2-methylpiperazin-1-yl)-6-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)pyridazin-3-yl)methyl)-1H-pyrazole-5-carboxamide (170 mg, 0.374 mmol) and phosphorus oxychloride (6.00 mL) were added to the reaction bottle. The reaction mixture was reacted at 100°C for 1 hour and the reaction was stopped. The reaction solution was concentrated under reduced pressure, and the obtained residue was purified by reverse phase preparation (acetonitrile / water containing 0.05% formic acid) to obtain the target compound (6.68 mg, yield 4.09%, white solid). LC-MS (ESI) m / z 437.3 [M+H] + .1 H NMR(400MHz,MeOD-d4)δ7.83–7.51(m,2H),7.13(s,1H),5.80(s,1H),4.55–4.48(m,3H),3.87–3.80(m ,2H),3.74–3.42(m,4H),3.30–3.05(m,4H),2.24-2.12(m,3H),2.04–1.93(m,4H),1.26-1.13(m,3H).
[0748] Example 30: 3-(4-(4,4-difluoro-2-methylpiperidin-1-yl)-7-(1H-pyrazol-3-yl)imidazo[1,5- b]pyridazin-2-yl)-8-oxa-3-azabicyclo[3.2.1]octane
[0749]
[0750] Step 1: Synthesis of 1-(3,6-dichloropyridazin-4-yl)-2-methylpiperidin-4-one
[0751]
[0752] DIEA (6.09 g, 60.2 mmol) was added to a solution of 2-methylpiperidin-4-one hydrochloride (3.00 g, 20.1 mmol) and 3,4,6-trichloropyridazine (4.41 g, 24.1 mmol) in N-methylpyrrolidone (50.0 mL). The reaction mixture was stirred at 60 °C for 16 hours under nitrogen protection to stop the reaction. The reaction solution was then diluted with ethyl acetate (100 mL), washed with saturated brine (60.0 mL × 3), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was separated and purified by column chromatography (PE: EA = 5: 1) to obtain the target compound (3.00 g, yield 57.5%, yellow solid). LC-MS (ESI) m / z 260.0 [M+H] + .
[0753] Step 2: Synthesis of 3,6-dichloro-4-(4,4-difluoro-2-methylpiperidin-1-yl)pyridazine
[0754]
[0755] Add diethylaminosulfur trifluoride (2.60 g, 16.2 mmol) to a solution of 1-(3,6-dichloropyridazine-4-yl)-2-methylpiperidin-4-one (2.8 g, 10.7 mmol) in dichloromethane (50.0 mL) at 0°C under nitrogen protection. Stir the reaction mixture at 0°C under nitrogen protection for 1 hour to stop the reaction. Then, concentrate the reaction mixture under reduced pressure to obtain the target compound (1.80 g, yield 59.3%, yellow oil). LC-MS (ESI) m / z 281.9 [M+H]+ .
[0756] Step 3: Synthesis of 3-(6-chloro-5-(4,4-difluoro-2-methylpiperidin-1-yl)pyridazin-3-yl)-8-oxa-3-azabicyclo[3.2.1]octane
[0757]
[0758] DIEA (2.47 g, 19.1 mmol) was added to a solution of 3,6-dichloro-4-(4,4-difluoro-2-methylpiperidin-1-yl)pyridazine (1.80 g, 6.38 mmol) and 8-oxa-3-azabicyclo[3.2.1]octane hydrochloride (1.43 g, 9.57 mmol) in N-methylpyrrolidone (50.0 mL). The reaction mixture was stirred at 145°C for 16 hours under nitrogen protection to stop the reaction. The reaction solution was then diluted with ethyl acetate (85.0 mL), washed with saturated brine (55.0 mL×3), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was separated and purified by column chromatography (PE:EA=1:1) to obtain the target compound (1.80 g, yield 78.6%, yellow solid). LC-MS (ESI) m / z 359.0 [M+H] + . 1 H NMR(400MHz, CDCl3)δ6.23(s,1H),4.54–4.50(m,2H),4.09–3.96(m,1H),3.86–3.74(m,2H),3.47–3.37(m,1H),3.26–3.19(m,2 H),3.13–2.99(m,1H),2.32–2.23(m,1H),2.23–2.08(m,2H),2.04–1.97(m,3H),1.90–1.84(m,2H),1.14(d,J=16.6,6.7Hz,3H).
[0759] Step 4: Synthesis of 6-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-4-(4,4-difluoro-2-methylpiperidin-1-yl)pyridazine-3-carbonitrile
[0760]
[0761] 2-(Diphenylphosphonyl)cyclopentadienyl iron (556 mg, 1.00 mmol) and tris dibenzylideneacetone dipalladium (459 mg, 0.501 mmol) were added to a solution of 3-(6-chloro-5-(4,4-difluoro-2-methylpiperidin-1-yl)pyridazin-3-yl)-8-oxa-3-azabicyclo[3.2.1]octane (1.8 g, 5.02 mmol) and zinc cyanide (1.18 g, 10.0 mmol) in N,N-dimethylformamide (30.0 mL). The reaction mixture was stirred at 140°C for 16 hours under nitrogen protection, and the reaction was stopped. The reaction solution was then diluted with ethyl acetate (65.0 mL), washed with saturated brine (40.0 mL × 3), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The resulting residue was separated and purified by column chromatography (PE: EA = 1: 1) to obtain the target compound (1.50 g, yield 85.6%, yellow solid). LC-MS (ESI) m / z 350.1 [M+H] + . 1 H NMR(400MHz, CDCl3)δ5.93(s,1H),4.53–4.50(m,2H),4.42–4.33(m,1H),4.01–3.90(m,2H),3.51–3.42(m,2 H),3.31–3.26(m,2H),2.29–2.15(m,2H),2.11–1.99(m,4H),1.84–1.80(m,2H),1.24(dd,J=6.9,1.7Hz,3H).
[0762] Step 5: Synthesis of (6-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-4-(4,4-difluoro-2-methylpiperidin-1-yl)pyridazin-3-yl)methanamine
[0763]
[0764] To a solution of 6-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-4-(4,4-difluoro-2-methylpiperidin-1-yl)pyridazine-3-carbonitrile (1.50 g, 4.29 mmol) in tetrahydrofuran (30.0 mL) was added Raney nickel (1.26 g, 21.5 mmol). The reaction mixture was reacted at room temperature for 16 hours under hydrogen atmosphere, and the reaction was stopped. The reaction solution was then filtered and concentrated under reduced pressure. The residue obtained was the target compound (1.20 g, yield 79.1%, yellow oil). LC-MS (ESI) m / z 354.0 [M+H] + .
[0765] Step 6: Synthesis of N-((6-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-4-(4,4-difluoro-2-methylpiperidin-1-yl)pyridazin-3-yl)methyl)-1H-pyrazole-5-carboxamide
[0766]
[0767] To a solution of (6-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-4-(4,4-difluoro-2-methylpiperidin-1-yl)pyridazin-3-yl)methanamine (1.20 g, 3.40 mmol) and 1H-pyrazole-5-carboxylic acid (342 mg, 3.06 mmol) in tetrahydrofuran (30.0 mL) was added 2-(3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)-1,1,3,3-tetramethylurea hexafluorophosphate (1.55 g, 4.07 mmol,) and DIEA (1.32 g, 10.2 mmol). The reaction mixture was reacted at room temperature for 1 hour to stop the reaction. The reaction solution was then filtered and concentrated under reduced pressure. The residue was separated and purified by column chromatography (EA) to obtain the target compound (1.00 g, yield 65.8%, yellow solid). LC-MS (ESI) m / z 448.0 [M+H] + . 1 H NMR (400MHz, CDCl3) δ8.76 (s, 1H), 7.59 (d, J = 2.1Hz, 1H), 6.80 (d, J = 2.2Hz, 1H),6.44(s,1H),4.87–4.72(m,2H),4.55–4.50(m,2H),3.86–3.77(m,2H), 3.49(s,2H),3.38–3.31(m,1H),3.26–3.21(m,2H),2.35–2.22(m,2H),2.03 –1.99(m,2H),1.90–1.84(m,2H),1.50–1.47(m,2H),1.02(d,J=6.2Hz,3H).
[0768] Step 7: Synthesis of 3-(4-(-4,4-difluoro-2-methylpiperidin-1-yl)-7-(1H-pyrazol-3-yl)imidazo[1,5-b]pyridazin-2-yl)-8-oxa-3-azabicyclo[3.2.1]octane
[0769]
[0770] N-((6-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-4-(4,4-difluoro-2-methylpiperidin-1-yl)pyridazin-3-yl)methyl)-1H-pyrazole-5-carboxamide (200 mg, 0.447 mmol), phosphorus oxychloride (685 mg, 4.47 mmol) and acetonitrile (5 mL) were added to the reaction bottle at room temperature. The reaction mixture was reacted at 100°C for 1 hour and the reaction was stopped. The reaction solution was concentrated under reduced pressure and the residue was purified by reverse phase preparation (acetonitrile / water containing 0.05% formic acid) to obtain the target compound (110 mg, yield 57.3%, white solid). LC-MS (ESI) m / z 430.2 [M+H] + . 1 H NMR(400MHz,DMSO-d6)δ7.81–7.59(m,2H),7.10(s,1H),5.92(s,1H),4.71–4.59(m,1H),4.47(s,2H),3.88–3.79(m,3H),3 .47–3.40(m,1H),3.07(d,J=11.1Hz,2H),2.44–2.28(m,1H),2.22–2.04(m,3H),1.89-1.81(m,4H),1.21(d,J=5.6Hz,3H).
[0771] Example 3 1 and 32: 3-(4-((R)-4,4-difluoro-2-methylpiperidin-1-yl)-7-(1H-pyrazol-3-yl)imidazo[1,5-b]pyridazin-2-yl)-8-oxa-3-azabicyclo[3.2.1]octane, and 3-(4-((S)-4,4-difluoro-2-methylpiperidin-1-yl)-7-(1H-pyrazol-3-yl)imidazo[1,5-b]pyridazin-2-yl)-8-oxa-3-azabicyclo[3.2.1]octane
[0772]
[0773] Chiral separation of 50 mg of 3-(4-(-4,4-difluoro-2-methylpiperidin-1-yl)-7-(1H-pyrazol-3-yl)imidazo[1,5-b]pyridazin-2-yl)-8-oxa-3-azabicyclo[3.2.1]octane racemate was performed (Waters SFC 150 (room temperature, 100 bar, 214 nm) and 250*25mm10mm DAICELCHIRALPAKIG (supercritical carbon dioxide: MEOH (+0.1% 7.0 mol / l Ammonia in MEOH), 45:55, 3.2 min, 100 mL / min)) to obtain P1 (14.40 mg, ee 100.00%) which was eluted first (with a shorter retention time), and P2 (14.37 mg, ee 99.07%) which was eluted later (with a longer retention time). LC-MS (ESI) m / z 430.2 [M+H] + .
[0774] LC-MS (ESI) m / z 430.2[M+H]+. (P1):1H NMR(400MHz,MeOD-d4)δ7.71(s,1H),7.55(s,1H),7.13(s,1H),5.88(s,1H),4.71–4.63(m,1H),4.50(s,2H),3.87–3.76(m, 3H),3.58–3.50(m,1H),3.24–3.16(m,2H),2.44–2.28(m,1H),2.24–2.08(m,3H),2.01–1.94(m,4H),1.30(d,J=6.9Hz,3H);
[0775] (P2): 1 H NMR(400MHz,MeOD-d4)δ7.70(s,1H),7.54(s,1H),7.13(s,1H),5.88(s,1H),4.71–4.63(m,1H),4.50(s,2H),3.86–3.76(m, 3H),3.58–3.46(m,1H),3.22–3.17(m,2H),2.44–2.27(m,1H),2.25–2.08(m,3H),2.02–1.94(m,4H),1.30(d,J=7.3Hz,3H).
[0776] Example 34: 1-((R)-4-(6-((1R,5S)-8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-1- (1H-pyrazol-3-yl)-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methylpiperazin-1-yl)ethan-1-one
[0777]
[0778] Step 1: Synthesis of 1-((R)-4-(6-((1R,5S)-8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-1-(1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-1H-pyrazolyl[3,4-b]pyridin-4-yl)-3-methylpiperazin-1-yl)ethan-1-one
[0779]
[0780] (1R,5S)-3-(4-iodo-1-(1-(tetrahydro-2H-pyran-2-yl-1H-pyrazol-3-yl)-1H-pyrazolo[3,4-b]pyridin-6-yl)-8-oxa-3-azabicyclo[3.2.1]octane (1 g, 1.97 mmol), (R)-1-(3-methylpiperazin-1-yl)ethan-1-one (561 mg, 3.95 mmol), Ruphos G2 (155 mg, 0.2 mmol), cesium carbonate (1.93 g, 5.91 mmol) were added to NMP (10 mL) in sequence, and the reaction solution was reacted in a microwave at 150 degrees for 1 hour. After the reaction was completed, the reaction solution was cooled, and water (20 mL) was added, extracted with EA (20 mL × 3), and the organic phases were combined, washed with water and saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain a crude product. The crude product was separated and purified by a reverse phase column (MeOH:H2O=5%:95%-95%:5%) to obtain the target compound (60 mg, yield 6.0%). LC-MS (ESI) m / z 521.2 [M+H] + .
[0781] Step 2: Synthesis of 1-((R)-4-(6-((1R,5S)-8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-1-(1H-pyrazol-3-yl)-1H-pyrazolo[3,4-b]pyridin-4-yl)-3-methylpiperazin-1-yl)ethan-1-one
[0782]
[0783] 1-((R)-4-(6-((1R,5S)-8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-1-(1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-1H-pyrazolyl[3,4-b]pyridin-4-yl)-3-methylpiperazin-1-yl)ethan-1-one (60 mg, 0.12 mmol) was added to 6M aqueous hydrochloric acid solution / tetrahydrofuran (1 mL / 2 mL) and stirred at room temperature overnight. After the reaction was completed, the pH was adjusted to >8 with saturated aqueous sodium bicarbonate solution, extracted with EA (20 mL×3), the organic layers were combined and concentrated under reduced pressure to obtain a crude product, which was washed with EA (2 mL) to obtain the target solid (7 mg, yield 14.0%, green solid). LC-MS (ESI) m / z 437.3 [M+H] + . 1 H NMR(400MHz, CDCl3)δ7.97(s,1H),7.66(s,1H),6.82(s,1H),5.63(s,1H), 4.62–4.49(m,2H),4.46–4.33(m,1H),4.01–3.81(m,2H),3.74(s,2H),3.6 6–3.45(m,2H),3.46–3.34(m,1H),3.34–3.18(m,2H),3.18–3.03(m,1H),2 .24–2.10(m,3H),2.05–1.95(m,2H),1.92–1.83(m,2H),1.25–1.17(m,3H).
[0784] Example 35: (4-(6-((1R,5S)-8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-1-(1H-pyrrolidone oxazol-3-yl)-1H-pyrazolo[3,4-b]pyridin-4-yl)morpholin-3-yl)methanol
[0785]
[0786] Step 1: Synthesis of (4-(6-((1R,5S)-8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-1-(1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-1H-pyrazolo[3,4-b]pyridin-4-yl)morpholin-3-yl)methanol
[0787]
[0788] (1R,5S)-3-(4-iodo-1-(1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-1H-pyrazolo[3,4-b]pyridin-6-yl)-8-oxa-3-azabicyclo[3.2.1]octane (300 mg, 0.6 mmol), morpholin-3-ylmethanol (144 mg, 1.2 mmol), RuphosPdG2 (48 mg, 0.06 mmol) and cesium carbonate (582 mg, 1.8 mmol) were added to NMP (12 mL) in sequence, and the reaction was stirred at 150 °C in a microwave for 1 hour. After the reaction, EA (20 mL × 3) was used for extraction, the organic layers were combined, washed with water (20 mL × 5), washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain a crude product, which was separated and purified by silica gel column (DCM: MeOH = 30: 1) to obtain the target compound (29 mg, yield 9.7%, white solid). LC-MS (ESI) m / z: 496.3 [M + H] + .
[0789] Step 2: Synthesis of (4-(6-((1R,5S)-8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-1-(1H-pyrazol-3-yl)-1H-pyrazolo[3,4-b]pyridin-4-yl)morpholin-3-yl)methanol
[0790]
[0791] (4-(6-((1R,5S)-8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-1-(1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-1H-pyrazolo[3,4-b]pyridin-4-yl)morpholin-3-yl)methanol (29 mg, 0.06 mmol) was added to 6M aqueous hydrochloric acid solution / tetrahydrofuran (2 mL / 4 mL) and stirred at 50°C overnight. After the reaction was completed, the pH was adjusted to >8 with saturated aqueous sodium bicarbonate solution, extracted with EA (20 mL×3), the organic layers were combined, washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure to obtain a crude product. The target product (10 mg, yield 40.5%, white solid) was obtained by separation and purification on a silica gel column (DCM:MeOH=15:1). LC-MS (ESI) m / z: 412.2. 1H NMR(400MHz, CDCl3)δ8.02(s,1H),7.61(d,J=1.5Hz,1H),6.80(s,1H),5.69(s,1H),4.57–4.47(m,2H),4.21(d,J=11.7Hz,1H),4.17–4.09(m, 1H),4.10–3.98(m,2H),3.91–3.79(m,4H),3.80–3.69(m,1H),3.53(d, J=5.8Hz,2H),3.28–3.18(m,2H),2.06–1.91(m,3H),1.91–1.79(m,2H).
[0792] Example 36: 3-(7-(3,3-dimethylmorpholino)-3-(1H-pyrazol-5-yl)pyrazolo[1,5-a]pyrimidine-5-yl 1-(2-(2-nitrophenyl)-8-oxa-3-azabicyclo[3.2.1]octane
[0793]
[0794] Step 1: Synthesis of 4-(5-chloropyrazolo[1,5-a]pyrimidin-7-yl)-3,3-dimethylmorpholine
[0795]
[0796] 5,7-Dichloropyrazolo[1,5-a]pyrimidine (540mg, 2.9mmol), 3,3-dimethylmorpholine hydrochloride (1.0g, 8.6mmol) and DIEA (1.1g, 8.6mmol) were added to NMP (15mL). The resulting mixture was reacted at 100°C for 0.5 hours under the protection of nitrogen in a microwave oven. After the reaction, water (15mL) was added to the reaction mixture and extracted with EA (20mL×3). The combined organic phases were washed with water (30mL×5) and saturated brine (30mL×2), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure to obtain a crude product, which was separated and purified by silica gel column (PE:EA=7:3) to obtain the target compound (0.9g, yield 116.3%, white solid). LC-MS(ESI)m / z:267.0[M+H] + .
[0797] Step 2: Synthesis of 3-(7-(3,3-dimethylmorpholino)pyrazolo[1,5-a]pyrimidin-5-yl)-8-oxa-3-azabicyclo[3.2.1]octane
[0798]
[0799] 4-(5-chloropyrazolo[1,5-a]pyrimidin-7-yl)-3,3-dimethylmorpholine (200 mg, 0.8 mmol), (1R,5S)-8-oxa-3-azabicyclo[3.2.1]octane hydrochloride (225 mg, 1.5 mmol), and DIEA (290 mg, 2.3 mmol) were added to NMP (10 mL) in sequence. The reaction mixture was reacted at 140 ° C in a microwave for 2 hours. After the reaction, water (15 mL) was added to the reaction mixture, and it was extracted with EA (20 mL × 3). The organic phases were combined and washed with water (30 mL × 5) and saturated brine (30 mL × 2), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain a crude product. The target product (202 mg, yield 78.6%, white solid) was obtained by separation and purification on a silica gel column (PE:EA = 57%: 43%).
[0800] Step 3: Synthesis of 3-(7-(3,3-dimethylmorpholino)-3-iodopyrazolo[1,5-a]pyrimidin-5-yl)-8-oxa-3-azabicyclo[3.2.1]octane
[0801]
[0802] 3-(7-(3,3-dimethylmorpholino)pyrazolo[1,5-a]pyrimidin-5-yl)-8-oxa-3-azabicyclo[3.2.1]octane (202 mg, 0.6 mmol) and N-iodosuccinimide (135 mg, 0.6 mmol) were added to acetonitrile (5 mL) and stirred at room temperature for 0.5 hours. After the reaction was completed, the mixture was concentrated under reduced pressure to obtain a crude product, which was separated and purified by silica gel column (PE:EA=1:1) to obtain the target compound (224 mg, yield 79.7%, white solid).
[0803] Step 4: Synthesis of 3-(7-(3,3-dimethylmorpholino)-3-(1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-5-yl)pyrazolo[1,5-a]pyrimidin-5-yl)-8-oxa-3-azabicyclo[3.2.1]octane
[0804]
[0805] 3-(7-(3,3-dimethylmorpholino)-3-iodopyrazolo[1,5-a]pyrimidin-5-yl)-8-oxa-3-azabicyclo[3.2.1]octane (172 mg, 0.4 mmol), 1-(tetrahydro-2H-pyran-2-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxybenzofuran-2-yl)-1H-pyrazole (153 mg, 0.6 mmol), potassium phosphate (233 mg, 1.1 mmol) and [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium (24 mg, 0.04 mmol) were added to dioxane / water (10 mL / 2 mL) in sequence. The reaction mixture was reacted in an oil bath at 80°C for 1 hour. After the reaction was completed, water (15 mL) was added to the reaction mixture, extracted with EA (20 mL × 3), and the combined organic phases were washed with water (30 mL × 5) and saturated brine (30 mL × 2), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure to obtain a crude product, which was separated and purified by silica gel column (PE: EA = 1: 4) to obtain the target compound (68 mg, yield 37.2%, white solid). LC-MS (ESI) m / z: 494.0 [M + H] + .
[0806] Step 5: Synthesis of 3-(7-(3,3-dimethylmorpholino)-3-(1H-pyrazol-5-yl)pyrazolo[1,5-a]pyrimidin-5-yl)-8-oxa-3-azabicyclo[3.2.1]octane
[0807]
[0808] 3-(7-(3,3-dimethylmorpholino)-3-(1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-5-yl)pyrazolo[1,5-a]pyrimidin-5-yl)-8-oxa-3-azabicyclo[3.2.1]octane (68 mg, 0.1 mmol) was added to 6M aqueous hydrochloric acid solution / tetrahydrofuran (2 mL / 4 mL) and stirred at 50°C for 1 hour. After the reaction was completed, the pH was adjusted to > 8 with saturated aqueous sodium bicarbonate solution, extracted with EA (20 mL×3), the organic layers were combined, washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain a crude product, which was separated and purified by silica gel column (DCM / MeOH=30 / 1) to obtain the target compound (38 mg, yield 67.9%, white solid). LC-MS (ESI) m / z: 410.2 [M+H] + . 1H NMR (400MHz, DMSO-d6) δ8.21 (s, 1H), 7.57 (s, 1H), 6.70 (s, 1H), 5.97 (s, 1H), 4.54-4.40 (m, 2H), 4.05 (d, J = 11.3 Hz, 2H), 3.88-3.75 (m, 2H), 3.59-3.50 (m, 2H), 3.45 (s, 2H), 3.12 (d, J = 10.4 Hz, 2H), 1.90-1.69 (m, 4H), 1.32 (s, 6H). Active Examples
[0809] Unless otherwise specified, the experimental materials, reagents, operations and methods used in the following active examples can be obtained from commercial channels or can be easily known or prepared based on existing technologies.
[0810] Activity Example 1: Kinase ATR inhibition assay
[0811] This experiment used Cisbio's homogeneous time-resolved fluorescence technology Conduct testing.
[0812] Experimental method: Prepare buffer as follows:
[0813] name source Final concentration Mother liquor concentration Volume(uL) HEPES (mM) Gibco, Cat# 15630-080 25 1000 75 Brij35 Sigma, Cat#9002-92-0 0.01% 1% 30 BSA (mg / mL) Sigma, Cat# B2064-50G 1 100 30 DTT(mM) Sigma, Cat# D0632-10G 5 1000 15 glycerin Sigma, Cat#G5516-500ML 1% 50% 60 <![CDATA[MnCl2(mM)]]> Sigma, Cat#7773-01-5 10 1000 30 <![CDATA[H2O]]> 2760 Total(uL) 3000
[0814] Prepare the test compound solution. Prepare the solution of the example compounds shown in the table below using DMSO as the solvent, and the stock solution is usually 10mM. In this experiment, the maximum starting concentration is 3μM, and DMSO is diluted 3 times in series, with a total of 10 concentrations, added to the corresponding wells of a 384-well plate (geriner bio-one, Cat#784075), with final concentrations of 3000, 1000, 333, 111, 37, 12.3, 4.12, 1.37, 0.457, and 0.152nM, respectively. Add the corresponding amount of DMSO to other wells, to be used as negative control wells or positive control wells respectively.
[0815] Dissolve the enzyme and substrate separately in the buffer prepared above and dilute them in two tubes. The concentrations are as shown in the following table:
[0816] name source Final concentration after adding to the plate Preparation concentration Mother liquor concentration ATR(A tube) eurofins,Cat#14-953M 30nM 60 nM 410.26nM p53 (B tube) eurofins,Cat#14-953M 40nM 80nM 9720nM ATP(Tube B) Sigma, Cat#R0441 150 nM 300nM 10000nM
[0817] Use an electric multichannel pipette to add the ATR solution in tube A to the compound wells and negative control wells of the experimental plate at a volume of 5uL per well, and add an equal volume of the above-prepared buffer (medium only, no enzyme) to the positive control well. Centrifuge at 1000 rpm for one minute, then place the experimental plate in a constant temperature incubator at 25°C for 15 minutes. Then use the same method to add 5uL of the substrate mixed solution in tube B to the positive control, negative control and compound wells of the experimental plate, centrifuge and incubate at 25°C for 90 minutes.
[0818] During the reaction, after ATR phosphorylates the substrate p53, two antibodies are added. Anti-phospho-p53-Eu can specifically bind to the phosphorylation site on p53 as an energy donor, while anti-GST-d2 can specifically bind to the GST tag carried on p53 as an energy acceptor. If excited by a laser of a certain wavelength (the excitation light wavelength in this experiment is 340nm), the energy donor can emit an emission light with a wavelength of 615nm. At the same time, when the spatial distance between the energy donor and the energy acceptor is close enough (that is, the two antibodies are simultaneously connected to p53), energy transfer can occur between the energy donor and the energy acceptor, causing the energy acceptor to emit an emission light with a wavelength of 665nm. Use a plate reader to detect the two emission lights and calculate the ratio of the two signals of 665nm and 615nm. The IC of the sample to be tested can be calculated by drawing and calculating. 50 .
[0819] During the detection, the two antibodies were diluted in HTRF detection buffer (Cisbio, Cat#62SDBRDF, Lot#17A) as shown in the following table:
[0820] Detection Reagents source Dilution multiple Mother liquor concentration anti-phospho-p53-Eu Cisbio, Cat# 61P08KAZ 400 400 units anti-GST-d2 Cisbio, Cat#61GSTDLB 200 200 units
[0821] The detection solution was added to the positive control, negative control and compound wells of the experimental plate at a volume of 10 uL per well using an electronic multichannel pipette, centrifuged and incubated overnight at 4°C, and read using an Envision 2104 plate reader.
[0822] Calculate compound inhibition using interpolation: calculate the average of the positive and negative controls, respectively, using the formula:
[0823] Single well inhibition rate = 1-(single well signal value-positive control signal average) / (negative control signal average-positive control signal average)
[0824] The inhibition rate of the compound well can be calculated. Use the four-parameter Logistic equation curve to make a compound inhibition curve: convert the compound concentration into a logarithm with a base of 10, and import the concentration and inhibition rate into the XLfit software. The formula is:
[0825] Inhibition rate = minimum response + (compound concentration ^ curve slope) * (maximum response - minimum response) / (compound concentration ^ curve slope + half inhibition concentration ^ curve slope)
[0826] Thus, the IC value of each compound on the enzyme activity was obtained. 50 value.
[0827] Table 1 ATR kinase inhibitory activity
[0828]
[0829]
[0830] Activity Example 2: Cell Proliferation Assay
[0831] Using CellTiter-Glo TM The living cell detection kit tests the inhibitory effect of the compounds of the present invention on cell proliferation. The kit uses luciferase as a detection substance. Luciferase requires the participation of ATP in the luminescence process. CellTiter-Glo is added to the cell culture medium. TM Reagents are used to measure the luminescence value. The light signal is proportional to the amount of ATP in the system, and ATP is positively correlated with the number of living cells, thereby determining the cell proliferation activity.
[0832] Cell culture and inoculation: Harvest cells LOVO (human colon cancer cells) (ATCC CCL-229) in the logarithmic growth phase and count the cells using a platelet counter. Detect cell viability using the trypan blue exclusion method to ensure that the cell viability is above 90%. Add 90 μL of cell suspension (RPMI1640 + 10% fetal bovine serum) to a 96-well transparent flat-bottom black wall plate (Thermo, 165305) and adjust the cell concentration to 3000 / well / 90ul. Culture the cells in the 96-well plate overnight at 37°C, 5% CO2, and 95% humidity (Thermo, Model 3100 Series).
[0833] First, DMSO was used as a solvent to prepare a 10mM stock solution of the test compound, and then diluted 100 times with PBS to prepare a solution with a 10-fold final concentration, with a maximum concentration of 100μM. 10μL of the test compound solution was added to each well of the 96-well plate inoculated with cells, and then diluted 10 times to reach a final concentration of 10μM. The final concentration of the test compound was started from 10μM, and a 3-fold serial dilution was made, with a total of 9 concentrations, each with 3 replicates. The 96-well plate with the test compound and cells added was placed at 37°C, 5% CO2, and 95% humidity for 96 hours, and then CellTiter-Glo analysis was performed.
[0834] Thaw CellTiter-Glo Reagent ( Luminescent Cell Viability Assay, Promega, G7572) and equilibrate the cell plate to room temperature for 30 minutes. Add an equal volume of CellTiter-Glo solution to each well and shake on an orbital shaker for 5 minutes to lyse the cells. Place the cell plate at room temperature for 20 minutes to stabilize the luminescence signal, and read the luminescence value using a SpectraMax multi-label microplate reader (MD, M3).
[0835] The data were analyzed using GraphPad Prism 7.0 software, and nonlinear S-curve regression was used to fit the data to obtain the dose-effect curve, from which the IC 50 value.
[0836] Cell survival rate (%) = (Lum 待测药 -Lum 培养液对照 ) / (Lum 细胞对照 -Lum 培养液对照 )×100%
[0837] Table 2 Cell proliferation assay results
[0838] Compound number. <![CDATA[LOVO IC 50 (μM)]]> Compound number. <![CDATA[LOVO IC 50 (μM)]]> 1 0.304 16 0.310 2 0.479 19 0.620 3 0.067 20 0.039 4 0.140 26 1.268 5 0.384 29 0.488 6 0.097 31 0.158 8 0.243 32 0.156 9 0.592 34 0.424 11 2.642 35 0.522 14 0.419 36 0.148 15 0.186
[0839] Activity Example 3: Metabolic stability experiment of human and mouse liver microsomes
[0840] According to the standard method of in vitro metabolic stability study conventional in the art, for example, the method described in (Kerns, Edward H. and Di Li (2008). Drug-like Properties: Concepts, Structure Design and Methods: from ADME to Toxicity Optimization. San Diego: Academic Press; Di, Li et al., Optimization of a Higher Throughput Microsomal Stability Screening Assay for Profiling Drug Discovery Candidates, J. Biomol. Screen. 2003, 8 (4), 453.), the hepatic microsomal metabolic stability test of the compounds of the present invention is similarly performed as follows.
[0841]
[0842] Liver microsomes (protein concentration of 0.56 mg / mL) were added with 1 μM compound working solution (10 mM DMSO stock solution was diluted to 100 μM with 100% acetonitrile, organic phase content: 99% ACN, 1% DMSO), pre-incubated at 37°C for 10 min, and then the reaction was started by adding cofactor (NADPH) (prepared with magnesium chloride solution). After incubation for an appropriate time (such as 5, 10, 20, 30 and 60 minutes), samples were taken and an appropriate stop solution (ice acetonitrile (i.e., acetonitrile at 4°C) containing 200 ng / mL tolbutamide and 200 ng / mL labetalol) was added to terminate the reaction.
[0843] Sample treatment (n=1): add appropriate samples, vortex and centrifuge at high speed, take the supernatant, and use HPLC-MS / MS to detect the substrate. The peak area at the 0min time point is taken as 100%. The peak area at other time points is converted to the percentage residual amount, and the natural logarithm of the percentage residual amount at each time point is plotted against the incubation time to calculate the slope (-k), and then calculate Clint (μL / min / mg) and the half-life of the compound (T 1 / 2 The results are shown in Table 3.
[0844] Table 3. Results of metabolic stability experiments on human and mouse liver microsomes
[0845]
[0846] Activity Example 4: Pharmacokinetic (PK) Determination of the Compounds of the Invention in Mice
[0847] The PK assay for each compound was performed as follows: 6 CD-1 mice (Shanghai Lingchang Biotechnology Co., Ltd.) were divided into two groups, 3 mice in each group. One group was administered intravenously (IV) at a dose of 1 mg / kg, with a vehicle of 5% DMSO / 95% (20% Captisol); the other group was administered orally (Po) by gavage at a dose of 5 mg / kg, with a vehicle of 1% HPMC. Blood was collected from the saphenous vein of the lower leg at 0, 0.083, 0.25, 0.5, 1, 2, 4, 6, 8, and 24 h after administration in each group. Approximately 40 μL of blood was collected into an anticoagulant tube containing EDTA-K2. After collection, the blood collection tube was quickly inverted at least 5 times to ensure uniform mixing, and then placed on ice. The blood collected at each time point was centrifuged at 4°C / 8000 rpm for 5 minutes to obtain plasma. Another 1.5 mL centrifuge tube was taken, labeled with the compound name, animal number, and time point, and the plasma was transferred to the tube. The plasma was stored at -80°C until analysis.
[0848] The concentration of the compound in plasma was determined by UPLC-MS / MS, and the pharmacokinetic parameters were calculated using Phoenix WinNolin 6.4 pharmacokinetic software.
[0849] The specific experimental results are as follows, which show that the compound has good drug absorption and pharmacokinetic advantages.
[0850] Table 4. In vivo PK results of the compounds in the examples
[0851]
[0852] Activity Example 5: Equilibrium Solubility Determination of the Compounds of the Present Invention in FaSSIF
[0853] According to the standard solubility determination method conventional in the art well known to those skilled in the art, for example, the method described in (Kerns, Edward H. and Di Li (2008). Drug-like Properties: Concepts, Structure Design and Methods: from ADME to Toxicity Optimization. San Diego: Academic Press), FaSSIF (pH 6.5) (simulating the small intestinal fluid of a person in a hungry state before a meal) was used as the test system to examine the solubility properties of the compounds of the present invention as follows.
[0854] The sample powder of each compound was weighed in a volumetric flask, and 450 μL of pH 6.5 FaSSIF solution was added to obtain a supersaturated suspension. The sample was vortexed for at least 2 minutes, and the volumetric flask was shaken on a vibrating screen at 800 rpm for 24 hours. Then, it was centrifuged at 4000 rpm for 20 minutes. The compressed filtrate was added to the HPLC system, and its concentration was calculated using the standard curve method. The results are shown in Table 5.
[0855] The composition of the rapid simulated intestinal fluid FaSSIF is: 0.056% (w / v) lecithin, 0.161% (w / v) sodium taurocholate, 0.39% (w / v) potassium phosphate, 0.77% (w / v) potassium chloride, deionized H2O, pH 6.5.
[0856] Table 5. Solubility of the compounds of the present invention in FaSSIF
[0857] Example FaSSIF pH=6.5(μg / mL) 1 1140.8 3 1144.7 BAY-1895344 33.4
[0858] The above experimental results show that compared with the control, the example compounds of the present invention unexpectedly have significantly higher solubility and thus have better drugability.
[0859] The structural formula of the reference compound BAY-1895344 used in the above experiments is (purchased from Shanghai Pre-derivative Technology Co., Ltd., CAS NO.1876467-74-1), or can be prepared and characterized according to the method of Example 111 of WO2016020320.
[0860] Those skilled in the art will appreciate that the above description is exemplary and illustrative in nature and is intended to illustrate the present invention and its preferred embodiments. Through routine experimentation, the skilled person will appreciate that obvious modifications and changes can be made without departing from the spirit of the present invention. All such modifications within the scope of the appended claims are intended to be included therein. Therefore, the present invention is intended to be defined not by the above description but by the following claims and their equivalents.
[0861] All publications cited in this specification are herein incorporated by reference.
Claims
1. A compound of formula (I) or a pharmaceutically acceptable salt thereof, in A 1 , A 2 , A 3 , A 4 and A 5 Two of them are N or NR 5 , the rest are C or CR 4 ; X is O, C(R 6 ) 2 or NR 7 ; Y is N or CR 8 ; R 1 and R 2 are independently H, -OH, oxo, halogen, CN, -C 1-6 Alkyl or -OC 1-6 Alkyl, where C 1-6 The alkyl group is optionally substituted with one or more halogen or hydroxyl groups; or R 1 and R 2 Connect together to form C 1-3 Alkylene bridge; R 3 is H or halogen; R 4 Is H or -C 1-6 Alkyl, where C 1-6 The alkyl group is optionally substituted with one or more halogen or hydroxyl groups; R 5 Is H or -C 1-6 Alkyl, where C 1-6 The alkyl group is optionally substituted with one or more halogens; R 6 are independently H, halogen, CN, -OH, -C 1-6 Alkyl or C(O)-C 1-6 alkyl; R 7 It is H, -C 1-6 Alkyl or -C(O)-C 1-6 alkyl; R 8 is H, -OH or halogen; n and m are each independently an integer from 0 to 4.
2. A compound of formula (I) according to claim 1 or a pharmaceutically acceptable salt thereof, wherein A 1 ~A 5 The six-membered and five-membered heteroaryl moiety has a structure selected from the following:
3. A compound of formula (I) according to claim 2 or a pharmaceutically acceptable salt thereof, wherein A 1 ~A 5 The six-membered and five-membered heteroaryl moiety has a structure selected from the following:
4. A compound of formula (I) according to claim 1 or a pharmaceutically acceptable salt thereof, wherein R 4 Yes H, R 5 Is H or C 1-6 alkyl.
5. A compound of formula (I) according to claim 1 or a pharmaceutically acceptable salt thereof, wherein the six-membered ring containing X and Y Selected from 6. A compound of formula (I) according to claim 1 or a pharmaceutically acceptable salt thereof, wherein X is selected from -O-, -NH-, -N(C 1-6 Alkyl)-, -CH 2 -, -C (halogen) 2 .
7. A compound of formula (I) according to claim 1 or a pharmaceutically acceptable salt thereof, wherein Y is N or CR 8 , where R 8 It's OH.
8. A compound of formula (I) according to any one of claims 1 to 7, or a pharmaceutically acceptable salt thereof, wherein one of m and n is 0, the other is 1, R 1 or R 2 Each is independently C 1-6 The alkyl group, optionally substituted by one or more halogens, is attached to the ortho position of Y or the ortho position of X.
9. A compound of formula (I) according to any one of claims 1 to 7, or a pharmaceutically acceptable salt thereof, wherein one of m and n is 0, the other is 2, R 1 or R 2 Each is independently C 1-6 The alkyl group, optionally substituted with one or more halogens, is attached to an ortho position to Y, to an ortho position to X, or to an ortho position to X and Y, respectively.
10. A compound of formula (I) according to any one of claims 1 to 7, or a pharmaceutically acceptable salt thereof, wherein m and n are both 1, R 1 and R 2 Each is independently C 1-6 The alkyl group, optionally substituted with one or more halogen groups, is attached to the ring at an ortho position to Y, to an ortho position to X, or to an ortho position to Y and an ortho position to X, respectively.
11. A compound of formula (I) according to any one of claims 1 to 7, or a pharmaceutically acceptable salt thereof, wherein one of m and n is 0, the other is 1, R 1 or R 2 It is C 1-6 The alkyl group is connected to the ortho position of Y or the ortho position of X.
12. A compound of formula (I) according to any one of claims 1 to 7, or a pharmaceutically acceptable salt thereof, wherein m=1 and n=1, R 1 and R 2 They are connected to the adjacent position of Y and together form C 1-3 Alkylene bridge.
13. A compound of formula (I) according to claim 12 or a pharmaceutically acceptable salt thereof, wherein m=1 and n=1, R 1 and R 2 They are connected to the adjacent position of Y and together form C 2 Alkylene bridge.
14. A compound of formula (I) according to any one of claims 1 to 7, or a pharmaceutically acceptable salt thereof, wherein m=1 and n=1, R 1 and R 2 They are connected to the adjacent position of X and together form C 1-3 Alkylene bridge.
15. A compound of formula (I) according to claim 14 or a pharmaceutically acceptable salt thereof, wherein m=1 and n=1, R 1 and R 2 They are connected to the adjacent position of X and together form C 2 Alkylene bridge.
16. A compound of formula (I) according to any one of claims 1 to 7 or a pharmaceutically acceptable salt thereof, wherein R 3 It's H.
17. A compound of formula (I) according to claim 1 or a pharmaceutically acceptable salt thereof, wherein Contains A 1 ~A 5 The six-membered and five-membered heteroaryl moieties are selected from: The six-membered ring containing X and Y is selected from R 1 and R 2 Each independently is H or -C 1-6 Alkyl, where C 1-6 The alkyl group is optionally substituted with one or more OH or halogen; or R 1 and R 2 Connect together to form C 1-3 Alkylene bridge; R 3 is H or halogen; R 4 It is H; R 5 Is H or -C 1-6 alkyl; R 6 are each independently H or halogen, -C 1-6 Alkyl or -OC 1-6 Alkyl, where -C 1-6 The alkyl group is optionally substituted with one or more halogens; R 7 Is H or -C 1-6 Alkyl, where -C 1-6 The alkyl group is optionally substituted with one or more halogens; R 8 is H, -OH or halogen; n and m are each independently an integer from 0 to 2.
18. A compound of formula (I) or a pharmaceutically acceptable salt thereof according to claim 17, wherein A 1 ~A 5 The six-membered and five-membered heteroaryl moieties are selected from 19. A compound of formula (I) according to claim 17 or 18, or a pharmaceutically acceptable salt thereof, wherein the six-membered ring containing X and Y Selected from 20. A compound of formula (I) according to claim 19 or a pharmaceutically acceptable salt thereof, wherein R 1 and R 2 Each independently is H or -C 1-6 alkyl.
21. A compound of formula (I) according to claim 19 or a pharmaceutically acceptable salt thereof, wherein one of n and m is 0, the other is 1, and R 1 or R 2 Connected to the ortho position of Y or the ortho position of X.
22. A compound of formula (I) according to claim 19 or a pharmaceutically acceptable salt thereof, wherein one of n and m is 0, the other is 2, R 1 or R 2 It is simultaneously connected to the ortho position of Y, the ortho position of X, or is separately connected to the ortho position of Y and the ortho position of X on the ring.
23. A compound of formula (I) according to claim 22 or a pharmaceutically acceptable salt thereof, wherein one of n and m is 0, the other is 2, R 1 or R 2 Both are connected to the ortho position of Y.
24. A compound of formula (I) according to claim 19 or a pharmaceutically acceptable salt thereof, wherein n and m are both 1, R 1 and R 2 Each is independently connected to the ortho position of Y or the ortho position of X on the ring.
25. A compound of formula (I) according to claim 19 or a pharmaceutically acceptable salt thereof, wherein n and m are both 1, R 1 and R 2 Both are connected to the ortho position of Y.
26. A compound of formula (I) according to claim 19 or a pharmaceutically acceptable salt thereof, wherein n and m are both 1, and R connected to the ortho position of Y or the ortho position of X is 1 and R 2 Connect together to form C 1-3 Alkylene bridge.
27. A compound of formula (I) or a pharmaceutically acceptable salt thereof according to claim 26, wherein n and m are both 1, and R connected to the ortho position of Y or the ortho position of X is 1 and R 2 Connect together to form C 2 Alkylene bridge.
28. A compound of formula (I) according to claim 19 or a pharmaceutically acceptable salt thereof, wherein R 3 It's H.
29. A compound of formula (I) according to claim 19 or a pharmaceutically acceptable salt thereof, wherein R 5 Yes-C 1-6 alkyl.
30. A compound of formula (I) according to claim 29 or a pharmaceutically acceptable salt thereof, wherein R 5 Yes-CH 3 .
31. A compound of formula (I) according to claim 19 or a pharmaceutically acceptable salt thereof, wherein R 6 are each independently H or halogen.
32. A compound of formula (I) according to claim 31 or a pharmaceutically acceptable salt thereof, wherein R 6 Each is independently H or F.
33. A compound of formula (I) according to claim 19 or a pharmaceutically acceptable salt thereof, wherein R 7 Is H or -C 1-6 alkyl.
34. A compound of formula (I) according to claim 33 or a pharmaceutically acceptable salt thereof, wherein R 7 Yes-CH 3 .
35. A compound or a pharmaceutically acceptable salt thereof, wherein the compound is selected from 36. A pharmaceutical composition comprising a compound according to any one of claims 1 to 35 or a pharmaceutically acceptable salt thereof, and optionally one or more pharmaceutically acceptable carriers.
37. Use of a compound according to any one of claims 1 to 35 or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to any one of claims 36, in the preparation of a medicament for treating or preventing a disease associated with ATR kinase.
38. The use according to claim 37, wherein the disease associated with ATR kinase is selected from hematological malignancies, and solid tumors.
39. The use according to claim 38, wherein the disease associated with ATR kinase is selected from leukemia, multiple myeloma, lymphoid malignancies, myelodysplastic syndrome, breast cancer, lung cancer, central nervous system tumors, gastrointestinal cancer, skin cancer, melanoma, bone cancer, head and neck cancer and teratoma.
40. The method according to claim 38, wherein the disease associated with ATR kinase is selected from chronic lymphocytic leukemia, acute lymphocytic leukemia, acute myeloid leukemia, chronic myeloid leukemia, lymphoma, non-small cell lung cancer, small cell lung cancer, glioma, dysembryoplastic neuroepithelial tumor, glioblastoma multiforme, medulloblastoma, retinoblastoma, neuroblastoma, germ cell tumor, gastric cancer, esophageal cancer, liver cancer, bile duct cancer, colorectal cancer, small intestine cancer, pancreatic cancer, thyroid cancer, salivary gland cancer, prostate cancer, testicular cancer, ovarian cancer, uterine cancer, vulvar cancer, bladder cancer, renal cancer, osteosarcoma, leiomyosarcoma, soft tissue sarcoma, Ewing's sarcoma and Kaposi's sarcoma.
41. The use according to claim 38, wherein the disease associated with ATR kinase is selected from mixed glioma, Hodgkin's disease, non-Hodgkin's lymphoma, cervical cancer, endometrial cancer, chondrosarcoma, gastrointestinal tissue cancer, gastrointestinal stromal tumor.
42. The use according to claim 38, wherein the disease associated with ATR kinase is pediatric cancer.
43. The use according to claim 38, wherein the diseases associated with ATR kinase are pediatric rhabdomyosarcoma and pediatric neuroblastoma.
44. The use according to claim 38, wherein the disease associated with ATR kinase is squamous cell carcinoma or bronchoalveolar carcinoma.
45. The use according to claim 38, wherein the disease associated with ATR kinase is selected from lung cancer, prostate cancer, melanoma, ovarian cancer, breast cancer, endometrial cancer, kidney cancer, gastric cancer, sarcoma, head and neck cancer, central nervous system tumors and their metastases, and acute myeloid leukemia.
